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SUMMARY 
 
 Knowledge of protein structure, sequence motifs or function is required for the construction 
of trans-dominant mutants. The information for the majority of herpesvirus proteins, however, 
is too limited to allow a knowledge-based construction of dominant negative (DN) proteins. A 
systematic screen of the essential murine cytomegalovirus (MCMV) protein pM53 revealed an 
accumulation of DN mutations within conserved region (CR) 2 and CR4. Whereas the strong 
inhibitory potential of the CR4 mutants allowed the characterisation of their phenotype, the DN 
effect of the mutations in CR2 was too weak to be analysed. Based on preliminary data obtained 
from pM53 proteins composed of the pM53 N-terminus fused to the C-terminal CRs of 
homologous herpesvirus proteins we hypothesised that chimeric pM53 proteins carrying one 
conserved, but non-complementing domain of the respective homologue will be inhibitory for 
MCMV replication. In addition to the domain shuffling approach, the CRs were also targeted by 
deletion. Thus, the present study describes the construction of pM53 mutants in which the single 
CRs were disrupted by targeted mutagenesis and the subsequent investigation of their inhibitory 
effect on MCMV replication using an established conditional expression system.  
 Indeed, the pM53 mutants with shuffled CR2 and CR4 as well as CR2 deletion were 
inhibitory for MCMV replication, whereas neither the shuffled nor the CR3 deletion mutant 
was. The phenotype induced by the strong CR2 DN mutant was analysed in detail. 
Overexpression of the CR2-deficient pM53 inhibited MCMV production by 10,000-fold, which 
was due to interference with capsid export from the nucleus and viral genome 
cleavage/packaging. In addition, the fate of the nuclear egress complex in the presence of DN 
pM53 overexpression was analysed. The CR2 mutants were able to bind to pM50, albeit to a 
lesser extent than the wild-type protein, and re-localised the wild-type nuclear egress complex 
in infected cells. Unlike the CR4 DN, the CR2 DN mutants did not affect the stability of pM50. 
 The second part of this study deals with the establishment of a high-throughput suitable 
screening system for the identification of inhibitory alleles of essential MCMV genes. In this 
screen, the site-specific recombination of an MCMV genome, cloned as bacterial artificial 
chromosome, and a rescue vector, which is mediated by the Flp recombinase, was transferred 
from the bacterial background to MCMV permissive host cells. Using a reference set of 
characterised pM53 mutants it was shown that the novel system is generally applicable to 
identify non-complementing as well as inhibitory mutants in a reduced time frame.  
 Last, the biological and biochemical properties of pM99, a protein suggested to be involved 
in the secondary envelopment process, were investigated to provide the basis for the application 
of the novel screening tools to test a comprehensive library of pM99 mutants. 
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ZUSAMMENFASSUNG 
 
 Zur Konstruktion trans-dominanter Mutanten sind Informationen über die Struktur oder funktionelle 
Motive eines Proteins erforderlich. Für die Mehrheit der Herpesvirus-Proteine ist dieses Wissen jedoch zu 
begrenzt für eine gezielte Konstruktion dominant negativer (DN) Proteine. Eine systematische 
Untersuchung des essentiellen Proteins pM53 des murinen Zytomegalievirus (MCMV) ließ eine 
Ansammlung von DN Mutationen in den konservierten Regionen 2 (CR2) und 4 (CR4) erkennen. Die 
Mutationen in CR4 unterdrückten die Funktion des Wildtyp pM53, so dass ein Phänotyp charakterisiert 
werden konnte. Im Gegensatz dazu war der Effekt der CR2-Mutanten zu schwach um analysiert zu 
werden. Aufgrund bestehender Daten über pM53 Proteine, welche aus dem pM53 N-Terminus und den 
C-terminalen konservierten Regionen homologer Herpesvirusproteine aufgebaut sind, wurde spekuliert, 
dass chimäre pM53 Proteine mit einer konservierten, aber nicht komplementierenden Domäne eines 
Homologs inhibitorisch für die MCMV-Replikation sein würden. Zusätzlich zum Domain-Austausch 
wurden die konservierten Regionen deletiert. Basierend auf dieser Vermutung beschreibt die vorliegende 
Arbeit die Konstruktion von pM53 Mutanten, bei denen die einzelnen konservierten Regionen durch 
gezielte Mutagenese inaktiviert wurden, und die anschließende Analyse des inhibitorischen Effekts auf 
die MCMV-Replikation mittels eines konditionalen Expressionssystems. 
 Den Erwartungen entsprechend inhibierten die pM53 Mutanten mit ausgetauschter CR2 und CR4 
sowie die CR2-Deletionsmutante die MCMV-Replikation, während dies für keine der CR3-Mutanten 
zutraf. Der durch die CR2 DN Mutante induzierte Phänotyp wurde genauer analysiert. Überexpression 
der CR2-Deletionsmutante blockierte den Kapsidexport aus dem Zellkern und verringerte zusätzlich die 
Generierung von Genomen mit spezifischer Größe, so dass die MCMV-Produktion um das 10.000-Fache 
reduziert war. Darüber hinaus wurde das Verhalten des sogenannten Kern-Austritt-Komplexes in 
Anwesenheit von DN pM53 untersucht. Die CR2-Mutanten interagierten mit geringerer Effizienz mit 
pM50 als Wildtyp pM53. Außerdem delokalisierten sie den Wildtyp Kern-Austritt-Komplex in infizierten 
Zellen. Im Gegensatz zu den CR4 DN Mutanten hatten die pM53 CR2 Mutanten keinen Einfluss auf die 
Stabilität von pM50. 
 Der zweite Teil dieser Studie beschreibt die Etablierung eines Hochdurchsatz-geeigneten 
Screeningsystems zur Identifikation inhibitorischer Allele essentieller MCMV Gene. Für diesen Screen 
wurde die durch die Flp-Rekombinase katalysierte sequenzspezifische Rekombination zwischen dem 
MCMV-Genom und einem Plasmidvektor von Bakterien in MCMV-permissive eukaryotische Zellen 
übertragen. Mittels einer Auswahl an bereits charakterisierten pM53 Mutanten konnte gezeigt werden, 
dass dieses neue System allgemein anwendbar ist um sowohl nicht-komplementierende als auch 
inhibitorische Mutanten mit reduziertem Zeitaufwand zu identifizieren. 
 Im letzten Teil wurden die biologischen und biochemischen Eigenschaften des Proteins pM99 
untersucht, welches im sekundären Verhüllungsprozess involviert sein könnte. Diese Untersuchung bietet 
die Basis für die Anwendung des neuen Screeningsystems, um eine umfangreiche Bibliothek an pM99 
Mutanten zu testen. 
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1 INTRODUCTION 
 
 
1.1 Herpesviridae 
 Herpesviruses are large double stranded DNA viruses that infect vertebrates as well 
as non-vertebrates. Up to date, more than 90 herpesviruses have been identified 
including several human pathogens [63]. A feature shared by all herpesviruses is their 
capacity to establish life-long persistence in the infected host. Based on their host range, 
biology and genetics, the family of herpesviridae is classified into the three main groups 
of alpha-, beta- and gamma-herpesvirinae. Alpha-herpesviruses, such as the human 
pathogen herpes simplex virus (HSV), tend to replicate rapidly in cell culture 
accompanied by cytopathic effects and establish latency in neurons in sensory ganglia. 
An important non-human pathogen belonging to the alpha-herpesvirinae is 
pseudorabies virus (PrV), which infects swine and other farm animals. It has 
extensively been used as animal model to study aspects of alpha-herpesvirus biology 
[reviewed in 128].  
 Gamma-herpesviruses such as Epstein-Barr virus (EBV) replicate very slowly in 
tissue culture and establish latency in lymphoid tissues. Since exploration of EBV 
pathogenesis in humans is limited, infection of mice with murine herpesvirus 68 
(MHV68) has been exploited as suitable model for gamma-herpesvirus biology [65, 
119].  
 Human cytomegalovirus (HCMV) is a widespread pathogen belonging to the beta-
herpesvirinae. Cytomegaloviruses (CMVs) are characterised by strict species 
specificity, tropism for hematopoietic tissue and secretory glands and a relatively slow 
replication cycle in vitro. In humans, after resolution of a primary acute infection that 
generally proceeds asymptomatically in immuno-competent patients, CMVs establish 
life-long persistence with alternate stages of virus reactivation and true latency, where 
no infectious virus can be detected [10, 81, 84, 114, 164]. However, perinatal infection 
as well as infection of immuno-compromised individuals such as AIDS patients or 
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transplantation recipients may result in severe and life-threatening illness including 
colitis, encephalitis, esophagitis, hepatitis, pneumonitis and retinitis. Intra-uterine 
infections of the foetus lead to embryopathies characterised by damages of the central 
nervous system causing hearing loss, seizures, mental retardation, or even abortion 
[reviewed in 84]. The strict species specificity of HCMV has hindered its study in 
animals. Since murine cytomegalovirus (MCMV) shares many features with HCMV, 
the mouse model has extensively been used for studying the pathogenesis of acute, 
latent and recurrent virus infection [99, 132]. 
 
1.1.1 Structure of the herpesvirus particles 
 A herpesvirus virion consists of three major structural elements: the capsid 
containing the linear double stranded viral DNA, the tegument layer and the envelope 
(Figure 1.1). The size of mature virions ranges between 120 and 260 nm due to the 
variable thickness of the tegument [137]. The icosahedral capsid, about 120 nm in 
diameter, is composed of 162 capsomers, which themselves are complexes of structural 
proteins. It is embedded in the tegument, a proteinaceous meshwork assumed to play a 
major role shortly after infection and during early gene expression. The tegument also 
contains both viral and host cell RNA that can be translated immediately after infection 
[20, 54]. A lipid bilayer originating from the host cell forms the viral envelope. Virus-
encoded glycoproteins are incorporated in the envelope, allowing virus attachment to 
host cell receptors and mediating fusion with the membrane of the target cell. 
 Two more particle types are produced during a lytic herpesvirus infection besides 
mature virions: non-infectious enveloped particles (NIEPs), which are similar to mature 
virions but lack viral DNA, as well as so-called dense bodies (DBs), which lack both the 
capsid and the genome [64, 169]. A similar capsid-lacking structure, called L particles, 
was also described for HSV-1 [101]. 
 Herpesviruses have the largest genomes among vertebrate viruses, ranging from 
125 kb for varicella-zoster virus (VZV) to 230 kb for cytomegaloviruses [11, 131]. The 
core genes, which are highly conserved throughout the subfamilies, are located in the 
centre of the linear double stranded DNA genome. The products of these essential genes 
are involved in vital viral functions such as DNA replication, genome packaging or 
maturation of infectious viral particles. The core genes are flanked by genes shared 
within the subfamily. The genes located towards the ends of the genome define the 
14 
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species specificity of the different viruses and are mainly involved in the cross talk with 
the host. 
 
nucleocapsid
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genomic DNA
envelope
viral
glycoproteins
A B
 
Figure 1.1: Herpesvirus virion morphology  
(A) Schematic representation of a herpesvirus virion (© Marko Reschke, University of 
Marburg, 1994-1997). (B) Electron microscopy of an extracellular HCMV virion. Scale bar, 
100 nm [109]. Major virion components are indicated. The icosahedral capsid enclosing the 
linear ds DNA is embedded in the tegument, a macromolecular meshwork containing viral 
proteins as well as viral and host cell mRNAs playing an important role directly after infection. 
The host cell-derived lipid envelope comprises viral glycoproteins that mediate attachment to 
the target cell. 
 
 
1.1.2 Herpesvirus replication cycles 
 Host cell infection is initiated by virion attachment to cell surface receptors [167] 
and internalisation of the capsid together with tegument components. Depending on the 
cell type and its receptors, up-take occurs via fusion of the viral and cellular membrane 
or by endocytosis [reviewed in 35, 177]. The capsid is transported along microtubules 
[166] until it docks to a nuclear pore and delivers the linear genome into the nucleus. 
The genome circularises and either is silenced by the host cell, leading to latency, or the 
transcription of viral genes is forced, initiating the lytic replication cycle. Latently 
infected cells maintain viral genomes in a circular form and express only a minimal 
gene set to ensure persistence [51]. Infectious viral particles are not detected during 
latency. 
 The start of the lytic cycle is characterised by a strictly regulated consecutive viral 
transcription cascade, resulting in three classes of gene products [61]. Immediate-early 
(IE) proteins participate in the transcriptional activation of most of the other viral genes, 
15 
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whereas early proteins are involved in the replication of the viral genome. Products of 
late genes are mainly structural components that are involved in capsid assembly and 
DNA encapsidation, maturation and egress. 
 
 
Figure 1.2: Lytic replication cycle of herpesviruses 
Schematic representation of a lytic replication cycle, exemplified by electron micrographs for 
PrV. Virions attach (1) and penetrate (2) the target cell and are transported to the nucleus (3) via 
interaction with microtubules (4). The viral DNA is released into the nucleus upon docking to 
the nuclear pore (5), where transcription and replication of viral genes and genomes takes place 
(6). Concatemeric replicated DNA is cleaved into unit length genomes during packaging (8) 
into pre-assembled capsids (7). Mature capsids exit the nucleus by budding through the nuclear 
envelope (9-11). Cytosolic capsids are tegumented and bud into vesicles of the trans-Golgi 
network (12) containing viral glycoproteins (black spikes), resulting in enveloped particles 
within intracellular vesicles. Those are transported to the cell membrane (13), the membranes 
fuse (14) and mature, enveloped virions are released. G, Golgi apparatus; M, mitochondrion; 
MT, microtubule; N, nucleus; NM, nuclear membrane; NP, nuclear pore; RER, rough 
endoplasmic reticulum; TGN, trans-Golgi network. The picture was reproduced from [109] and 
modified. 
 
 Viral replication and capsid assembly occurs within the nucleus of infected cells, 
whereas maturation of the virions takes place in the cytoplasm. Production and release 
of infectious viral particles, whether in primary infection or recurrence from latency, is 
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invariably accompanied by destruction of the host cell. Lytic replication of 
herpesviruses disrupts the cytoskeleton, leading to cytopathic effects such as massive 
enlargement of the host cell (cytomegalia) or induces fusion of infected cells (syncytia). 
Replication of the viral genome produces concatemeric DNA that is cleaved into unit 
length genomes simultaneously to its encapsidation into pre-assembled capsids [104]. 
These mature, DNA-filled capsids are targeted to the nuclear rim and exit the nucleus 
by a complex course of envelopment and de-envelopment processes through the nuclear 
membrane (section 1.1.3). Final maturation occurs then in the cytoplasm, where the 
capsids are tegumented and acquire their secondary envelope by budding into vesicles 
of the trans-Golgi network (section 1.1.4) [149]. They are transported via the secretory 
pathway to the cell surface, where the membranes fuse und infectious virions are 
released into the extracellular space (Figure 1.2). 
 
1.1.3 Role of the nuclear egress complex 
 The inner nuclear membrane (INM) of eukaryotic cells is lined by a complex 
fibrillar network, the nuclear lamina, which provides mechanical stability and anchors 
the nuclear core complexes embedded in the nuclear envelope. Since herpesvirus 
capsids exceed the size tolerated for transport through the nuclear pores (~39 nm) [122], 
they require an alternative exit mechanism. Capsid export through enlarged pores has 
been observed for HSV-1 and bovine herpesvirus [88, 174] and a recent study of PrV 
shows nuclear envelope breakdown as means of nuclear capsid exit [74]. Yet, the most 
prominent pathway requires budding through the nuclear envelope akin to the 
mechanism reported recently for large ribonucleoprotein granules during synaptic Wnt 
signalling [168]. First, mature capsids bud into the INM, forming capsid-containing 
vesicles in the perinuclear space [41]. By fusion of this primary envelope with the outer 
nuclear membrane (ONM), the nucleocapsids are liberated into the cytoplasm. This 
process is facilitated by a number of viral and host cell protein interactions (Figure 1.3). 
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Figure 1.3: Nuclear egress of herpesvirus capsids 
Schematic illustration of the nuclear egress of herpesviral capsids. DNA-filled nucleocapsids 
acquire a primary tegument (1) and are targeted to the nuclear rim (2). The respective members 
of the pUL31 and pUL34 families interact at the inner nuclear membrane (INM) (3), forming 
the nuclear egress complex by recruiting further viral and cellular proteins. This serves as 
docking station for the capsids, which bud into the INM (4). The thus acquired primary 
envelope fuses with the outer nuclear membrane, thereby releasing the capsids into the 
cytoplasm (5). ER, endoplasmic reticulum; NPC, nuclear pore complex; PNS, perinuclear 
space. The figure was produced by adapting schematic representation from [66, 108]. 
 
 Studies in alpha-herpesviruses have shown that two viral proteins, pUL31 and 
pUL34, play a critical role in primary envelopment [49, 75, 140, 159]. Homologues of 
these proteins are found in all herpesviruses studied so far and are assigned to the 
pUL31 and pUL34 herpesviral protein families. The corresponding gene products in 
MCMV are called pM53 and pM50. Proteins of the pUL34 family are expressed in the 
early to late phase of infection. They are type II C-terminally anchored membrane 
proteins that primarily reside in the nuclear envelope. pUL31 family members are 
expressed late in infection. In the absence of other viral proteins, pM53 is distributed 
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throughout the nucleosol. It is targeted to the INM by interaction with pM50, a 
mechanism that is conserved among herpesviruses [22, 39, 46, 49, 50, 83, 95, 135, 151, 
152, 159, 183]. pM50 and pM53 (and their homologues) form the nuclear egress 
complex (NEC) and serve as docking station for further cellular and viral proteins, such 
as protein kinase C and viral kinases. Those participate in the phosphorylation of 
nuclear lamins, which loosens the meshwork and allows contact between nucleocapsid 
and INM [15, 27, 73, 98, 111, 113, 115, 118, 123, 134, 136, 144]. Other lamina 
constituents such as emerin and the lamin B receptor are also displaced during infection 
[85, 86, 112, 154].  
 The mechanism by which the pUL31 and pUL34 homologues mediate capsid 
transition through the nuclear envelope is still not fully understood, but disruption of 
either partner usually leads to retention of viral capsids within the nucleus [22, 46, 49, 
75, 95, 140, 185]. Insights into this mechanism were gained from studying the PrV 
proteins pUL31 and pUL34, which induce vesicle formation in the nuclei of transfected 
cells in the absence of other viral components [71], supporting their role in the capsid 
envelopment process at the INM. The reciprocal binding sites, which result in NEC 
targeting to the INM, are well characterised in pM53 and pM50, and are conserved 
throughout the pUL31 family [22, 49, 50, 89, 95, 148, 152]. Furthermore, recent studies 
of HSV-1 suggest a second essential interaction between the N-terminal domain of 
pUL34 and the C-terminus of pUL31, which results in membrane wrapping. This 
interaction is distinct from that required for INM targeting [14, 138, 139]. 
 In addition to its role in primary envelopment, pUL31 family members are involved 
in an upstream step of capsid maturation and DNA cleavage/packaging, which is 
independent of the pUL34 binding [29, 52, 72, 82, 130]. Furthermore, a recent study in 
HSV-1 ascribes to pUL31 the function of targeting DNA-filled capsids from the 
nucleosol to the INM [184]. 
 
1.1.4 Role of the secondary envelopment complex 
Viral particles loose their primary envelope upon entering the cytoplasm, where 
final tegumentation and addition of the secondary envelope at the trans-Golgi network 
(TGN) takes place. It is still not fully understood how tegumented capsids reach this so-
called assembly complex and how viral glycoprotein assembly occurs, but is has been 
shown that the conserved viral homologues of the pUL11 and pUL16 protein families 
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are major players in these processes. Notably, while the pUL11 and pUL16 homologues 
are dispensable for viral replication in cell culture in alpha- and gamma-herpesviruses 
[5, 6, 31, 78, 96, 146], their homologues in beta-herpesviruses are essential [21, 45, 97, 
125, 161].  
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Figure 1.4: Role of pM94/pM99 in secondary envelopment of herpesviruses 
Depicted is a model of the secondary envelopment. The pUL16/pUL11 complex is targeted to 
trans-Golgi derived vesicles containing viral tegument and glycoproteins (1). pUL16 docks 
tegumented capsids to these vesicles (2), which are enfolded, forming enveloped virions within 
cellular vesicles (3). The vesicles are transported to the cell surface (4) and virions  are released 
upon fusion of the vesicle to the plasma membrane (5). ECS, extracellular space; PM, plasma 
membrane. Adapted from [108]. 
 
 The pUL11 homologue of HCMV, pUL99 (pp28), is a small (190 amino acids) 
myristoylated and palmitoylated phospho-protein [67], which is expressed in the late 
phase of infection [70, 76] and accumulates at the cytoplasmic interface of Golgi-
derived membranes [60, 149]. It has been shown to interact with the tegument protein 
pUL94 (the pUL16 homologue) in the absence of other viral proteins [90], forming the 
secondary envelopment complex (SEC), which is crucial for the functionality of both 
proteins [126]. This interaction was also confirmed for the MCMV proteins pM99 and 
pM94 [97] as well as for pUL11 and pUL16 [93, 178, 186]. In HCMV, disruption of 
either protein leads to retention of DNA-filled, tegumented capsids in the cytoplasm that 
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fail to acquire their final envelope, thereby completely blocking the production of 
infectious virions [125, 161]. Furthermore, pUL99 shows aberrant localisation in 
absence of its binding partner and vice versa, indicating that their interaction is a 
prerequisite for proper localisation to the assembly complex.  
During infection, pUL94 and its homologues are found in the cytoplasm as well as 
the nucleus [91, 106, 121], suggesting that pUL94 targets the capsids to the assembly 
complex by interacting with TGN-associated pUL99 to permit secondary envelopment 
(Figure 1.4). 
 
 
1.2 Reverse genetics in herpesviruses 
Traditionally, irradiation or chemicals were used to increase the mutation rate during 
replication, and interesting phenotypes were subsequently investigated regarding the 
causative genetic change (forward genetics). However, comprehensive genetic analysis 
of herpesviruses by this approach was not feasible and the application of traditional 
methods of molecular cloning has long been limited due to the very size of their 
genomes. Primarily the establishment of genetic systems that permit targeted 
mutagenesis of the gene of interest in its genomic context facilitated the generation of 
virus mutants in order to analyse resulting phenotypic alterations (reverse genetics). 
 
1.2.1 Site-directed mutagenesis 
Functional analyses of isolated genes were enabled by cloning of viral fragments 
that could be modified in vitro and re-introduced into the viral genome. In principle, the 
cellular recombination machinery is exploited to replace the target sequence by the 
modified viral gene together with a marker gene (Figure 1.5A). Yet, the recombination 
frequency is low and the majority of produced viruses do not carry the desired mutation. 
Selection procedures are required to isolate mutated viruses, which can be tedious for 
mutants with growth deficits [reviewed in 143].  
Further advance was gained with the cloning of the HSV-1 genome as set of 
overlapping cosmid fragments [176]. Assembly of the fragments by homologous 
recombination in permissive cells reconstitutes the virus. This system has two 
advantages, the wild-type (wt) genome is not required and mutations can be introduced 
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in any of the cosmid fragments by standard techniques. However, since full assembly 
necessitates several recombination events, the risk for unwanted mutations is increased. 
Besides, null mutations of essential genes cannot be generated using this approach 
[reviewed in 143]. 
 
wt mut
mut wt
mut
wt
wt
mut
A B
mutmut
mut
BAC
BAC
wt
mut
BAC
 
Figure 1.5: Approaches of herpesvirus mutagenesis 
(A) Site-directed mutagenesis in eukaryotic cells. Infected cells are transfected with linear DNA 
fragments containing the mutation (red box). The mutated fragment replaces the wild-type (wt) 
sequence (green box) in some viral genomes by homologous recombination (crossed lines), 
resulting in a pool of wt and recombinant mutant (mut) viruses. (B) Mutagenesis based on 
bacterial artificial chromosomes (BACs). Recombinant BACs are generated using the E. coli 
recombination system. Mutant viruses are reconstituted by transfecting permissive cells with 
DNA derived from a verified BAC clone. Adapted from [143]. 
 
 
1.2.2 Mutagenesis of bacterial artificial chromosomes 
The disadvantages of uncontrollable cellular recombination was overcome when full 
length herpesvirus genomes were cloned as infectious bacterial artificial chromosomes 
(BACs), which was pioneered for MCMV [107], and subsequently adapted to numerous 
herpesviruses such as HSV-1, PrV, HCMV, EBV and MHV68 [1, 17, 43, 147, 165]. 
Using BACs, herpesviral genomes can be readily modified using techniques developed 
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for bacterial genetics. Besides, the expression of viral functions is not required for the 
maintenance in E. coli, decreasing the risk of unwanted changes due to frequent sub-
culturing of viral progeny. The modified DNA is transfected into permissive eukaryotic 
cells to reconstitute infectious virus, which results in pure, clonal viral populations, and 
even allows the production of attenuated mutants (Figure 1.5B). While the function of 
non-essential genes can be studied in the virus context using deletion and loss-of-
function mutants, this approach is not applicable for essential genes. The study of null- 
or non-functional mutants of essential genes requires functional analysis by trans-
complementation or the application of DN mutants [reviewed in 55]. 
   
1.2.3 Complementation systems for defects of essential genes 
Viruses with inactivating mutations in essential genes can be propagated only if the 
target gene is provided in addition. This can be realised by expressing the 
complementing feature separately from the virus genome (trans-complementation), for 
example by a modified helper cell line or helper viruses. Trans-complementation is 
commonly used for IE gene products, which are required in small amounts for viral 
replication and whose expression is not detrimental for the cell. Alternatively, the 
complementing element can be inserted into the viral genome at an ectopic position 
(cis-complementation), often accompanied with regulating features. Recently, a 
conditional replication system has been adapted to MCMV [142], in which the two 
elements required for conditional gene expression – regulated transcription unit as well 
as regulator – were integrated as one cassette into the viral BAC genome. Combining 
regulator and regulated cassette has two major advantages. Since the conditional 
expression unit is present in the MCMV genome, the effect of the mutants can be 
studied upon induction in any permissive cell type as well as in vivo. Additionally, the 
cassette is inserted at an apparently neutral locus, so that regulation of the gene of 
interest should not interfere with the viral gene expression programme. Thus, the gene 
of interest is regulated as independently as possible from the viral genetic programme. 
The tet-regulated system has successfully been applied to the conditional expression of 
both essential genes and dominant negative (DN) alleles in the virus context [97, 130, 
141]. 
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1.3 Dominant negative mutants 
 Essential genes are not easily studied using traditional approaches because mutant 
viruses are difficult to reconstitute. However, functional inactivation of such proteins by 
co-expression of dominant negative (DN) mutants makes them amenable to 
comprehensive genetic analysis [58]. 
 
1.3.1 Inhibitory principle of DN proteins 
 DN alleles are able to induce the null phenotype in the presence of the wt gene 
product and permit functional analysis of essential genes. Prerequisites for effective DN 
mutants are that their wt counterparts are multi-functional proteins of essential genes 
that preferentially act in complexes. The DN mutant then out-competes the wt protein(s) 
when over-expressed, thus interrupting the physiological pathways and allowing the 
study of specific gene products as well as protein-protein interactions (Figure 1.6). 
 Well-known examples are transcription factors (TF). If the DNA-binding domain is 
intact, but the activation domain is non-functional, the mutant TF inhibits wt function 
by occupying the binding site, which prevents wt TF engagement, but does not activate 
transcription. Another example could be a protein that acts in a multimeric complex. 
The DN mutant still allows partial complex formation, but interferes with the execution 
of downstream functions. Thus, DN proteins may affect protein interactions as well as 
enzymatic functions. 
 A DN mutant can induce the same phenotype as the deletion of that gene. However, 
investigation of deletion mutants of essential genes requires propagation on a trans-
complementing cell line. This is not necessary for DN mutants. Conditionally regulated 
DN mutants, integrated into the viral genome, circumvent this problem. Viruses are 
easily produced, and expression of the DN protein is induced on demand, enabling to 
study the function of the wt counterpart. Null-mutants only reveal the first dominant 
role of a protein. DN alleles, in contrast, have the potential to arrest viral pathways at 
different stages, thereby addressing multiple essential functions of a protein [reviewed 
in 117]. Therefore, DN mutants of important viral genes with specific and strong 
inhibitory activity are very valuable for both basic and applied research. 
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Figure 1.6: Inhibitory principle of DN proteins 
(A) A mutation (red arrowhead) in the catalytic domain of an enzyme may allow substrate 
binding, but no conversion. Alternatively, a DN mutation does not permit binding of another 
subunit of a multimeric complex. (B) A DN transcription factor (TF) bound to DNA blocks the 
binding site for the wt TF, preventing gene expression. (C) Schematic illustration of a 
phosphorylation reaction which depends on substrate binding and homo-dimerisation of the 
membrane protein. A DN mutation may prevent substrate binding or result in irreversible 
substrate binding. Inactivation of the active site of one of the homo-dimers blocks 
phosphorylation of the target molecule. Grey bar, plasma membrane. (D) Incorporation of a 
conformationally altered subunit prevents assembly of a homotypic multimeric complex. 
Adapted from [117]. 
 
 
1.3.2 Identification of DN mutants 
 Isolation and characterisation of DN alleles became a standard procedure in 
genetics. Using in-depth functional knowledge and detailed experimental information 
regarding protein structure, such inhibitory mutants can be created by targeted 
introduction of crucial, but subtle mutations or by deleting a domain that represents an 
independent folding entity [reviewed in 58, and 117]. However, so far such data are 
limited for the majority of herpesvirus proteins, impeding a knowledge-based 
construction of DN mutants. Consequently, the entire coding sequence of a target gene 
needs to be subjected to a random mutagenesis to identify potential DN candidates [34, 
97, 130, 141]. A standard method for random mutagenesis is the application of 
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transposons (Tn), mobile genetic elements that are randomly inserted into target DNA 
[36].  
 
Flp
no progeny
43 °C
30 °C
……
BAC GoI
BAC GoI
BAC GoI
Flp
BAC GoI BAC GoI
Flp
no progeny
43 °C
30 °C
BAC GoI
BAC GoI
BAC GoI
Flp
BAC GoI BAC GoI
……
BA
 
Figure 1.7: Two-step screening approach for the identification of viral DN alleles 
(A) Illustration of the cis-complementation assay. Shuttle plasmids containing individual 
mutants of the gene of interest (GoI) generated by transposon mutagenesis (yellow box with 
black line) are inserted into an MCMV BAC lacking this gene by Flp-mediated recombination 
between FRT sites (grey arrowhead) at 30 °C. Flp recombinase is expressed from a temperature-
sensitive plasmid, which is lost at 43 °C. Transfection of fibroblasts with BAC DNA results 
either in viral progeny or failure in reconstitution, which indicates essential sites. (B) Scheme of 
the inhibitory assay. Same principle as in (A), but using a wt MCMV BAC as acceptor for the 
shuttle plasmid. Failure in reconstitution indicates inhibitory regions. Figure was reproduced 
and modified from [97]. 
 
 For comprehensive mutagenesis of a single viral gene, the open reading frame 
(ORF) is subcloned and the Tn mutagenesis performed on plasmid basis. The modified 
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plasmids are inserted individually into a BAC deficient for this gene and the targeting of 
essential and non-essential sites is identified by its ability to restore viral reconstitution. 
Loss-of-function mutants are then tested in a similar screen for their potential to inhibit 
the wt protein function by using a wt BAC as acceptor (Figure 1.7). 
 
 
1.4 Aims 
Inactivation of gene products by DN mutants is a valuable tool to assign functions to 
yet uncharacterised proteins, to map protein-protein interactions or to dissect 
physiological pathways. Detailed functional and structural knowledge about the target 
protein would allow the construction of inhibitory mutants by targeted mutagenesis. 
Yet, such data are limited for the majority of viral proteins, so that the target gene needs 
to be subjected to random mutagenesis to identify potential DN mutations. However, for 
herpesviruses the random mutagenesis requires a two-step screening approach which is 
time-consuming and labour-intensive. Thus, new approaches are called for which 
reduce screening efforts or enable faster screenings. 
Analysis of numerous mutants derived from a random mutagenesis of the essential 
MCMV protein pM53 revealed an accumulation of inhibitory mutations in two of the 
four conserved regions (CRs) [95, 130] and that the homologous proteins could not 
complement each other [152], suggesting sub-family specific features. Based on these 
data we hypothesised that it should be possible to construct pM53 DN mutants by 
targeted mutagenesis of the CRs, which were either replaced by the homologous domain 
of another pUL31 family member (domain shuffling) or removed by deletion (domain 
deletion). The inhibitory potential of the resulting pM53 mutants was to be analysed in 
the viral context using conditional expression.  
A further aim of this study was the establishment of an assay for the identification of 
inhibitory alleles of MCMV genes, which is suitable for high-throughput screening. The 
basis for this assay was the assumption that the Flp-mediated recombination of an 
MCMV BAC with a shuttle plasmid could occur in permissive host cells instead of 
E. coli. To circumvent the two-step screening, first an MCMV BAC lacking the 
essential gene to be tested could serve as acceptor genome which allows the 
identification of non-complementing mutations. The resulting non-functional mutants 
27 
 
 
Introduction 
were then to be discriminated from the DN mutants using a wt MCMV genome as 
acceptor that lacks an essential viral feature which cannot be trans-complemented.  
Finally, the new assay system was to be applied to test a set of pM99 mutant. Its 
homologues have been shown to be involved in secondary envelopment of herpesviral 
capsids [6, 31, 161]. To confirm this role in MCMV, the biological and biochemical 
properties of pM99, including its essentiality, were to be studied first.  
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2 MATERIALS AND METHODS 
 
2.1 Materials  
2.1.1 Devices 
 Typhoon 9400 Amersham Bioscience, Freiburg, D 
 Tissue cell culture lamina flow BDK, Sonnenbühl-Genkingen, D 
 Centrifuge Avanti™ J-20 XP Beckman Coulter, Krefeld, D 
 Optima™ L-80 XP Ultracentrifuge Beckman Coulter, Krefeld, D 
 PCR machine TGradient Biometra, Göttingen, D 
 Photo documentation apparatus (Eagle Eye) Bio-Rad, München, D 
 Mini-PROTEAN® 3 Cell Bio-Rad, München, D 
 Trans-Blot™ SD Semi-Dry Electrophoretic  
      Transfer cell Bio-Rad, München, D 
 Axiovert 200M (confocal microscope) Carl Zeiss, Jena, D 
 Axiovert 25 (phase contrast microscope) Carl Zeiss, Jena, D 
 Econo-Submarine Electrophoresis System C.B.S., Del Mar, CA, USA 
 pH meter 430 Corning, Miami, FL, USA 
 Bio-Photometer Eppendorf, Hamburg, D 
 Centrifuge 5417 R Eppendorf, Hamburg, D 
 Thermomixer 5436 Eppendorf, Hamburg, D 
 Branson Digital Sonifier® W-250D Heinemann Ultraschall- und  
  Labortechnik, Schwäbisch Gmünd, D 
 Incubator B5050E Heraeus, Hanau, D 
 Incubator BB16CU Heraeus, Hanau, D 
 Multifuge 3 S-R Heraeus, Hanau, D 
 Water Bath F10 Julabo, Seelbach, D 
 Amaxa® 4D-Nucleofector™ System  
      with 96-well Shuttle™ Device Lonza, Cologne, D 
 Crosslinker BLX-254 MS Laborgeräte, Wiesloch, D 
 Developing machine Optimax TR MS Laborgeräte, Wiesloch, D 
 Olympus IX17 (fluorescence microscope) Olympus, Hamburg, D 
 NanoDrop™ ND-1000 Spectrophotometer Peqlab, Erlangen, D 
 LightCycler® 2.0 Roche, Mannheim, D 
 Bacterial shaker Certomat R BS-1 Sartorius, Göttingen, D 
 CASY® cell counter Schärfe System, Reutlingen, D 
 Hybridisation Oven 612 UniEQuip, Martinsried, D 
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2.1.2 Consumables 
 Cell culture dishes (Ø 6 cm, Ø 10 cm) Becton Dickinson, Heidelberg, D 
 Cell culture dishes (Ø 14,5 cm) Sarstedt, Nümbrecht, D 
 Cell culture plates (6-, 12-, 48-, 96-well) Becton Dickinson, Heidelberg, D 
 Cell scraper (25 cm, 39 cm) Costar, Bodenheim, D 
 Combitips plus (5 mL, 10 mL) eppendorf, Hamburg, D 
 CryoTube™ Vials nunc, Langenselbold, D 
 Electroporation cuvettes Bio-Rad, München, D  
 Falcon conical tubes (15 mL, 50 mL) Becton Dickinson, Heidelberg, D 
 Gene Pulser® Cuvettes Bio-Rad, München, D 
 Hybond™-N+ Nylon membrane GE Healthcare, Freiburg, D 
 Hybond™-P PVDF Transfer membrane GE Healthcare, Freiburg, D 
 Hyperfilm™ ECL™ detection film GE Healthcare, Freiburg, D 
 Pipettes (2 mL, 5 mL, 10 mL, 25 mL) Sarstedt, Nümbrecht, D 
 Photometer cuvettes Brand, Wertheim, D 
 Reaction tubes (0.5 mL, 1.5 mL, 2 mL) eppendorf, Hamburg, D 
 Whatman blotting paper (0.7 mm) Macherey-Nagel, Düren, D 
 LightCycler® Capillaries (20 µL) Roche, Mannheim, D 
 
2.1.3 Reagents  
 If not listed below, reagents were purchased from Invitrogen (Karlsruhe, D), Merck 
(Darmstadt, D), Roth (Karlsruhe, D) or Sigma-Aldrich (Steinheim, D)  
 ammonium sulfate (> 99.5%, p.a.) Fluka Chemie, Buchs, CH 
 Bacto™ Agar Becton Dickinson, Heidelberg, D 
 Bacto™ Tryptone Becton Dickinson, Heidelberg, D 
 Bacto™ Yeast Extract Becton Dickinson, Heidelberg, D 
 calf intestinal alkaline phosphatase (CIP) NEB, Frankfurt/Main, D 
 Difco™ MacConkey Agar Base Becton Dickinson, Heidelberg, D 
 DNA ladder (100 bp, 1 kb) NEB, Frankfurt/Main, D 
 DNA polymerase I (Large Klenow fragment) NEB, Frankfurt/Main, D 
 EDTA (p.a.) VWR, Darmstadt, D 
 FCS PAN-Biotech, Aidenbach, D 
 FuGene Promega, Madison, USA 
 MOPS (≥ 99%) Fluka Chemie, Buchs, CH 
 dNTP mix NEB, Frankfurt/Main, D 
 Prestained Protein Marker Fermentas, St. Leon-Rot, D 
 Protease Inhibitor Cocktail Tablets Roche, Mannheim, D 
 restriction enzymes & buffers NEB, Frankfurt/Main, D 
 sodium dodecyl sulfate (p.a.) SERVA, Heidelberg, D 
 SuperFect® Transfection Reagent Qiagen, Hilden, D 
 T4 DNA ligase NEB, Frankfurt/Main, D 
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2.1.4 Commercially available kits 
 Amaxa® Cell Line 96-well 
      Nucleofector® Kit SG Lonza, Cologne, D 
 DIG Easy Hyb Granules Roche, Mannheim, D 
 DIG Luminescent Detection Kit Roche, Mannheim, D 
 DNeasy™ Blood and Tissue Kit Qiagen, Hilden, D 
 ECL Plus™ Western Blotting Detection   
      System GE Healthcare, Freiburg, D 
 Expand High Fidelity PCR System Roche, Mannheim, D 
 GFX™ Micro Plasmid Prep Kit GE Healthcare, Freiburg, D 
 GFX™ PCR and DNA Gel Band   
      Purification Kit GE Healthcare, Freiburg, D 
 NucleoBond® PC100 Plasmid DNA  
      Purification Kit Macherey-Nagel, Düren, D 
 PCR DIG Probe Synthesis Kit Roche, Mannheim, D 
 QIAquick Gel Extraction Kit Qiagen, Hilden, D 
 Superscript™ RNase H – Reverse 
       Transcriptase Invitrogen, Karlsruhe, D 
 
 
2.1.5 Plasmids 
Table 2.1: Commercially available and published plasmids 
Name Comments 
pCAGGS-Flpe Gene Bridges GmbH, Heidelberg, D; expression plasmid for enhanced 
Flp recombinase (Flpe) [24] 
pCP20 [30]; encodes Flp recombinase, contains a temperature sensitive ori 
pSC101 
pEF5/FRT-V5-
DEST 
Invitrogen 
pENTR11 Invitrogen 
pIRES2-AcGFP1 Clontech Laboratories, Inc. 
pLitmus28 New England Biolabs 
pL-M53 [95] 
pOriR6K-zeo [22]; expression vector containing the R6K origin permitting plasmid 
replication only in PIR1 bacteria [77] and a gene conferring resistance 
to zeocin 
pO6-ie-M50 [22]; constitutive expression of pM50, original name pOriR6K-zeo-ie-
M50 
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Table 2.1: Commercially available and published plasmids, continued 
Name Comments 
pO6-ie-M53 i46, 
i104, i115, i128, 
i146, i207, i212, 
i220, i313, s168 
[95]; constitutive expression of pM53 and indicated pM53 mutants, 
original name of first plasmid pOriR6K-zeo-ie-M53 
pO6-ie-M666 [152]; encodes a pM53 mutant with CR2-4 exchanged for CR2-4 of 
MHV68 pORF69 
pOriR6K-zeo-MPPP [152]; encodes a pM53 mutant with CR2-4 exchanged for CR2-4 of 
PrV pUL31 
pO6T-M53s309 [130]; encodes the truncated mutant pM53 s309 
pO6-ie-FlagM53 [95]; constitutive expression of Flag-tagged pM53 
pO6-SVTe [142]; vector containing the “empty” dox-inducible expression cassette 
pO6-SVT-M53 [130]; dox-inducible expression of pM53 
pO6-SVT-Flag-∆N-
s309 
[130]; contains an M53 mutant which lacks the N-terminal Sak epitope 
that is recognised by the polyclonal anti-M53 antiserum 
pO6T-C-M53 
pO6T-N-M50 
pO6T-N-M50DM 
[152]; constitutive expression of BlaC-tagged pM53, BlaN-tagged 
pM50 and the BlaN-tagged, pM53 binding deficient mutant pM50DM 
 
 
 
Table 2.2: Plasmids constructed during this study 
All pO6-derived plasmids (including the pDNS vectors) were propagated in E. coli PIR1, all 
other plasmids in E. coli DH10B. During plasmid construction, DNA fragments obtained by 
endonuclease digest were referred to according to their size, beginning with fragment A (fraA) 
for the biggest fragment. The primers referred to are listed in the Supplement, Table 6.3. 
Name 
(Resistance) 
Comments 
pDEST-pac 
(amp) 
generated by inserting the amplicon PCR-MCMVpac (PCR on pSM3fr-
Δ1-16-FRT using primer pair 34/35) into pEF5/FRT-V5-DEST after 
treatment with NdeI/RsrII 
pDEST-pac- 
M53, i115, i128, 
i146, i207, i220, 
i313, s309 
constitutive expression of pM53 mutants; 
The indicated M53 genes were excised from the pO6-ie-derived vector and 
inserted into pENTR11 using KpnI/NotI. All genes were transferred from 
the pENTR11 vector into pDEST-pac employing the LR reaction of the 
Gateway system. 
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Table 2.2: Plasmids constructed during this study, continued 
Name 
(Resistance) 
Comments 
pDNS-M99F 
(kan) 
constitutive expression of Flag-tagged pM99 under control of PCMV; 
generated by insertion of pMA-T-M99F fraB (synthesised by GeneArt, 
Invitrogen) into pO6-A5-DNS-Che after NheI/SalI treatment  
pDNS-M99F-
igfp 
(kan) 
constitutive expression of Flag-tagged pM99 under control of PCMV, IRES-
coupled GFP expression; generated by ligation of pDNS-M99F fraA and 
pIRES2-AcGFP1 fraB after treatment with NotI/SalI 
pDNS-M99-igfp 
(kan) 
constitutive expression of pM99 under control of PCMV; 
generated by insertion of the NheI/SalI treated amplicon PCR-M99 (PCR 
on pDNS-M99F using primer pair 27/28) and fraB of NotI/SalI cleaved 
pIRES2-AcGFP1 into NheI/NotI opened pDNS-M99F 
pDNS-PM99F-
igfp 
(kan) 
constitutive expression of Flag-tagged pM99 under control of PM99; 
generated by insertion of the NheI/PacI treated amplicon PCR-P(M99) 
(PCR on pSM3fr-Δ1-16-FRT using primer pair 36/37) into 
NheI/PacI opened pDNS-M99F-igfp 
pDNS-PM99-
igfp 
(kan) 
constitutive expression of pM99 under control of PM99; 
generated by insertion of the NheI/SalI treated amplicon PCR-M99 (PCR 
on pDNS-M99F using primer pair 27/28) and NheI/PacI treated amplicon 
PCR-P(M99) (PCR on pSM3fr-Δ1-16-FRT using primer pair 36/37) 
into PacI/SalI opened pDNS-M99F-igfp 
pDNS-
PM99∆Gly2-igfp 
(kan) 
constitutive expression of pM99 lacking the N-terminal Gly under control 
of PM99; generated by insertion of the PCR-amplified M99 amplicon (PCR 
on pDNS-PM99-igfp using primer pair 29/28) into pDNS-PM99-igfp fraA 
by treatment with NheI/SalI 
pDNS-
PM99∆M94-igfp 
(kan) 
constitutive expression of pM99 lacking aa 22-43 under control of PM99; 
generated by insertion of PacI-treated PCR-5’-∆M94 (primer pair 36/30) 
and SalI-treated PCR-3’-∆M94 (primer pair 30/28) into pDNS-PM99-igfp 
opened with PacI/SalI (fraA), PCR on pDNS-PM99-igfp 
pDNS-
PM99∆AC-igfp 
(kan) 
constitutive expression of pM99 lacking aa 43-55 under control of PM99; 
generated by insertion of PacI-treated PCR-5’-∆AC (primer pair 36/32) 
and SalI-treated PCR-3’-∆AC (primer pair 33/28) into pDNS-PM99-igfp 
opened with PacI/SalI (fraA), PCR on pDNS-PM99-igfp 
pO6-A5-DNS-
Che 
(kan) 
constitutive expression vector; assembled from pIRES-Che-pA (provided 
by Sigrig Seelmeir) fraA and pDEST-pac fraB following NdeI/RsrII 
cleavage; the resulting plasmid was cut with PacI, blunted using T4 DNA 
polymerase, re-ligated, cleaved with AfeI/MluI and unified with 
pO6-A5-CMVgfp (provided by Simone Boos) fraA treated with the same 
enzymes 
pO6-BlaC-
M53Δ2 
(zeo) 
constitutive expression of BlaC-tagged pM53Δ2; 
generated by insertion of pO6-SVT-M53∆2 fraB into pO6T-C-M53 by 
treatment with BsiWI/PshAI 
33 
 
 
Material and Methods 
Table 2.2: Plasmids constructed during this study, continued 
Name 
(Resistance) 
Comments 
pO6-BlaC-
M53Δ3 
(zeo) 
constitutive expression of BlaC-tagged pM53Δ3; 
generated by insertion of pO6-SVT-M53∆3 fraB into pO6T-C-M53 by 
treatment with PshAI/PstI 
pO6-BlaC-
M53s309 
(zeo) 
constitutive expression of BlaC-tagged truncated mutant pM53s309; 
generated by insertion of pO6T-M53s309 fraB into pO6T-C-M53 by 
treatment with NotI/SacII 
pO6-ie-M53Δ2 
(zeo) 
constitutive expression of pM53Δ2; 
generated by insertion of AscI/StuI excised fraB of pO6-SVT-M53∆2 into 
AscI/HpaI treated pOriR6K-zeo 
pO6-ie-
FlagM53s168 
(zeo) 
constitutive expression of Flag-tagged truncated mutant pM53s168; 
generated by insertion of pO6-ie-FlagM53s168 fraB into pO6-ie-FlagM53 
by treatment with Acc65I/BspEI 
pO6-ie-
FlagΔNΔ2 
(zeo) 
 
constitutive expression of Flag-tagged pM53Δ2 lacking the epitope 
recognised by the α-M53 antiserum; 
generated by insertion of the PCR-amplified Flag-tag containing amplicon 
(primer pair 06/07 on pO6-SVT-Flag-∆N-s309) into pO6-ie-M53Δ2 by 
treatment with KpnI/SalI 
pO6-ie-
FlagΔNΔ2A, 
FlagΔNΔ2B, 
FlagΔNΔ3, 
FlagΔNM6MM, 
FlagΔNMM6M, 
FlagΔNMMM6 
(zeo) 
constitutive expression of Flag-tagged pM53 mutants lacking the epitope 
recognised by the α-M53 antiserum; 
The M53 mutant genes were transferred from the conditional pO6-SVT-
backbone by excision with AscI/StuI and insertion into the AscI/HpaI 
treated pOriR6K-zeo vector. The Sak epitope was deleted by inserting the 
PCR-amplified Flag-tag containing amplicon (primer pair 06/07 on pO6-
SVT-Flag-∆N-s309) by treatment with KpnI/SalI. 
pO6-ie-M56 constitutive expression of pM56;  
The M56 ORF was PCR-amplified in fragments from pSM3fr-16FRT17 
using primer pairs 17/18 (PCR-M56-1, AgeI/KpnI), 19/20 (PCR-M56-2, 
AgeI/HindIII), 21/22 (PCR-M56-3, BsiWI/BamHI) and 23/24 
(PCR-M56-4, BsiWI/NsiI). Each amplicon was inserted into into 
pLitmus28 after cleavage with the indicated enzymes, giving rise to 
pL-M56-x. pL-M56-2 fraA was ligated with pL-M56-3 fraB after 
treatment with BsiWI/SacII, giving rise to pL-M56-23. Finally, 
BspEI/BspMI treated pL-M56-23 fraB and BspMI/NsiI treated pL-M56-4 
fraB were inserted into spEI/NsiI opened pL-M56-1, giving rise to 
pL-M56. pL-M56 fraB and pOriR6K-zeo-MPPP [152]were ligated after 
cleavage with KpnI/NsiI. 
pO6-ie-M99Flag 
(zeo) 
constitutive expression of Flag-tagged pM99; generated by insertion of 
PCR-M99Flag (PCR on pSM3fr-Δ1-16-FRT using primer pair 25/26) into 
pOriR6K-zeo after treatment with KpnI/NotI 
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Table 2.2: Plasmids constructed during this study, continued 
Name 
(Resistance) 
Comments 
pO6-SVT-
M53∆2 
(zeo) 
dox-inducible expression of pM53∆2;  
generated by insertion of AscI cleaved PCR-5’-2A (primer pair 09/10) and 
PstI cleaved PCR-3’-2B (primer pair 14/12) into pO6-SVT-M53 opened 
by AscI/PstI, PCR on pO6-SVT-M53  
pO6-SVT-
M53∆2A 
(zeo) 
dox-inducible expression of pM53∆2A;  
generated by insertion of AscI cleaved PCR-5’-2A (primer pair 09/10) and 
PstI cleaved PCR-3’-2A (primer pair 11/12) into pO6-SVT-M53 opened 
by AscI/PstI, PCR on pO6-SVT-M53  
pO6-SVT-
M53∆2B 
(zeo) 
dox-inducible expression of pM53∆2B;  
generated by insertion of AscI cleaved PCR-5’-2B (primer pair 09/13) and 
PstI cleaved PCR-3’-2B (primer pair 14/12) into pO6-SVT-M53 opened 
by AscI/PstI, PCR on pO6-SVT-M53 
pO6-SVT-
M53∆3 
(zeo) 
dox-inducible expression of pM53∆3;  
generated by insertion of AscI cleaved PCR-5’-3 (primer pair 09/15) and 
PstI cleaved PCR-3’-3 (primer pair 16/12) into pO6-SVT-M53 opened by 
AscI/PstI, PCR on pO6-SVT-M53 
pO6-SVT-
M6MM 
(zeo) 
dox-inducible expression of pM6MM;  
The fraB of pMA-CR2_M6MM (synthesised by GeneArt, Invitrogen) was 
inserted into pL-M53 after treatment with BglII/SacII, giving rise to 
pL-M6MM. The M6MM fragment (fraB) was excised using AscI/StuI and 
ligated into the AscI/HpaI treated pO6-SVTe. 
pO6-SVT-
MM6M 
(zeo) 
dox-inducible expression of pMM6M;  
The fraB pMA-CR3_ORF69 (synthesised by GeneArt, Invitrogen) was 
ligated into pL-M53 after treatment with PmlI/PstI, giving rise to 
pL-MM6M. The AscI/PvuII excised fraB of pL-MM6M was inserted into 
AscI/HpaI treated pO6-SVTe. 
pO6-SVT-
MMM6 
(zeo) 
dox-inducible expression of pMMM6;  
The PCR-amplified N-terminal two thirds of the M53 ORF (primer pair 
03/04 on pO6-ie-M53) were inserted into pL-M53 after treatment with 
BglII/XhoI, giving rise to pL-MMM. pL-M666 was generated by inserting 
pO6-ie-M666 fraB into pL-M53 by treatment with SalI/XbaI. The XhoI 
recognition site in pL-M666 was removed by cleavage with NotI/XbaI and 
re-ligation subsequent to blunting using the Klenow fragment of DNA 
polymerase I, giving rise to pL-M666∆X. The CR4 of MHV68 ORF69 
PCR-amplified (primer pair 05/08 on pL-M666∆X), cleaved with 
PvuII/XhoI and ligated with the StuI/XhoI treated pL-MMM, giving rise to 
pL-MMM6. Finally, the AscI/StuI excised fraB of pL-MMM6 was inserted 
into AscI/HpaI treated pO6-SVTe. 
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2.1.6 Bacterial artificial chromosomes 
Table 2.3: Published BACs and BACs available in the lab 
Name Comments 
pSM3fr-16FRT17 [23]; wt MCMV genome with an FRT site inserted between 
genes m16 and m17, BAC-derived virus has wt growth 
properties 
pSM3fr-Δ1-16-FRT [97]; MCMV with ORFs 1 to 16 deleted, BAC-derived virus 
has wt-like growth properties  
pSM3fr-ΔM53 [95]; MCMV with M53 deleted 
pSM3fr-ΔM53-
EM53K128A 
[95]; MCMV with an M53 gene having a point mutation at 
position 128 of the M53 protein resulting in attenuated 
growth 
pSM3fr-Δm157rekegfp [145]; MCMV with m157 replaced by the egfp gene 
pSM3fr-Δ1-16-FRT-
ΔM56 
MCMV genome lacking ORF M56; provided by Sigrid 
Seelmeir 
pSM3fr-Δ1-16-FRT-
ΔM104 
MCMV genome lacking ORF M104; provided by Sigrid 
Seelmeir 
pSM3fr-Δ1-16-FRT-
SCPiChe 
mCherry expression coupled by an IRES element to SCP 
expression; provided by Sigrid Seelmeir 
 
 
Table 2.4: BACs constructed during this study 
Name 
(Resistance) 
Comments 
SVT-Δ2 
SVT-Δ2A 
SVT-Δ2B 
SVT-Δ3 
SVT-M6MM 
SVT-MM6M 
SVT-MMM6 
(cam, zeo) 
exemplified for SVT-∆2: generated by ectopic insertion of 
pO6-SVT-M53Δ2 into pSM3fr-Δ1-16-FRT via the Flp/FRT system, 
dox-inducible expression of pM53Δ2 in addition to wt pM53; 
other listed BACs were constructed similarly 
∆pac 
(cam, kan) 
generated by homologous recombination to replace the packaging 
signal of pSM3fr-Δ1-16-FRT by a kan resistance cassette 
∆M99 
(cam, amp) 
generated by homologous recombination to replace the M99 ORF of 
pSM3fr-Δ1-16-FRT by an amp resistance cassette 
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Table 2.4: BACs constructed during this study, continued 
Name 
(Resistance) 
Comments 
SCPiChe-∆M99 
(cam, amp) 
generated by homologous recombination to replace M99 ORF of 
pSM3fr-Δ1-16-FRT-SCPiChe by an amp resistance cassette 
∆M99EPM99 
(cam, amp, kan) 
generated by ectopic insertion of pDNS-PM99-igfp into the ∆M99 
BAC via the Flp/FRT system, constitutive pM99 expression under control 
of PM99 
∆M99EPM99F 
(cam, amp, kan) 
generated by ectopic insertion of pDNS-PM99F-igfp into the ∆M99 
BAC via the Flp/FRT system, constitutive pM99F expression under 
control of PM99 
 
 
2.1.7 Viruses  
 The viruses used in this study were derived from the BACs listed in Table 2.3 and 
Table 2.4. For virus reconstitution, BAC DNA was transfected into murine fibroblasts 
as described in section 2.7.1. Viruses were called as their respective BACs tagged with 
an “MCMV” prefix. Further viruses used were MCMV-SVT-M53 [MCMV-SVT-M53R 
in 130] and MCMV-SVT-gfpSCP [18, SCP-GFP-2 in 142]. 
 
2.1.8 Oligonucleotides  
 All oligonucleotides were synthesised by metabion GmbH (Martinsried, D). 
Oligonucleotides longer than 33 nt were HPLC purified. Standard primers for 
sequencing were provided by GATC Biotech (Konstanz, D). For sequences, refer to 
supplementary tables in section 1.1. 
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2.1.9 Antibodies  
Table 2.5: List of primary antibodies and antisera 
Antibody/ 
antiserum 
Description Comments/Source 
CROMA101 
(α-pp89) 
mouse monoclonal antibody provided by S. Jonjic, University 
of Rijeka, Croatia 
α-Flag M2 mouse monoclonal antibody Sigma-Aldrich 
α-Flag M2 HRP mouse monoclonal antibody Sigma-Aldrich 
α-GAPDH rabbit monoclonal antibody Cell Signaling 
α-HA (3F10) rat monoclonal antibody Roche 
α-M50 rabbit polyclonal immune serum [118] 
α-M53 rat polyclonal immune serum [95] 
α-M991 
 
rabbit polyclonal immune serum Eurogentec GmbH, Cologne, D 
α-MCP rat polyclonal immune serum [142] 
1 #700: raised against the epitope spanning aa 98-112 (C+SAKNGAGVKKKVRAL) 
  #701: raised against the epitope spanning aa 12-33 (DSLKDSSGRRVDLGT+C) 
The terminal cysteines were introduced to couple the epitopes to the adjuvant. 
 
 
 Horseradish peroxidase (HRP) coupled secondary antibodies (directed against 
mouse, rabbit and rat) were purchased from Dianova (Hamburg, D). Alexa Fluor 
conjugated secondary antibodies (directed against mouse, rabbit and rat) were obtained 
from MoBiTec (Göttingen, D). 
 Primary antibodies were used in 1/1,000 dilution for Western blot analysis and 
1/100 for immunofluorescence (IF). Secondary antibodies were diluted 1/8,000 for 
Western blots and 1/150 for IF. 
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2.2 Bacterial culture  
 Bacteria (Table 2.6) were grown either in suspension or on agar plates using Luria-
Bertani (LB) medium (10 g/L Bacto tryptone, 5 g/L Bacto yeast extract, 5 g/L NaCl) or 
LB agar (15 g/L). The respective antibiotics (Table 2.7) were added for plasmid and/or 
BAC selection. E. coli DH10B and PIR1 were grown at 37 °C, whereas SW102 were 
grown at 32 °C. Cell density was determined by measuring the optical density of the 
bacterial suspension at 600 nm (OD600).  
 For long-term availability of the bacteria bearing the DNA of interest, glycerol 
stocks were prepared by suspending 600 µL of bacterial culture in 400 µL of 
50% glycerol to a final concentration of 20% (volume/volume) and stored at -80 °C. 
 
Table 2.6: Bacterial strains used during this study 
E. coli strain Genotype 
DH10B F− mcrA Δ(mrr−hsdRMS−mrcBC) Φ80lacZΔM15 ΔlacX74 recA1 
endA1 araD139 Δ(ara, leu) 7697 galU galK rpsL nupG λ− 
(Invitrogen, Karlsruhe, D) 
PIR1 F− Δlac169 rpoS(Am) robA1 creC510 hsdR514 endA recA1 
widA(ΔmluI)::pir-116 (Invitrogen, Karlsruhe, D) 
SW102 DH10B [λc1857 (cro-bioA)<>Tet] gal490 ΔgalK  
[181] 
 
Table 2.7: Commonly used antibiotic concentrations 
Antibiotic Concentration 
ampicillin (amp) 50 µg/mL in solution, 100 µg/mL in LB agar plates 
chloramphenicol (cam) 25 µg/mL 
kanamycin (kan) 50 µg/mL 
zeocin (zeo) 30 µg/mL 
 
2.2.1 Generation of electro-competent bacteria 
 Unless stated otherwise, all steps were performed at 4 °C or on ice. To prepare 
electro-competent E. coli strains DH10B and PIR1, 400 mL of LB were inoculated with 
1.5 mL of an overnight (o/n) culture and grown shaking at 37 °C to an OD600 ~ 0.5 
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(middle logarithmic phase). After reaching the desired cell density, the culture was 
chilled on ice for 30 min and centrifuged at 6,000 × g for 10 min (Beckman Coulter™ 
Avanti™, JLA 16.250). To remove all salt residuals, the pellet was washed once with 
200 mL pre-cooled dH2O and twice with 200 mL pre-cooled 5% glycerol using the 
same centrifugation parameters to collect the bacteria. Cells were then resuspended in 
10 mL of pre-cooled 10% glycerol and centrifuged at 3,500 rpm/2,600 × g for 15 min 
(Heraeus Multifuge 3 S-R). Finally, the volume of the cell pellet was estimated and 
resuspended in an equal volume of 10% glycerol Aliquots of 50 µL bacterial suspension 
were immediately frozen in liquid nitrogen and stored at -80 °C until usage. 
 Electro-competent E. coli SW102 were always prepared freshly on the day of 
transformation. For this, 50 mL LB were inoculated with 500 µL of an o/n culture and 
grown at 32 °C/160 rpm to an OD600 of 0.55 to 0.6. Aliquots of 4 mL were pelleted 
(eppendorf 5417 R, 5,000 rpm, 5 min) and washed twice with 1 mL ice-cold sterile, 
distilled water to remove any salt contaminants. Each aliquot of the electro-competent 
E. coli SW102 was resuspended in 80-120 µL ice-cold water and kept on ice until 
transformation.  
 
2.2.2 Transformation of electro-competent bacteria  
Bacteria to be transformed were thawed on ice, DNA was added to the cell 
suspension and the mixture was transferred to 2 mm electroporation cuvettes (Gene 
Pulser® Cuvette), which had been pre-cooled to -20 °C. Cells were electro-shocked at 
2.5 kV (25 µF/200 Ω) using the GenePulser Xcell™ (Bio-Rad, München, D), 
immediately diluted in 1 mL LB, incubated by shaking under non-selective conditions 
(pCP20-containing E. coli DH10B 30 °C, E. coli SW102 32 °C, otherwise 37 °C) for 
one hour, plated in 100 µL-aliquots on LB agar plates containing the appropriate 
antibiotic(s), and incubated at the appropriate temperature until colonies formed 
(usually o/n). 
 
2.2.3 Generation of chemically competent bacteria  
 Unless stated otherwise, all experimental steps were performed at 4 °C or on ice. 
50 mL LB medium containing appropriate antibiotic(s) was inoculated with 1 mL of an 
o/n pre-culture and grown shaking at 37 °C. At OD600 ~ 0.5 (logarithmic growth phase) 
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cells were harvested, chilled on ice for 5 min, centrifuged at 2,600 × g for 15 min 
(Heraeus Multifuge 3 S-R), and resuspended in 10 mL ice-cold buffer TfB I (100 mM 
RbCl2, 50 mM MnCl2, 30 mM KAc, 10 mM CaCl2, pH 5.8). Cell suspension was 
incubated on ice for 50 min, centrifuged as above and resuspended in 1 mL ice-cold 
buffer TfB II (10 mM MOPS (pH 7.0), 10 mM RbCl2, 75 mM CaCl2, 15% glycerol). 
Aliquots of 100 µL were immediately frozen in liquid nitrogen and stored at -80 °C.  
 
2.2.4 Transformation of chemically competent bacteria  
 Chemically competent cells were thawed on ice, 10 ng of the DNA to be 
transformed was added and the mixture incubated on ice for 30 min. After a heat shock 
at 42 °C for 45 seconds and incubation on ice for 2 min, 1 mL LB was added, and cells 
were incubated by shaking at 30 °C (pCP20-containing bacteria) or 37 °C for one hour. 
Cultures were plated in 100 µL aliquots on LB agar plates containing the appropriate 
antibiotic(s) and incubated at 30 °C or 37 °C o/n. 
 
 
2.3 Isolation and purification of nucleic acid 
2.3.1 Small scale isolation of plasmid DNA 
 Bacteria were cultivated o/n (o/n) on Luria-Bertani (LB) agar plates (10 g/L Bacto 
tryptone, 5 g/L Bacto yeast extract, 5 g/L NaCl, 15 g/L agar) containing the appropriate 
antibiotic(s) for selecting the plasmid of interest. For small scale plasmid (mini)-
preparation, single clones were picked to inoculate 3 mL LB containing the respective 
antibiotic(s) and grown at 37 °C/160 rpm o/n. Plasmid DNA was isolated based on the 
alkaline lysis principle using the GFX™ Micro Plasmid Prep Kit (GE Healthcare) 
according to the manufacturer's instructions. As a variant of the protocol, DNA was 
recovered from the DNA binding column in 75 µL Tris-HCl (pH 8.0). Five µL of the 
purified DNA was subjected to restriction pattern analysis (section 2.4.3). 
 
2.3.2 Large scale isolation of plasmid DNA 
 Plasmid DNA in high quantity was purified from 200 mL cultures that were either 
inoculated with a single colony from an LB agar plate or a scratch of a glycerol stock. 
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Plasmids were purified using the NucleoBond® PC100 Plasmid DNA Purification Kit 
(Macherey-Nagel) according to the manufacturer’s instructions. Dried DNA was 
dissolved in 150 µL Tris-HCl (pH 8.0) at 4 °C o/n and stored at -20 °C.  
 
2.3.3 Small scale isolation of BAC DNA 
 For small scale isolation of BAC DNA, 10 mL LB containing 25 µg/mL 
chloramphenicol were inoculated with a single colony of E. coli strain DH10B 
containing the respective BAC, incubated at 37 °C and 160 rpm o/n and bacteria were 
harvested by centrifugation at 2,600 × g for 15 min (Heraeus Multifuge 3 S-R). Cells 
were resuspended in 300 µL of QIAGEN Resuspension buffer P1 (20 mM Tris-HCl, 
10 mM EDTA, pH 8.0), lysed in 300 µL of buffer 2 (0.2 M NaOH, 1% SDS), and 
neutralised by addition of 300 µL of QIAGEN Neutralization Buffer P3 (3 M KAc, 
pH 4.8). Suspensions were incubated on ice for 10 min and centrifuged at 14,000 rpm 
(eppendorf 5417 R) for 5 min. Proteins were removed from the supernatants by 
extraction with an equal volume of phenol/chloroform. Following gentle rotation for at 
least 10 min and centrifugation at 14,000 rpm for 10 min (eppendorf 5417 R), BAC 
DNA was precipitated from the aqueous fraction by addition of 1 mL isopropanol and 
centrifugation at 14,000 rpm for 30 min (eppendorf 5417 R). DNA pellets were washed 
with 1 mL of 70% ethanol (room temperature), centrifuged for 10 min, and dried at 
45 °C until pellets became opaque. DNA was dissolved in 50 µL Tris-HCl containing 
100 µg/mL RNase H (pH 8.0) by gently shaking at 37 °C for 15 min and stored at 4 °C 
until use. The total volume of DNA solution was subjected to restriction pattern analysis 
(section 2.4.3). 
 
2.3.4 Large scale isolation of BAC DNA 
 Large amounts of BAC DNA were obtained from 200 mL bacterial cultures using 
the NucleoBond® PC100 Plasmid DNA Purification Kit (Macherey-Nagel) according 
to the manufacturer’s instructions. BAC DNA was eluted with elution buffer N5 pre-
heated to 50 °C and applied in two steps. Dried DNA precipitates were recovered in 
100 µL Tris-HCl (pH 8.0) at 4 °C o/n and stored at 4 °C. For handling solutions 
containing BAC DNA during or after the preparation, pipette tips were cut with a pair 
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of scissors to minimise shear forces during pipetting that might cause damage to the 
BAC molecules. 
 
2.3.5 DNA isolation from cultured mammalian cells  
 To obtain DNA from mammalian cells, approximately 1 × 106 cells were harvested, 
washed once with PBS and DNA was isolated using the DNeasy™ Blood & Tissue Kit 
(Qiagen) according to the protocol “Purification of total DNA from Animal Blood or 
Cells (spin-column protocol)”. Finally, DNA was eluted from the column in 100 µL 
ddH2O applied in two successive aliquots. 
 
2.3.6 RNA isolation from cultured cells 
Approximately 1 × 106 mammalian cells were harvested and total cellular RNA was 
purified using the RNeasy® Mini Kit (Qiagen) according to the protocol “Animal Cells, 
Spin”. RNA was eluted in 30 µL RNase-free water. 
 
2.3.7 Determination of DNA concentration and purity  
 To determine the concentration and purity of the isolated nucleic acid, the optical 
density (OD) was measured at 260 nm and 280 nm using a NanoDrop® ND-1000 
Spectrophotometer (peqlab Biotechnologie GmbH). The content was calculated as 
1 unit of OD260 equalling 50 µg/mL double stranded DNA or 40 µg/mL RNA, 
respectively. The ratio OD260/OD280 provided an estimation of the purity and should 
optimally range around 1.8 for a DNA and around 2.0 for an RNA solution.  
 
 
2.4 Analysis and manipulation of nucleic acid 
2.4.1 Reverse transcription of RNA 
To generate cDNA, purified RNA (Section 2.3.6) was reverse transcribed using the 
Superscript™ RNase H – Reverse Transcriptase (Invitrogen). For this, 500 ng RNA was 
mixed with 5 µM Oligo (dT)20 Primer (Invitrogen) and 1 mM dNTP mix in a final 
volume of 10 µL in RNase-free water. The reaction was incubated at 70 °C for 10 min 
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and cooled down on ice, before further components were added to the mixture: 4 µL 
First Strand Reaction buffer, 5 mM MgCl2, 10 mM DTT, 40 U RNasin and 1200 U 
Superscript Transcriptase in a final volume of 20 µL in ddH2O. The mixture was 
incubated at 50 °C for 60 min, followed by 5 min at 85 °C. Finally, the remaining RNA 
was removed by incubation with 5 U RNase H at 37 °C for 20 min. 
 
2.4.2 Polymerase chain reaction (PCR) 
Amplification of DNA fragments for cloning 
 To ensure high specificity of the PCR product without the need of optimising the 
protocol for each template/primer pair, a touch down programme was used. The PCR 
started at an annealing temperature equal or above the expected annealing temperature 
of the primers and was decreased by one degree in each of the first 17 cycles. The 
primers then bind to the template at the highest temperature least-permissive for 
unspecific annealing. Thus, the first amplicons are those with highest primer specificity, 
which in most cases cover the region of interest. Due to the exponential nature of the 
PCR, these products will out-compete any unspecific fragments to which the primers 
may bind when the PCR proceeds to the cycles with lower annealing temperatures. 
Lower annealing temperatures, however, favour a higher yield and therefore improve 
the productivity of the PCR [44].  
 In general, 50 µL PCR reaction mix consisted of 10-50 ng template DNA, 300 nM 
of each forward and reverse primer, 200 µM dNTP mix, 1/10 volume of 10x Expand 
High Fidelity reaction buffer including MgCl2 as well as 3 U of Expand High Fidelity 
PCR system Polymerase (Roche). When BAC DNA was used as template, proper 
aliquoting was ensured by vigorous vortexing for at least 30 seconds before pipetting it 
to the reaction mixture. The PCR mixes were prepared on ice. Primers are listed in the 
Supplement. 
 PCRs were performed in a Tgradient PCR machine (Whatman Biometra® GmbH). 
Presence and specificity of the amplicons was confirmed by subjecting 5 µL of the 
reaction mix to agarose gel electrophoresis (1% agarose, TAE; section 2.4.5). The 
remaining DNA was purified using the GFX PCR DNA and Gel Purification Kit (GE 
Healthcare) according to the manufacturer’s instructions or by ethanol precipitation 
(section 2.4.7). 
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Table 2.8: General Touch Down PCR programme 
Step Temperature Time  
1 Denaturation 95 °C 5 min  
2 Denaturation (Touch Down) 95 °C 30 s  
3 Annealing (Touch Down) 62-45 °C 30 s per cycle -1 °C 
4 Elongation (Touch Down) 72 °C 0.5-3 min1 17x back to step 2
5 Denaturation (amplification) 95 °C 30 s  
6 Annealing (amplification) 45 °C 30 s  
7 Elongation (amplification) 72 °C * 20x back to step 5
8 End-elongation 72 °C 5 min  
9 End 4 °C ∞  
1 The elongation time was adjusted to the length of each amplicon by assuming DNA 
polymerase activity of approximately 1,000 bp per minute. 
 
 
 Synthesis of Southern blot probes 
 To generate the probe used in the Southern blot analysis (section 2.4.12), PCR was 
performed on 50 ng of the pSM3fr-Δ1-16-FRT BAC as described above using the PCR 
DIG Probe Synthesis Kit (Roche) according to the manufacturer’s instructions. 
 
 Quantitative PCR 
 To quantify the viral genome load during infection, quantitative PCR (qPCR) with 
real-time detection (also called real-time PCR) was performed. For this, 5 µL (~ 200 ng) 
of PaeI digested sample DNA was added to 15 µL reaction mix consisting of 10 µL 
QuantiTect™ SYBR® Green PCR Master Mix (Qiagen), 1 µL DNase-free water and 
0.5 µM of each primer and PCRed according to the protocol in Table 2.4 on a Light 
Cycler (Roche), followed by melting curve analysis to confirm specific amplification. 
Relative quantification was performed based on normalisation to the gene of the 
lamin B receptor (lbr) according to the equation 
)()54(2 lbrctMctratio   
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Table 2.9: PCR programme for qPCR 
Step Temperature Time  
1 Denaturation 95 °C 10 min  
2 Denaturation  95 °C 10 s  
3 Annealing  58 °C 3 s  
4 Elongation  72 °C 10 s 45x back to step 2
 
 
2.4.3 Restriction enzyme digest 
 For restriction pattern analysis of the DNA, 5 µL of the plasmid mini-preparation, 
corresponding to approximately 300-600 ng DNA, was suspended with 1/10 of the 
recommended 10x reaction buffer, 1 mg/mL BSA (if required), at least 10 U (1 µL) of 
the appropriate restriction enzyme and ddH2O in a total volume of 20 µL and incubated 
for 1-2 hours at the recommended temperature. For preparative digestion of plasmid 
DNA for cloning, 1 µg of DNA was digested in a total volume of 40 µL for at least 3 
hours using the same conditions as above. 
 Restriction pattern analysis of BAC DNA was performed in a total volume of 60 µL 
(without BSA) or 70 µL (if BSA was required). For that, the recommended 10x reaction 
buffer as well as 10-50 U (1 µL) of the appropriate restriction enzyme were added to the 
50 µL BAC mini-preparations (section 2.4.3) and incubated at the appropriate 
temperature for at least 3 hours. For restriction pattern analysis of large scale BAC 
preparation, 2 µg of BAC DNA was digested in a total volume of 40 µL for at least 3 
hours using the same conditions as above. 
 
2.4.4 Buffer exchange 
PCR products and digested DNA were prepared for further processing by buffer 
exchange using the GFX™ PCR DNA and Gel Band Purification Kit (GE Healthcare) 
according to the manufacturer’s instructions. DNA was eluted in 20 µL Tris-HCl 
(pH 8.0). 
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2.4.5 Agarose gel electrophoresis 
 To analyse DNA fragments obtained by restriction enzyme digest, DNA was 
subjected to horizontal, non-denaturing agarose gel electrophoresis. Digested plasmid 
DNA as well as PCR products were separated on 1% agarose gels in TAE buffer 
(40 mM Tris-HCl, 20 mM acetic acid, 1 mM EDTA, pH 8.0) at a field strength of 
10-15 V/cm, whereas BAC DNA fragments were separated on 0.8% agarose gels in 
TBE  buffer (90 mM Tris, 90 mM boric acid, 2.5 mM EDTA, pH 8.0) at a field strength 
of 1.5-3 V/cm. DNA was visualised by addition of 1 µg/mL ethidium bromide to the 
gels and monitored using UV light in an Molecular Imager ChemiDoc XRS System 
(Bio-Rad Laboratories GmbH). Data were processed using the Quantity One 1-D 
Analysis Software. 
 
2.4.6 Isolation of DNA fragments from agarose gels 
 Following preparative restriction enzyme digestion, DNA fragments to be used for 
cloning were separated by agarose gel electrophoresis. The desired bands were excised 
and the DNA was purified using the Qiaquick Gel Extraction Kit (QIAGEN) according 
to the manufacturer’s instructions. To avoid damage to the DNA during excision, very 
weak high wave length UV light was applied to visualise the DNA bands (IL-350-L 
366 nm, Bachofer GmbH). 
 
2.4.7 Ethanol precipitation  
 To concentrate DNA, 1/10 volume of 3 M sodium acetate (pH 5.3) and 
three volumes ice-cold 100% ethanol were added to the DNA containing solution and 
incubated at -80 °C for 20 min. The mixture was centrifuged at 14,000 rpm and 4 °C for 
30 min (eppendorf 5417 R). The precipitated DNA was washed with an equal volume of 
70% ethanol and centrifuged again for 15 min. Ethanol was removed carefully; DNA 
pellets were air-dried at r/t and dissolved in 10 µL distilled water. 
 
2.4.8 De-phosphorylation of DNA ends 
 To prevent re-circularisation of linearised vector DNA, the 5’ phosphate groups of 
the free DNA ends were removed using calf intestinal alkaline phosphatase (CIP). 1 µg 
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linearised vector DNA was suspended in a total volume of 20 µL containing 1/10 
volume of the recommended 10x reaction buffer and 0.5 U CIP and incubated at 37 °C 
for 60 min. The de-phosphorylated vector was purified by agarose gel extraction 
(section 2.4.6).   
 
2.4.9 Blunting DNA ends 
 To allow ligation of DNA fragments with non-complementary ends, the DNA ends 
were blunted using either T4 DNA polymerase or the Klenow fragment of DNA 
polymerase I. Both enzymes possess polymerisation and 3’-5’ exonuclease, but not 
5’-3’ exonuclease activity. 
 For the blunting reaction, 1 µg DNA was incubated in a total volume of 20 µL 
containing 1 U of the polymerase and 1/10 volume of any of the supplied 10x restriction 
enzyme buffers supplemented with 33 µM of each dNTP. The reaction was incubated at 
12 °C (T4) or 25 °C (Klenow) for 15 min and inactivated by addition of 10 mM EDTA 
and heating at 75 °C for 20 min. 
 
2.4.10 Ligation of DNA fragments 
 To join DNA fragments covalently, 100 ng vector DNA was mixed with 300 ng of 
(each) insert fragment, 100 U (1 µL) T4 DNA ligase and 1/10 volume of the 10x T4 
ligase reaction buffer in a total volume of 20 µL. The reaction was incubated at 16 °C 
o/n. 1 µL of the ligation mix was used to transform electro-competent cells (section 
2.2.2). 
 
2.4.11 LR reaction (Gateway® system) 
An LR reaction was performed to transfer a gene from a Gateway® entry plasmid to 
a destination vector. To this end, 50-150 ng of entry (pENTR11) and destination 
(pEF5/FRT-V5-DEST) vector were mixed with 2 µL LR Clonase™ II enzyme mix 
(Invitrogen) in TE buffer (pH 8.0) in a final volume of 10 µL and incubated at 25 °C for 
60 min. The reaction was terminated by addition of 1 µL proteinase K solution 
(Invitrogen) and incubation at 37 °C for 10 min. Competent cells were transformed with 
1 µL of this reaction. 
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2.4.12 Southern blot analysis 
 To assess viral cleavage/packaging, 1.5×106 M2-10B4 were infected at an MOI of 
0.1, cells were harvested 48 hpi and total DNA was purified using the DNeasy™ Blood 
and Tissue Kit as described in section 2.3.5. Using 40 U ApaLI, 6 µg of the purified 
DNA was digested at 37 °C for 16 hours and separated by 0.8% agarose gel 
electrophoresis. Size markers were documented by photographing the gel next to a ruler 
before the gel was cut to minimal size for detection of the required bands. DNA was 
mobilised within the gel by incubation in 0.25 M HCl twice for 10 min followed by 
45 min in denaturation buffer (1.5 M NaCl, 0.5 M NaOH) and final incubation in 
neutralisation buffer (1 M Tris, 1.5 M NaCl, pH 7.4) for 30 plus 10 min. The gel was 
rinsed briefly with water between the buffer changes. 
 The mobilised DNA was then transferred to a positively charged nylon membrane 
(Hybond™-N+, GE Healthcare) by capillary force. For this, the gel was placed on two 
layers of blotting paper of the same width, which were soaked with 20x SSC (3 M 
NaCl, 0.3 M sodium citrate). The membrane in gel size was placed on top of the gel and 
overlaid with two blotting papers soaked in 20x SSC and two dry ones, all in gel size. A 
tower of paper towels was built on top of this, balanced and fixed by weight. Following 
o/n blotting, the construction was disassembled and the DNA cross-linked to the 
membrane using 0.125 J UV-light, while successful DNA transfer was confirmed by 
UV illumination of the gel. The membrane was then incubated in 20 mL hybridisation 
buffer (prepared from DIG Easy Hyb Granules, Roche, according to the manufacturer’s 
instructions) at 60 °C for at least three hours in a hybridisation oven. 
 The probe was generated by a PCR on pSM3fr-Δ1-16-FRT using primers Apa2-for 
and Apa2-rev (Table 6.3) and the amplicon purified using the GFX PCR DNA and Gel 
Band Extraction Kit (GE Healthcare). 1.25 µg of probe DNA was heated to 95 °C for 
10 min to separate the strands, added to the hybridisation buffer and hybridisation 
allowed at 60 °C o/n. 
 The following day, the membrane was washed twice for 5 min with washing buffer I 
(2% SSC, 1% SDS) at r/t and twice for 15 min with washing buffer II (0.5% SSC, 1% 
SDS) at 60 °C. Bound DIG labelled probe was visualized using the DIG Luminescent 
Detection Kit (Roche) and exposure to chemiluminescence films. For signal 
quantification, chemiluminescence emission was measured using a Typhoon scanner 
and the resulting image processed using the ImageQuant software (GE Healthcare). 
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2.4.13 DNA sequencing 
 The accuracy of the generated constructs was confirmed using the sequencing 
service of GATC Biotech (Konstanz, D). For this, 30 µL of DNA (70-100 ng/µL) 
together with 10 µM primer flanking the region of interest was sent for analysis on an 
ABI sequencer. 
 
 
2.5 BAC mutagenesis 
 The MCMV genome became accessible for directed mutagenesis after stably 
introducing a BAC cassette encoding a selection marker (chloramphenicol) and the 
replication origin of the fertility factor (F-factor) [107]. Since the genome contains 
repetitive sequences, it is maintained in an E. coli strain with disrupted recABCD 
recombination system such as DH10B to prevent genomic rearrangements. 
Furthermore, control of the F-factor replicon allows only one BAC copy per cell, 
reducing risk of homologous recombination between different genomes [48].  
 Nevertheless, due to their large size and the high frequency of restriction sites, 
classical cloning strategies are not suitable for BACs. 
 
2.5.1 Homologous recombination using linear DNA fragments 
To construct recombinant MCMV BACs, linear DNA fragments were used to 
replace the sequences of interest, thereby introducing a selection marker (Figure 2.1). 
The linear fragment contains a selection marker, such as a gene encoding galactokinase 
or an antibiotic resistance, and at both ends approximately 50 bp homologous to the 
sequences flanking the region of interest.  
The bacterial strain used for this, E. coli SW102, contains the temperature-inducible 
λ prophage recombineering system. Furthermore, the galactokinase gene has been 
deleted from the galactose operon has been modified. The galactokinase function can be 
added in trans, thereby restoring the ability to grow on galactose as carbon source 
[181]. 
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Figure 2.1: Homologous recombination using a linear PCR fragment 
Recombinase expression is induced by a heat-shock at 42 °C in E. coli SW102 harbouring the 
target BAC followed by transformation of a linear PCR fragment that encodes a genetic marker 
and contains homologies (H1 and H2) to the regions flanking the feature of interest (FoI). After 
transformation, bacteria are grown at 32 °C to avoid further recombination and mutants are 
enriched in the presence of selection pressure for the marker. 
 
 
 The recombination fragment was PCR-amplified (section 2.4.2) using pGPS1.1-
derived plasmids as template, the amplicon purified from the PCR mix (section 2.4.4), 
and the template DNA disintegrated by DpnI digest for at least 2 hours. The remaining 
DNA was precipitated (section 2.4.7) and dissolved in 10 µL ddH2O. 
 E. coli SW102 harbouring the BAC to be modified were grown at 32 °C to an OD600 
of 0.55-0.6. Half of the culture was transferred into a new flask and heat-shocked at 
42 °C for exactly 15 min to induce recombinase expression. The remaining culture was 
left at 32 °C as control. After 15 min, both cultures were cooled in an ice/water bath 
slurry, washed twice with cold ddH2O, and transformed (section 2.2.2) with 100 ng of 
the PCR amplicon prepared before.  
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2.5.2 Gene insertion by Flp recombinase 
 Insertion of viral genes into BACs to allow for cis-complementation was performed 
by Flp recombinase-mediated recombination between two FRT sites (Figure 2.2) [102]. 
One FRT site is located at a neutral position in the viral genome cloned as BAC, the 
second is found on a shuttle plasmid carrying the genetic elements to be inserted. The 
shuttle plasmid is derived from pOriR6K [22]. Replication of this plasmid requires the 
π-protein that is expressed by E. coli PIR1, but not by the DH10B strain [77]. Thus, the 
shuttle plasmid is lost in DH10B if it is not integrated into the BAC.  
 
BAC
30 °C
pCP20
shuttle
plasmid
Flp
recombinase
43 °CE.coli
BAC
pCP20
E.coli
shuttle
plasmid
 
Figure 2.2: Flp-mediated gene insertion 
E. coli DH10B are transformed with a shuttle plasmid containing an FRT site (grey arrowhead). 
A second FRT site is located in the BAC already contained in the bacteria. The shuttle plasmid 
is integrated into the BAC site-specifically upon expression of Flp recombinase from the pCP20 
plasmid, which is lost subsequently due to its temperature sensitive origin of replication. 
Bacteria carrying recombinant BACs are selected using combined selection pressure. 
 
 In order to create recombinant viral DNA, electro-competent E. coli DH10B were 
transformed with an MCMV BAC and in a second step over-transformed (chemically) 
with the plasmid pCP20 encoding Flp recombinase. From transformants carrying BAC 
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and pCP20 electro-competent cells were prepared by propagation at 30 °C. Those 
bacteria were then transformed with 70-100 ng of the pOriR6K-derived shuttle plasmid.  
 Flp-mediated recombination was allowed by culturing the transformants at 30 °C for 
60 min in LB medium without any antibiotics. Bacterial clones were selected for 
insertion of the pO6-derived constructs on agar plates containing cam (for the BAC) and 
zeo (for the shuttle plasmid), as bacteria with successful insertions were resistant to both 
antibiotics. The pCP200 plasmid was eliminated by incubating the transformants at the 
non-permissive temperature of 43 °C o/n. Colonies were picked for BAC mini-
preparation to check for single copy insertions of the shuttle plasmid at the target site on 
the following day.  
 If all recombinant BACs carried multiple insertions, the incubation time under non-
selective conditions was shortened to 30 or 15 min. 
 
 
2.6 Cell Culture  
2.6.1 Cultivation of mammalian cells 
 All eukaryotic cells were maintained in Heraeus incubators at 37 °C in 5% CO2 and 
95% humidity. Cells were split as listed in Table 2.10. To split adherent cells, medium 
was removed, cells were washed once with PBS and detached from the plates by 
incubation with a few drops of 0.25% trypsin/ EDTA for 1-2 min at r/t. The trypsin was 
inactivated by adding the respective fully supplemented medium, in which the cells 
were resuspended and aliquots were seeded on fresh cell culture plates. 
 
 Doxycycline (dox; Sigma-Aldrich) 10 mg/mL stock solution was prepared in PBS 
and stored at -80 °C. Small aliquots of 1 mg/mL were stored at -20 °C and only used 
once after thawing at a final concentration of 1 µg/mL. In continuous experiments, fresh 
dox was applied every three days due to its light sensitivity. Phosphonoacetic acid 
(PAA) stocks were stored at -20 °C and applied at a final concentration of 300 µg/mL. 
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Table 2.10: Cell lines and growth conditions used during this study 
List of cell lines and culture medium, as prepared from commercially available media and 
additives. The last column indicates the ratio and intervals of splitting. ATCC, American 
Type Culture Collection; NEAA, non-essential amino acids. 
Cells Source and  
Description 
Basic medium 
Additives1,2 
Split ratio
Interval 
293 ATCC CRL-1573 
human embryonic kidney cells 
transformed with adenovirus 5 
DMEM 
10% FCS, P/S, Q 
1:6 
2-3 days 
293T ATCC CRL-11268 
human kidney carcinoma cells 
DMEM 
10% FCS, P/S, Q 
1:6 
2-3 days 
M2-10B4 ATCC CRL-1972 
bone marrow stroma cells from 
(C57BL/6J X C3H/HeJ) F1 mouse 
RPMI 
10% FCS, P/S 
1:6 
2-3 days 
MEF embryonic fibroblasts of Balb/c 
mice; preparation as described in 
[157] 
DMEM 
10% FCS, P/S 
1:2 
3-4 days 
NIH/3T3 ATCC CRL-1658 
murine embryonic fibroblast cell 
line from NIH Swiss mouse 
DMEM 
5% FCS, P/S 
1:6 
3-4 days 
Flpe-NIH murine fibroblasts (ATCC CRL-
1658) stably transformed with 
pCAGGS-FLPe (Gene Bridges) to 
express Flp recombinase, 
generated by Jens B. Bosse 
DMEM 
5% FCS, P/S 
3 µg/mL puromycin 
1:3 
2-3 days 
 
U-2 OS ATCC HTB-96 
human osteosarcoma cell line 
DMEM 
10% FCS, P/S, Q, 
NEAA 
1:10 
3-4 days 
1 P/S, 0.6% (w/v) penicillin, 1.3% (w/v) streptomycin; Q, 0.3 mg/mL glutamine 
2 FCS had been inactivated by incubation at 56 °C for 45 min prior initial use 
 
 
2.6.2 Freezing and thawing of cells 
 To keep a stock of cells with low passage numbers, cells were frozen as permanent 
cultures in liquid nitrogen. Cells were grown to 80% confluence and harvested using 
trypsin. The cell pellet (1,200 rpm, 5 min, Heraeus Multifuge 3 S-R) was resuspended 
in the usual culture medium supplemented with 10% DMSO and 25% serum (1 mL as 
equivalent for one 10 cm dish). Aliquots of 1 mL were transferred to cryo-tubes (Nunc) 
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and kept in cryo-boxes at -80 °C for 24 hours, before being placed in liquid nitrogen. 
Isopropanol-insulated cryo-boxes allowed gentle freezing of the cells (1 °C per minute). 
 Frozen cell aliquots were removed from liquid nitrogen and thawed in a 37 °C water 
bath. To remove the DMSO, each aliquot was washed with 20 mL adequate medium, 
centrifuged (1,200 rpm, 5 min, Heraeus Multifuge 3 S-R) and seeded on one or two 
10 cm cell culture dishes. 
 
2.6.3 Transfection of eukaryotic cells using FuGene and PEI 
To investigate proteins by immunofluorescence microscopy (section 2.8.6), U-2 OS 
cells were transfected with the respective expression vectors using FuGene Transfection 
Reagent. For this, 8 well 1 µ-Slides (ibidi GmbH) were coated with 10 µg/mL 
fibronectin from bovine plasma for one hour at 37 °C and washed three times with PBS, 
before 2 × 104 cells were seeded per well and allowed to attach for 6 hours. DNA was 
suspended in 50 µL Opti-MEM, FuGene was added to yield a DNA-to-reagent ratio of 
1:1, the mixture was incubated at r/t for 30 min and added drop wise onto the cells.  
To analyse proteins by immunoprecipitation (section 2.8.2), protein 
complementation assay (section 2.8.5) or Western blot (section 2.8.4), aliquots of 
7.5 × 105 293 or 293T cells were seeded in 6-well plates and allowed to attach for 5-6 
hours. Required DNA (usually 3-4 µg) was suspended in 100 µL Opti-MEM, 15 µL 
polyethylenimine (PEI) were added, vigorously mixed, incubated at r/t for 40 min and 
added drop-wise into the culture media.  
 
2.6.4 Nucleofection of eukaryotic cells 
To perform nucleofection reactions, 0.5 µg BAC DNA was mixed with 0.5 µg 
plasmid DNA (preferably in a maximum volume of 4 µL) in a 96-well plate with 
conical bottom. Low-passage Flpe-expressing NIH/3T3 were harvested, pelleted at 
90 × g for 10 min (Heraeus Multifuge) and suspended in aliquots of 5 × 105 cells in 
20 µL solution SG onto the DNA mixtures. Samples were mixed and transferred air 
bubble-free into the Lonza electroporation stripes and nucleofected by means of the 
Amaxa® 96-well Nucleofection System using the programme EN-158. After 10 min 
recovery at r/t in the electroporation cuvettes, cells were mixed with 80 µL 
supplemented medium and aliquots of 1 × 105 Flpe-expressing cells were seeded into 
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12-well plates, which already contained 3 × 105 non-modified NIH/3T3. Plates were 
incubated at 37 °C for 5-7 days, before cells were fixed and processed for microscopic 
analysis. 
 
 
2.7 Virological methods 
2.7.1 Virus reconstitution from BAC DNA 
 To reconstitute virus from viral BACs, BAC DNA was transfected into MEF using 
SuperFect® Transfection Reagent. 
 MEF were thawed and seeded on 10 cm cell culture dishes. Once they reached 
confluence, they were split 1:3 on 6 cm dishes. For transfection, 1.5 µg of the 
appropriate BAC DNA was suspended in non-supplemented DMEM in a total volume 
of 150 µL and 10 µL of ice cold SuperFect® was added. After 10-15 min incubation at 
room temperature, 1 mL of fully supplemented DMEM was added to the transfection 
mixture and placed on the cells, which had been washed with PBS during the incubation 
time. Following 2.5-3 hours of incubation at 37 °C/5% CO2, the transfection mix was 
replaced by fully supplemented medium as listed in Table 2.10. 
 One day post-infection, cells as well as supernatants were transferred from 6 cm to 
10 cm cell culture dishes and further passaged in 1:2 splits every 7 days from then on. 
Development of viral plaques was monitored by light microscopy (Axiovert 25, Carl 
Zeiss AG) as well as fluorescence microscopy (Olympus IX17, Olympus Corp., Tokyo, 
Japan). After complete lysis, cells were harvested together with the supernatants and 
stored at -80 °C. 
 A reconstitution experiment was considered valid if the transfection with wt MCMV 
BAC produced plaques after one week (positive control), pSM3fr-ΔM53-EM53K128A 
BAC resulted in plaque formation between two and four weeks post-transfection 
(attenuated virus control), and no plaques were detected upon transfection with the 
∆M53 BAC for six weeks (negative control). Likewise, a viral element was assumed to 
be essential if no viral progeny was detected for six weeks after transfection. 
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2.7.2 Preparation of MCMV stocks 
 To prepare concentrated virus inocula for infection experiments, 6 confluent 
14.5 cm cell culture dishes of M2-10B4 cells were harvested, mixed with 10 mL 
inoculum of either a reconstitution (section 2.7.1) or a previous virus stock and re-
seeded onto 20 dishes. Upon complete lysis, cells were harvested together with the 
supernatants and viruses purified as described below. Optional, the suspension could be 
stored at -80 °C until virus preparation. 
 Unless indicated otherwise, all subsequent steps were performed on ice or in 
centrifuges cooled to 4 °C. Virus suspension was centrifuged at 6,000 × g for 20 min 
(Beckman Coulter™ Avanti™, JLA 16.250). The supernatant was collected and stored 
on ice until use. The pellet was resuspended in 5 mL non-supplemented DMEM and 
cells disrupted by three cycles of freezing (20-30 min at -80 °C) and thawing (10 min at 
37 °C). Cellular debris was removed by centrifugation at 3,500 rpm for 5 min (Heraeus 
Multifuge 3 S-R). The supernatants were combined and virus particles were harvested 
by centrifugation at 30,000 × g for 3.5 hours (Beckman Coulter™ Avanti™, 
JLA 16.250). The pellet was resuspended in 1.5 mL PBS and virus particles separated 
by douncing 20 times. The remaining cell debris was precipitated by triple sequential 
centrifugation at 3,500 rpm and 4 °C for 5 min (eppendorf 5417 R). Aliquots of 50 µL 
were stored at -80 °C and virus titre was determined by plaque assay (section 2.7.3). 
 
2.7.3 Quantification of virus infectivity by plaque assay 
 To determine the titre of the virus stocks, a standard plaque assay was performed 
[133].   
 For this, MEF were seeded on 48-well plates and grown to confluence. Cells were 
infected with 200 µL of serial dilutions of the virus prepared in cold, non-supplemented 
DMEM. After one hour incubation at 37 °C to allow for virus adsorption, infectious 
medium was removed and medium containing methylcellulose (MEM supplemented 
with 7.5 g/L carboxy-methylcellulose, 5% FCS, 0.3 mg/mL glutamine, 5% of 100x non-
essential amino acids, 0.6% (w/v) penicillin, 1.3% (w/v) streptomycin, 7.5% NaHCO3) 
added. Using methylcellulose, secondary plaque formation is prevented, as infectious 
particles are unable to diffuse into medium of such high viscosity. After 4 days, plaque 
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formation was monitored using phase contrast microscopy and virus titre determined 
according to the following equation 
 
 
dilutionfectiousinofvolume
dilutioncountedplaques
mLpfutitrevirus

/  
 
 Virus titration was performed in triplicate samples for virus stocks and in duplicates 
for growth curves. 
 
2.7.4 Infection of cultured cells with MCMV 
 For standard infection, cells were trypsinised, cell numbers determined using trypan 
blue and cells either infected directly or seeded onto multi-well plates and allowed to 
attach for 5-6 hours. For direct infection, the total number of cells required for one 
experiment was incubated with the appropriate virus dilutions for 30 min at 37 °C, 
washed twice with pre-warmed media (1,200 rpm/300 × g, 5 min, Heraeus Multifuge 
3 S-R) and aliquots seeded in absence and presence of 1 µg/mL dox. To infect adherent 
cells, virus preparations were added and incubated at 37 °C for one hour. 
 Where a higher multiplicity of infection (MOI) was required, viruses were added to 
attached cells and subjected to centrifugation (2,000 rpm/860 × g, 30 min, r/t, Heraeus 
Multifuge 3 S-R) followed by one hour incubation at 37 °C before the inoculum was 
replaced by fresh medium. Centrifugation enhances infection efficiency approximately 
10-fold [59]. 
 
2.7.5 Preparation of growth curves 
 The growth kinetics of the generated mutant viruses were compared to each other 
and to control viruses under multi-step growth conditions. For this, cells were harvested, 
cell numbers determined using trypan blue and the appropriate number of cells 
(equalling one aliquot of 1.5 × 105 per day and condition) was mixed in a Falcon with 
the required viruses at an MOI of 0.1 and incubated for 30 min at 37 °C. Subsequently, 
cells were washed twice with pre-warmed medium (300 × g, 5 min, Heraeus 
Multifuge 3 S-R) and seeded in aliquots of 1.5 × 105 cells per well. If it was required, 
half of the samples were supplemented with 1 µg/mL dox. 
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 Supernatants were harvested daily over a period of five days and the viral load of the 
culture supernatants was determined by plaque assay (section 2.7.3). The experiments to 
assess viral growth kinetics were performed in technical duplicates in two independent 
experiments.  
 
2.7.6 Transmission electron microscopy (TEM) 
NIH/3T3 cells were grown on carbon-coated sapphire discs and infected at an MOI 
of 5 using centrifugal enhancement at 1,000 × g for 30 min. Residual virus was removed 
one hour post infection and dox applied. Cells were fixed 48 hours post-infection by 
high-pressure freezing with an HPF 01 instrument (M. Wohlwend GmbH), freeze-
substituted, and plastic embedded as described previously [25]. Embedded samples 
were sectioned and viewed on a JEOL JEM-1400 transmission electron microscope 
equipped with an Olympus Veleta CCD camera at an acceleration voltage of 80 kV. 
 
 
2.8 Protein analysis 
2.8.1 Protein extraction from eukaryotic cells 
 For protein analysis, cells were scraped from the plates at appropriate time points, 
washed and resuspended in 1 mL PBS. All subsequent steps were performed on ice.  
 Transfected cells were harvested 48-72 hpt as described above. Of the cell 
suspension, 10% were pelleted at maximum speed for 10 min (eppendorf 5417 R) and 
resuspended in 50 µL total lysis buffer (TLB; 62.5 mM Tris (pH 6.8), 2% SDS, 
10% glycerine, 6 M urea, 0.01% bromphenol blue, 0.01% phenol red) freshly 
supplemented with 5% β-mercaptoethanol (ß-EtSH). Nucleic acids were disintegrated 
by sonication at 30% amplitude for 5 s. The remaining 90% were pelleted and stored at 
-80 °C until use. As an exception, the protein samples of FlagM53s168 were stored at 
4 °C, since it was instable at -80 °C. 
 Infected cells from a 6 well plate were lysed in 100 µL TLB and treated as described 
above. 
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2.8.2 Immunoprecipitation 
 Immunoprecipitation experiments were performed using proteins from isolated 
expression upon transfection. All steps were carried out on ice or at 4 °C. 
 Cells were lysed in 1 mL high salt lysis buffer (HSLB; 400 mM NaCl, 20 mM Tris 
(pH 8.0), 1% Triton® X-100) supplemented with a protease inhibitor cocktail (PIC) for 
90 min at 4 °C on a roller shaker. Cell debris was precipitated by centrifugation at 
maximum speed for 30 min (eppendorf 5417 R) and supernatant added to anti-Flag 
matrix (EZview™ Red ANTI-FLAG M2 Affinity Gel; Sigma-Aldrich) that had been 
washed three times with HSLB/PIC. Samples were incubated on a roller shaker at 4 °C 
o/n to allow optimal binding. Unbound protein was removed by sequential washing 
steps (14,000 rpm, 1 min, eppendorf 5417 R, soft acceleration): four times with washing 
buffer I (400 mM NaCl, 20 mM Tris, pH 8.0), once with washing buffer II (150 mM 
NaCl, 20 mM Tris, pH 8.0) and once with washing buffer III (20 mM Tris, pH 8.0) all 
supplemented with PIC. Bound proteins were eluted from the beads with 50 µL TLB/ß-
EtSH and incubation at 95 °C for 10 min. Samples were stored at -80 °C until analysis. 
 
2.8.3 SDS-polyacrylamide gel electrophoresis 
 Proteins to be analysed were separated by size using polyacrylamide gel 
electrophoresis under denaturing conditions. Protein samples were obtained from 
isolated expression in 293T cells (Section 2.6.3) or from expression in the virus context 
in M2-10B4 cells (section 2.7.4). 
 
Table 2.11: Composition of gels for SDS-PAGE 
Component Separating gel (10%) Stacking gel (4.5%) 
acrylamide (Rotiphorese® 30) 3.3 mL 500 µL 
gel buffer (4x)1 2.6 mL 410 µL 
H2O 4 mL 2.1 mL 
TEMED 4 µL 3 µL 
APS (10%) 100 µL 30 µL 
1The 4x separating gel buffer consisted of 1.5 M Tris (pH 8.8) and 0.4% SDS. The 4x 
stacking gel buffer was composed of 0.5 M Tris (pH 6.8) and 0.4% SDS. 
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 Polyacrylamide gels were poured in a Mini-PROTEAN® 3 gel system (Bio-Rad) 
according to the recipes below. Prior to loading, samples were heated at 95 °C for 
10 min. Proteins were separated by electrophoresis in 1x Laemmli buffer (2.5 mM Tris, 
1% SDS, 25 mM glycine) at 160 V until sufficient separation was achieved. Following 
separation, proteins of interest were detected by Western blot analysis (section 2.8.4). 
 
2.8.4 Western blot analysis 
 Following separation by SDS-PAGE, proteins were transferred from the SDS-gel to 
a Hybond®-P membrane (18 V, 45 min) in the presence of blotting buffer (25 mM Tris, 
192 mM glycine, 20% methanol) using a Trans-Blot® SD Semi-Dry Electrophoretic 
Transfer Cell (Bio-Rad). Prior to the transfer, membranes were activated by soaking in 
methanol and washing with water.  
 Membranes were blocked in TBS-T (150 mM NaCl, 10 mM Tris-HCl (pH 8.0), 
0.05% Tween 20) containing 5% non-fat dry milk for one hour at r/t to saturate 
unspecific protein binding sites. To detect proteins of interest, membranes were 
incubated with specific primary antibodies (1/1,000 - 1/2,000 dilution) in TBS-T at 4 °C 
o/n. Unbound antibodies were removed by three washings with TBS-T. To detect the 
specific deposition of the primary antibodies the membranes were reacted with 
horseradish peroxidase-conjugated secondary antibodies (1/8,000 in TBS-T; Dianova). 
After three washings with TBS-T, proteins were visualised using an ECL Plus™ 
Western Blotting Detection System and Hyperfilm™ ECL™ detection films (GE 
Healthcare). 
 
2.8.5 Protein Complementation assay (PCA) 
 To study protein interaction by PCA, 7.5 × 105 293T cells were co-transfected with 
plasmids expressing M50 and M53 versions fused to either the N-terminal or the 
C-terminal part of the ß-lactamase (BlaN and BlaC, respectively) [152].  
 Co-transfected 293T were harvested 48 hpt by scraping from the plate, washed once 
with PBS and lysed in 75 µL luciferase reporter lysis buffer (Promega) for 60 minutes 
on ice. Following lysate clearing at 21,000 × g at 4 °C for 10 minutes, 50 µL of each 
sample was added to 135 µL phosphate buffer (pH 7) and 15 µL nitrocefin and Bla 
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activity was determined on an ELISA plate reader for 30 min at 37 °C by measuring the 
colour conversion rate of nitrocefin leading to increasing absorption at 495 nm. 
 
2.8.6 Confocal laser scanning microscopy 
 Cells were fixed with 4% paraformaldehyde (PFA) at 36 hpi or hpt for 15 min at 
37 °C, washed three times with PBS, permeabilized by treatment with 0.1% Triton 
X-100 in PBS for 15 min at r/t, washed three times, blocked for 60 min with 5% donkey 
serum in PBS and stained with specific primary antibodies or antisera (1/100 - 1/200 
dilution) at 4 °C o/n and washed again three times. Primary antibodies were in turn 
reacted with the appropriate Alexa Fluor-coupled secondary antibodies (Molecular 
Probes; 1/150 dilution) for 60 min at r/t in the dark. To prevent unspecific binding, 
antibodies were diluted in PBS containing 5% donkey serum and 0.02% Triton X-100. 
DNA was visualized by staining with TO-PRO-3 iodide (Molecular Probes). Finally, 
cells were washed three times with PBS and fluorescence images were taken on a Zeiss 
LSM510 microscope with 488, 543, and 633 nm laser illumination and filter sets 
appropriate for Alexa Fluor 488, 555, and TO-PRO-3. 
 Pictures were processed using the ImageJ software (National Institutes of Health; 
http://rsbweb.nih.gov/ij/). 
 
 
2.9 Bioinformatics  
 Cloning strategies were planned using the Vector NTI software from Invitrogen. 
DNA sequencing data were analysed using different programmes of the Vector NTI 
package. Protein alignments were performed by means of the Vector NTI Align X 
programme via the BLOSUM 62 similarity matrix. 
 Statistical analyses were performed using the GraphPad Prism software (GraphPad 
Software Inc., La Jolla, USA). 
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3 RESULTS 
 
 
3.1 Construction of M53 mutants based on predictions 
 Random linker-scanning mutagenesis of the MCMV protein pM53 identified 
numerous insertion and few deletion mutations that were inhibitory for virus replication 
[130]. The inhibitory pM53 proteins with mutations within their conserved region 
(CR) 4 could inhibit MCMV replication up to the million-fold. Further analysis of these 
mutants in the virus context showed that their overexpression phenotype showed 
impaired nuclear egress and genome cleavage/packaging defects. However, the 
inhibitory potential of the individual insertion mutations in CR2 was weaker, inhibiting 
viral growth only by about 100-fold. This degree of inhibition did not allow further 
studies. Thus, although the random screen indicated a functional site in CR2, it did not 
produce a DN allele with sufficient inhibitory potential for phenotypic analysis.  
 The DN effect of a mutant protein can be improved by local insertion, replacement, 
or deletion of functionally important amino acids or motifs. This notion is supported by 
previous observations for the viral protein pM50, in which the deletion of a putative 
domain resulted in a stronger inhibitory phenotype than that observed for subtle 
insertion mutants [141]. Furthermore, chimeric pM53 proteins comprising the pM50 
binding domain fused to the C-terminal domains of other pUL31 family members were 
not able to complement wt pM53 function [152], indicating that at least one essential 
motif located within the C-terminal sequences is not conserved among the homologues. 
Based on those observations, a set of pM53 mutants was generated, in which the 
conserved regions were either replaced by the respective sequences from a homologous 
protein, or partly/completely deleted. Both strategies aimed at identifying mutant 
proteins with strong inhibitory potential. The mutants were studied in a tet-based 
conditional expression system, which allows quantitative assessment of their inhibitory 
potential [142].  
 
Results 
3.1.1 Construction of M53 mutants 
 Alignment of the amino acid sequences of the pUL31 family members indicates four 
regions with high similarity (Figure 3.1A). Previous studies identified the pM50 binding 
site in pM53 in CR1 and a nuclear localisation signal (NLS) within the variable 
N-terminus [95]. Additionally, preliminary data showed that chimeric proteins, which 
carry CR2 to CR4 domains of alpha- or gamma-herpesvirus homologues, bind pM50 
but cannot complement the M53 null mutation [152]. Consequently, to generate pM53 
mutants, which might interfere with viral replication, the N-terminal part spanning the 
NLS and the pM50 binding domain was kept in all cases. 
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Figure 3.1: M53 mutants constructed by domain shuffling and domain deletion 
(A) The amino acid (aa) sequences of 36 pUL31 homologues were aligned using the Vector 
NTI AlignX program (Invitrogen) via the BLOSUM 62 similarity matrix. The similarity plot was 
calculated using a 5 aa window size, with scores for weak and strong similarity and identity of 
0.2, 0.5, and 1.0, respectively. The x axis represents the number of amino acids in the consensus 
sequence. Conserved regions (CR) are indicated below the diagram [95]. (B) Schematic 
overview of the pM53 mutants. Proteins are depicted as grey bars, conserved regions are 
indicated as black boxes. White boxes labelled “69” represent sequences exchanged with the 
respective stretches of the MHV68 homologue pORF69 (aa 128-161 for M6MM, aa 165-245 
for MM6M, aa 253-292 for MMM6). Deletion mutants are shown with bridged spacing. The 
numbers on the right indicate the amino acids of pM53 affected by the mutation. VR, variable 
region; CR, conserved region. 
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 Two mutational strategies were exploited in order to generate inhibitory M53 alleles 
based on the alignment data (Figure 3.1). The first approach consisted of domain 
shuffling of single CRs by sequence replacement. Thus, three out of the four pM53 CRs 
were individually replaced with the corresponding coding sequences from pORF69, the 
M53 homologue of the murine gamma-herpesvirus MHV68, as follows: the coding 
sequence for amino acids (aa) 128 to 161 of pORF69 replaced the coding sequence of 
aa 178 to 211 of M53 to yield the protein pM6MM; aa 165 to 245 of pORF69 replaced 
aa 213 to 294 of pM53 to yield pMM6M; and aa 253 to 292 of pORF69 replaced aa 304 
to 333 of pM53 to yield pMMM6. 
 The second strategy comprised deletion of potential domains. For this, mutants 
lacking either the complete CR2 coding sequence (aa 181 to 207 (∆2)), parts of CR2 
(aa 181 to 197 (∆2A) and aa 197 to 207 (∆2B)), or the complete CR3 (aa 214 to 294 
(∆3)) were generated (Figure 3.1B). A CR4 deletion mutant was not included, as the 
pM53s309 mutation, truncating the protein close to the beginning of CR4, was already 
studied extensively [130]. 
 
 To investigate the effect which the newly generated M53 alleles exhibit on viral 
replication, they have to be expressed in the viral context. Thus, the mutant expression 
cassette either has to be delivered in trans, or recombinant viruses have to be 
constructed which selectively express the mutants. Using the latter, the transcription 
unit encoding the mutant gene needs to be silent during virus reconstitution and 
switched on when analysis of the phenotype is called for. This permits parallel analysis 
of the phenotypes resulting from the absence and presence of the mutant protein from 
the same construct.  
 To this end, the mutated M53 alleles were placed in a conditional expression 
cassette in a pOriR6K-derived shuttle vector. This vector contains an FRT site, which 
allows recombination by the Flp/FRT system. Furthermore, expression of the mutant 
allele is selectively induced by addition of dox, which neutralises the transcription 
blockade mediated by the tet repressor (TetR) (Figure 3.2). The TetR is constitutively 
expressed under control of the CMV promoter and binds to the tet-operator sequences 
(tetO2) in the SV40 promoter region of the mutant gene, which prevents transcription of 
the mutant gene (OFF). Its expression is turned on by dox addition, which binds to the 
TetR, thereby blocking it from tetO2 binding (ON) [142]. 
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Figure 3.2: Expression cassette for conditional gene expression in MCMV 
Schematic representation of the dox-inducible expression cassette. The constitutively expressed 
tet repressor (TetR) binds to the tet-operator sequences (tetO2) in the promoter region of the 
gene of interest, thereby preventing transcription. However, the TetR is bound by dox, allowing 
assembly of the transcription complex and expression of the gene of interest. Adapted from 
[142]. 
 
 
3.1.2 Analysis of M53 mutants in the viral context 
 To investigate the inhibitory potential of the chimeric proteins, the expression 
plasmids were inserted individually into the wt MCMV BAC as an additional M53 
allele. To compensate genome overlength, the MCMV genome used as background 
lacked the genes m01 to m16, which are dispensable for virus replication in cell culture. 
The growth properties of the virus derived from this BAC are identical to those of a wt 
virus [97].  
 Insertion of the expression vectors into the viral BAC was performed using the 
Flp/FRT recombination system as described in Figure 2.2 (section 2.5.2). The Flp 
recombinase was expressed from the temperature-sensitive plasmid pCP20 [30]. It 
recognises and specifically recombines the two FRT sites located on the BAC and the 
shuttle plasmid harbouring the mutant gene, thereby inserting the plasmid into the 
MCMV genome. Recombinant BACs were isolated and analysed by restriction enzyme 
digest to confirm single insertion of the shuttle plasmid, as exemplified in Figure 3.3. 
Recombinant viruses were then reconstituted from the respective BACs by transfection 
of MEF in the absence of dox. Virus production was monitored and the inocula were 
harvested after completion of the cytopathic effect. 
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Figure 3.3: Analysis of the BAC DNA based on restriction patterns 
An example is shown for specific changes in the restriction pattern after flip-in. BAC DNA of 
wt MCMV (wt) and SVT-∆2 (∆2) was digested with DraI, HindIII and SfiI (right panel) and the 
restriction patterns compared to a theoretical digest (left panel). For example, cleavage of wt 
MCMV with DraI resulted, amongst others, in fragments of 0.9, 2.2, 2.7, 3.0, 3.1 and 6.2 kbp. 
In contrast, DraI-digested SVT-∆2 DNA showed, as a result of the flip-in reaction, additional 
fragments at 0.6, 0.7, 1.0 and 1.6 kbp (indicated with green arrowheads). A double or multiple 
insertion of the shuttle plasmid could be discriminated by a further fragment at 1.3 kbp, as 
illustrated in the left panel (dbl). The HindIII digest produced additional bands at 0.6, 0.95 and 
2.1 kbp for SVT-∆2 in comparison to wt MCMV, whereas cleavage with SfiI showed an extra 
fragment at 6.8 kbp.  
 
 
 Subsequently, the inhibitory potential of the mutated pM53 proteins on viral 
replication was investigated comparing the phenotypes induced in the absence and 
presence of dox (Figure 3.4). Addition of dox selectively allowed transcription of the 
mutant allele as illustrated in Figure 3.2. 
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Figure 3.4: Analysis of the inhibitory effect of the mutant alleles in the viral 
context 
(A) Construction of recombinant viral BACs. The gene of interest (yellow box) is mutated and 
cloned into an FRT site-containing dox-inducible expression vector, which is subsequently 
inserted into the wt MCMV BAC by Flp-mediated site-specific recombination via FRT sites 
(grey arrowheads) in E. coli. Recombinant viruses are reconstituted by transfection of murine 
fibroblasts with BAC DNA in the absence of dox. (B) Mutant analysis in the viral context. Cells 
are infected with MCMV mutant viruses. In the absence of doxycycline (dox; left panel) the 
constitutively expressed tet repressor (tetR, black box) blocks transcription of the mutant gene 
(grey box with black line), leading to virus replication similar to that observed for wt. The 
inhibitory potential of the mutant proteins can be analysed upon dox application (right panel), 
which allows mutant expression by tethering TetR. Adapted from [141]. 
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3.1.3 Lack of the correct CR2, but not CR3 sequences results in pM53 
mutants with strong inhibitory effects 
 To investigate the inhibitory potential of the mutant alleles on virus replication, 
M2-10B4 cells were infected with the mutant viruses in the absence and presence of 
dox and the release of infectious viruses was analysed under multi-step growth 
conditions (Figure 3.5). The viruses were named as the corresponding BAC constructs 
tagged with an “MCMV” prefix. 
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Figure 3.5: Inhibition of MCMV replication by M53 mutants 
M2-10B4 cells were infected with the indicated viruses at an MOI of 0.1 in the absence (black 
diamonds) or presence (grey squares) of 1 µg/mL doxycycline (dox) and the viral load in the 
supernatant was quantified by plaque assay. Error bars represent the standard deviation of 
duplicate experiments using two separate clones. Dashed line, detection limit. 
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 As expected, in the absence of dox, all mutant viruses produced titres comparable to 
wt MCMV of at least 105 pfu/mL at 5 days post-infection (dpi). Neither addition of dox 
to wt MCMV, nor insertion and expression of a second wt gene copy 
(MCMV-SVT-M53), had any effect on viral titres (Figure 3.5, upper row). However, 
induction of the mutant alleles led to different results. Expression of pM6MM 
(MCMV-SVT-M6MM) reduced viral production by about 10,000-fold, which was a 
clear improvement of the inhibitory potential over the 100-fold effect reported for the 
i207 mutant derived from a transposon insertion library [130]. In addition, the presence 
of pMMM6 decreased virus production by about three orders of magnitude 
(MCMV-SVT-MMM6), whereas expression of pMM6M had only a moderate effect 
(MCMV-SVT-MM6M) (Figure 3.5, middle row). The latter two findings are in line 
with the observations reported for the random library, which showed that inhibitory 
mutations are preferentially located within CR4, and that insertions in CR3 do not 
inhibit wt protein function [130]. 
 The next step was to study whether the strong inhibitory phenotype of the CR2 
replacement could also be achieved by domain deletion. For this, the mutants lacking 
either the complete CR2 or parts of CR2 (Figure 3.1B) were tested as described above. 
Again, virus titres in the absence of dox reached ~105 pfu/mL (Figure 3.5, bottom row), 
whereas expression of pM53∆2 severely reduced virus release by approximately four to 
five orders of magnitude (MCMV-SVT-∆2). The presence of pM53∆2A 
(MCMV-SVT-∆2A) decreased virus replication to a comparable level as 
MCMV-SVT-∆2, while the inhibitory effect of pM53∆2B was less pronounced, 
reducing viral titres by about two orders of magnitude (MCMV-SVT-∆2B). 
 At last the pM53 mutant lacking CR3 was tested. This served in parallel as control 
whether the inhibitory phenotype of the CR2 deletion mutants could be specifically 
attributed to that domain. Induction of the M53∆3 allele by dox inhibited virus 
replication minimally (MCMV-SVT-∆3) (Figure 3.5, upper row). Altogether, from 
these and previous data it was concluded that deletion or alteration of CR2 and CR4, but 
not of CR3, results in mutant proteins with a strong inhibitory effect on virus 
replication. 
 
70 
 
 
Results 
3.1.4 Analysis of the intracellular distribution and expression of the 
CR2 mutants of pM53  
 The inhibitory effect of a mutant allele is dominant negative if the mechanism of its 
interference is specifically connected to the function of the wt allele. Changes in the 
coding sequence may result in proteins with aberrant folding properties, which are then 
trapped in compartments designated for degradation. To study whether the pM53 
mutants reached the correct cellular compartment where the wt protein is localised, 
U-2 OS cells were transiently transfected with plasmids expressing the M53 mutants 
and examined for protein signals 36 hours post-transfection (hpt). Confocal microscopy 
of the transfected cells revealed that all pM53 mutants correctly localised to the nucleus 
(Figure 3.6), indicating that all mutant proteins had the potential to obstruct viral 
maturation in the nucleus. Thus, the functional differences between the pM53 CR2 and 
CR3 deletion mutants were not due to aberrant protein localisation.  
 
∆
2
M53/Flag TO-PRO merge
M
53
Ai Aii Aiii
Bii Biii
Ci Cii Ciii
Bi
F
la
g-
∆
2A
F
la
g-
∆
2B
Di Dii Diii
Eii Eiii
Fi Fii Fiii
Ei
Gi Gii Giii
F
la
gM
6M
M
F
la
g-
∆
3
F
la
gM
M
6M
F
la
gM
M
M
6 Hi Hii Hiii
Flag TO-PRO merge
∆
2
M
53
F
la
g-
∆
2A
F
la
g-
∆
2B
F
la
gM
6M
M
F
la
g-
∆
3
F
la
gM
M
6M
F
la
gM
M
M
6
 
Figure 3.6: M53 mutants localise to the nucleus 
U-2 OS cells were transiently transfected with plasmids expressing the indicated M53 mutants. 
Cells were fixed 36 hpt and co-stained with a polyclonal antiserum specific for pM53 (panels A 
and B) or a monoclonal anti-Flag antibody followed by Alexa-conjugated secondary antibodies 
and analysed under a confocal immunofluorescence microscope. DNA was stained using 
TO-PRO 3. Scale bar, 10 µm. 
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 To interfere with viral morphogenesis, a DN protein must be present in sufficient 
amounts within the cell. To study whether induction of the different mutant alleles 
resulted in comparable levels of protein expression, M2-10B4 cells were infected at an 
MOI of 1 with wt MCMV, MCMV-SVT-M53, a virus carrying a second wt M53 allele, 
MCMV-SVT-∆2 or MCMV-SVT-∆3 in the absence and presence of dox. Cell lysates 
were prepared at 0, 1, 3 and 5 dpi, and subjected to Western blot analysis (Figure 3.7). 
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Figure 3.7: Expression of the wt NEC proteins in presence of pM53 mutants 
M2-10B4 cells were infected with the indicated viruses at an MOI of 1 in the absence (−) or 
presence (+) of 1 µg/mL doxycycline (dox). Cell lysates were prepared at the indicated time 
points, and probed for pp89, pM53 and pM50 by Western blotting with specific immune sera. 
GAPDH was detected using a specific monoclonal antibody. Signals corresponding to wt pM53 
are indicated by black arrowheads, signals for the truncated proteins pM53∆2 and pM53∆3 by 
the unfilled arrowheads. The bands for the pM50 degradation products are indicated by an 
asterisk. 
 
 The loading control, pp89, showed comparable levels for all viruses. A faint band 
representing wt pM53 was observed 24 hours post-infection (hpi), the intensity of which 
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increased over time (Figure 3.7). While the addition of dox had no effect on pM53 
expression in cells infected with wt MCMV, pM53 expression in cells infected with 
MCMV-SVT-M53 was up-regulated in the presence of dox (Figure 3.7A). Wt pM53 
was also detectable in the absence and presence of dox after infection with 
MCMV-SVT-∆2 and MCMV-SVT-∆3 (Figure 3.7B, black arrowhead). Although the 
endogenous and mutant M53 alleles had no detection tag, the two different pM53 
proteins could be discriminated due to size differences. pM53∆2 (35 kDa) and pM53∆3 
(29 kDa) were strongly expressed upon induction by dox and could be distinguished 
from the 38 kDa wt pM53 (Figure 3.7B, open arrowhead).  
 Since pM50 interacts with pM53 [95, 130], the effect of mutant pM53 
overexpression on pM50 steady state levels was also investigated. Following infection 
with each mutant, increasing pM50 signals were detected from 1 dpi, accompanied by 
accumulating levels of pM50 degradation products. In cells infected with 
MCMV-SVT-∆2 and MCMV-SVT-∆3, the pM50 degradation products appeared earlier 
(Figure 3.7, asterisk). However, pM53∆3 had no inhibitory function, therefore the early 
accumulation of pM50 degradation products did not yet explain the inhibitory effect of 
pM53∆2. 
 
 
3.2 Investigation of the M53 CR2 deletion mutant 
 Partial or complete deletion of M53 CR2 gave rise to DN mutants that strongly 
interfered with MCMV replication. The growth defects observed upon pM53∆2 and 
pM53∆2A expression were at least 100-fold stronger than the inhibitory potential of 
i207, the representative inhibitory insertion mutant (harbouring a mutation within M53 
CR2) obtained by random linker-scanning mutagenesis [130]. The strong DN effect 
now allowed a detailed characterisation of the CR2 mutant properties. 
 
3.2.1 Deletion of M53 CR2 prevents capsid egress from the nucleus 
 The NEC, consisting of pM53 and pM50, is involved in MCMV genome cleavage 
and the nuclear egress of viral capsids [130, 152]. The effect of CR2 deletions on virus 
morphogenesis was analysed by transmission electron microscopy (TEM).  
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Figure 3.8: Electron microscopic analysis of wt MCMV 
NIH/3T3 cells were infected with wt MCMV at an MOI of 5 using centrifugal enhancement in 
the absence (A, B) and presence (C, D) of 1 µg/mL doxycycline (dox). Cells were fixed 48 hpi 
by high-pressure freezing, freeze-substituted, plastic embedded, and sectioned. Samples were 
viewed on a JEOL JEM-1400 transmission electron microscope at 80 kV. The rounded outlines 
indicate the approximate borders of replication compartment-like structures (A, C). The boxes 
highlight areas of primary (A, C) and secondary envelopment (B, D). Scale bar, 1 µm. 
 
 NIH/3T3 cells grown on carbon-coated sapphire discs were infected at an MOI of 5 
with wt MCMV, MCMV-SVT-M53 and MCMV-SVT-∆2 in the absence and presence 
of dox and examined by TEM after high-pressure freezing at 48 hpi. Viral capsids were 
observed in the nucleus and cytoplasm of wt MCMV (Figure 3.8) and 
MCMV-SVT-M53-infected cells (Figure 3.9) as described previously [25].  
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Figure 3.9: Overexpression of pM53 does not change the infectious phenotype 
NIH/3T3 cells were infected with MCMV-SVT-M53 in the absence (A, B) and presence (C, D) 
of 1 µg/mL doxycycline (dox) and processed as described in Figure 3.8. The rounded outlines 
indicate the approximate borders of replication compartment-like structures (A, C). The boxes 
highlight areas of primary (A, C) and secondary envelopment (B, D). Scale bar, 1 µm. 
 
 In the absence of dox, the infection phenotype of MCMV-SVT-∆2 was similar to 
that shown by the wt virus. However, the phenotype of dox-treated MCMV-SVT-∆2-
infected cells differed from that of wt-infected cells. In this case, the viral capsids were 
trapped in the nucleus, indicating the blockade of nuclear maturation, similar to that 
described for the s309 mutant [130].  
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Figure 3.10: The M53 CR2 deletion virus shows a nuclear egress defect 
NIH/3T3 cells were infected with MCMV-SVT-Δ2 in the absence (A, B) and presence (C, D) of 
1 µg/mL doxycycline (dox) and processed as described in Figure 3.8. The rounded outlines 
indicate the approximate borders of replication compartment-like structures (A, C). The boxes 
highlight areas of primary (A) and secondary envelopment (B) or membrane accumulations (B, 
D). Scale bar, 1 µm. 
 
 Furthermore, the nuclear capsids in wt-infected cells were dispersed and surrounded 
an intranuclear structure of altered electron density reminiscent of replication 
compartments [79] (black lines in Figures 3.8, 3.9 and 3.10 A and C). Upon dox 
addition, however, the majority of the nuclear capsids clustered in regularly arranged 
groups within these replication compartment-like structures within MCMV-SVT-∆2-
infected nuclei (Figure 3.10C, black outline), indicating a capsid transport defect. 
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 During nuclear morphogenesis, a complex order of events leads to mature DNA-
filled capsids. Viral proteins are assembled into spherical scaffold-containing 
procapsids. These are believed to mature concurrently with genome packaging into 
C capsids, with high-density cores and a hexagonal appearance on TEM. In addition, 
two more products of capsid maturation can be distinguished. B capsids also contain 
scaffold-like procapsids, but these are icosahedral. They are thought to be the result of 
premature cleavage of the scaffold protein. The other form appears as A capsids, which 
are empty capsid shells with an icosahedral symmetry. A and B capsids are believed to 
be non-functional dead-end products of capsid maturation [188], and an increase in their 
number reflects disturbances of the processes involved in capsid maturation.  
 To quantify the influence of pM53∆2 expression on capsid morphogenesis, the 
nuclear capsids in the untreated and dox-treated wt MCMV-, MCMV-SVT-M53- and 
MCMV-SVT-∆2-infected cells seen on the TEM images were classified according to 
the stages described above (Figure 3.11). As it is not clear whether the procapsids are 
preserved by the TEM preparation protocol used here and because they can only be 
discriminated from B capsids by their shape, all capsids with apparent scaffold ring 
were classified into one class. Most of the capsids were classified either as 
procapsids/B capsids or as C capsids in wt- and MCMV-SVT-M53-infected cells in the 
absence and presence of dox and in cells infected with MCMV-SVT-∆2 in the absence 
of dox. There were almost no A capsids. By contrast, induction of the M53∆2 allele led 
to a significant increase in the number of immature A capsids from about 1% in the 
absence of dox to about 7%. There was also a significant increase in the number of 
immature pro- and B capsids (from about 47% to more than 80%). Accordingly, less 
than 10% of the nuclear capsids represented mature C capsids (Figure 3.11B).  
 In addition to inhibiting capsid maturation, expression of the pM53∆2 mutant 
induced membrane accumulation in the nucleus, which was distinct from the 
membrane-surrounded vesicles observed in wt-infected cells, which are formed by 
invaginations of the INM during capsid egress [25]. This accumulation seemed to 
comprise membranes folded into each other and connected by a high-staining material 
(compare black boxes in Figure 3.10 A with that in C). No capsids were found in the 
cytoplasm of most dox-treated MCMV-SVT-∆2-infected cells. Furthermore, the 
cytoplasmic assembly and maturation site [104], where the tegument layer is added and 
secondary envelopment occurs, was absent in dox-treated MCMV-SVT-∆2-infected 
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cells (Figure 3.10, right column). Instead, membrane stacks reminiscent of the Golgi 
apparatus were often observed, which again seemed to be connected by a high-staining 
material (Figure 3.10D, black box). 
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Figure 3.11: Quantification of the defect in nuclear capsid maturation 
NIH/3T3 cells were infected with the indicated viruses and treated as described in Figure 3.8. 
(A) Nuclear capsids were categorized according to their morphogenesis stage as shown in the 
example pictures: immature, unfilled A capsids, scaffold-containing procapsids and B capsids as 
well as mature C capsids. The capsids were counted for a given number of nuclei (n). Scale bar, 
100 nm. (B) Percentage of each category of nuclear capsid. White bars, A capsids; grey bars, 
procapsids and B capsids; black bars, C capsids. Data are expressed as the mean and standard 
deviation. ***p < 0.001, unpaired t-test (the two conditions for each virus were compared to 
each other and to the wt samples; no label means no significant difference). 
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3.2.2 M53 CR2 deletion mutants prevent unit length genome 
formation 
 The increased proportion of immature nuclear capsids found in dox-treated 
MCMV-SVT-∆2-infected cells indicated a morphogenesis block in viral development 
at, or prior to, the stage of viral DNA packaging. Therefore, genome cleavage and 
genome packaging was studied next.  
 Upon replication, MCMV genomes form concatemers [104]. The head of the viral 
DNA is inserted into newly assembled procapsids and cleaved into unit length genomes 
by the viral terminase (pM56 and pM89 in MCMV [131]). The processes of genome 
encapsidation and cleavage are linked and occur simultaneously. Thus, concatemeric 
and unit length genomes are present in parallel once viral replication has started.  
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Figure 3.12: Principle of the packaging assay 
Schematic representation of the Southern blot assay used to analyse MCMV genome 
cleavage/packaging. (A) Upon replication, MCMV genomes are connected head-to-tail. The 
concatemeric DNA is cleaved by the viral terminase at the indicated site (arrow) and unit length 
genomes are packaged into newly assembled capsids. (B) In the concatemeric form (upper 
panel), restriction digestion releases a 7.2 kbp control fragment and a 6.7 kbp fragment, which 
are both recognized by the same probe. By contrast, the unit length genome (bottom panel) 
gives rise to the 7.2 kbp control fragment, but also gives rise to a 5.5 kbp fragment representing 
genome cleavage. 
 
 
 
Results 
 To analyse the viral DNA with regard to cleavage/packaging, M2-10B4 cells were 
either mock-infected or infected with wt MCMV, MCMV-SVT-∆2, MCMV-SVT-∆2A 
or MCMV-SVT-∆2B in the absence and presence of dox. Total DNA was isolated at 
48 hpi, digested using ApaLI and subjected to Southern blot analysis. Restriction digest 
of concatemeric genomes gives rise to a 7.2 kbp control fragment, which was used for 
normalisation of the genomic load, and a 6.7 kbp fragment representing the uncleaved, 
concatemeric genome. The same fragments arise from digestion of circular BAC DNA, 
which mimics the concatemeric genomic form. However, restriction of unit length 
genomes cleaved by the viral terminase releases a 5.5 kbp fragment of the genome 
terminus in addition to the 7.2 kbp control fragment (Figure 3.12). 
 
 The expected fragments of 7.2 kbp and 6.7 kbp were detected at comparable levels 
after ApaLI digestion of circular wt MCMV BAC DNA (Figure 3.13A). The same 
pattern was observed for the BAC DNA of the mutant viruses (data not shown). DNA 
from mock-infected cells gave no signal at all, confirming the specificity of the probe. 
All three of the expected signals were detected after digestion of DNA from wt- and 
MCMV-SVT-∆2-infected cells, although the total amount of viral DNA from dox-
treated MCMV-SVT-∆2-infected cells was less than that from non-treated 
MCMV-SVT-∆2- or wt-infected cells. More importantly, expression of pM53∆2 
severely reduced the number of unit length genomes (Figure 3.13A). To quantify this 
effect, the chemiluminescence signal was measured in a Typhoon scanner and the ratio 
of cleaved to concatemeric genomes was calculated after normalisation to the control 
fragments. In absence of dox, MCMV-SVT-∆2 replicated just like wt MCMV and 
produced unit length genomes at wt levels. By contrast, induction of pM53∆2 reduced 
viral cleavage activity, resulting in a decreased number of unit length genomes and the 
accumulation of concatemeric DNA (Figure 3.13B). A similar pattern was observed in 
MCMV-SVT-∆2A-infected cells, i.e. wt-like replication in the absence of dox, but a 
marked reduction in the number of unit length genomes upon induction of pM53∆2A. 
Expression of pM53∆2B also resulted in a decrease of unit length genomes, but the 
effect was less pronounced, possibly reflecting the data observed for the growth 
kinetics. 
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Figure 3.13: M53 CR2 mutants inhibit the generation of unit length genomes 
(A) M2-10B4 cells were mock-infected (m) or infected with wt MCMV (wt), MCMV-SVT-∆2 
(∆2), MCMV-SVT-∆2A (∆2A) or MCMV-SVT-∆2B (∆2B) at an MOI of 0.1 for 48 hours in 
the absence (−) or presence (+) of 1 µg/mL doxycycline (dox). Total DNA was purified, 
digested with ApaLI for 16 hours and subjected to Southern blot analysis. B, BAC DNA. (B) 
The chemiluminescence signal generated in the Southern blot assay was measured in a Typhoon 
scanner, quantified using ImageJ software (http://rsbweb.nih.gov/ij/) and then plotted as the 
ratio of unit length genomes to concatemeric genomes normalised to the control fragment. Error 
bars represent the standard deviation of at least two independent experiments. 
 
 Taken together, the results obtained thus far suggest that expression of the CR2 
mutants of pM53 inhibits both capsid egress and genome cleavage/packaging, findings 
very similar to those observed for CR4 mutants [130]. 
 
3.2.3 M53 CR2 mutants have a DNA replication defect 
Quantification of the capsid types observed by TEM revealed a marked increase in 
the number of aberrant A capsids upon expression of the M53∆2 allele (Figure 3.11). In 
wt infection, cleavage and encapsidation of the viral DNA into procapsids proceeds 
concomitantly, resulting in mature capsids filled with one unit length genome each. An 
increase in the number of A capsids indicates a maturation defect. It is believed that 
more A capsids accumulate when the internal scaffold protein is processed before viral 
DNA has been recruited to the procapsid [188]. This could happen if the virus fails to 
 
Results 
produce enough DNA to be inserted. A hint in this direction was already observed in the 
packaging assay, where in dox-treated MCMV-SVT-∆2-infected cells the viral DNA 
load was decreased (Figure 3.13). 
To investigate whether the viruses expressing M53 alleles defective in CR2 replicate 
their DNA as wt MCMV, M2-10B4 cells were infected at an MOI of 0.1 in the absence 
and presence of dox. Total DNA was purified at 48 hpi, digested using PaeI and 
analysed by semi-quantitative PCR (qPCR). The samples were probed for the M54 
gene, encoding the catalytic subunit of the viral polymerase [131], and normalised to the 
cellular lamin B receptor (LBR) gene (Figure 3.14). 
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Figure 3.14: Viral DNA replication is reduced upon induction of the CR2 mutants 
M2-10B4 cells were infected at an MOI of 0.1 with wt MCMV (wt), MCMV-SVT-Δ2 (Δ2), 
MCMV-SVT-Δ2A (Δ2A) or MCMV-SVT-Δ2B (Δ2B) for 48 hours in the absence (−) or 
presence (+) of 1 µg/mL doxycycline (dox). Total DNA was purified and digested using PaeI, 
before 20 ng of it were analysed by qPCR, probing for lbr as cellular and M54 as viral reference 
gene. Depicted are mean and standard deviation of duplicate samples of two independent 
experiments. 
 
 Confirmative to the observation in the packaging assay, a 3-fold reduction of viral 
DNA was detected in the qPCR analysis in MCMV-SVT-∆2-infected cells with induced 
DN expression. Similar results were obtained upon expression of the partial deletion 
mutants pM53∆2A and pM53∆2B (ranging between 24% and 38% total DNA levels 
compared to non-treated cells), supporting the assumption that overexpression of M53 
deletion mutants not only interferes with DNA cleavage and encapsidation, but also 
with the upstream process of DNA replication. 
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3.2.4 The wt NEC is formed in the presence of the inhibitory pM53 
mutants 
 In addition to the interaction between pM53 and pM50, previous reports suggest that 
pM53 homologues show self-interacting homotypic activity [47, 148, 175, 179]. To 
study the protein-protein interactions between pM53 subunits in more detail, 293 cells 
were co-transfected with plasmids expressing Flag-tagged wt M53 together with either 
wt M53 or a CR2 or CR4 deletion mutant in the presence or absence of M50. Protein 
complexes were then precipitated using an anti-Flag matrix and analysed by Western 
blotting. In this setting, the anti-M53 antiserum detected both the Flag-tagged and 
untagged versions of pM53. As shown in Figure 3.15A, all proteins of interest were 
expressed at comparable levels (Figure 3.15A, Total).  
 Following immunoprecipitation (IP) with the anti-Flag matrix, a signal for wt pM53 
was detected in addition to a signal for pFlagM53, whereas co-precipitation of the 
pM53 CR2 deletion was almost lost, giving only a minute amount of residual signal, 
and the CR4 truncation mutant was not co-precipitated (Figure 3.15A, Flag-IP, lanes 3 
to 5). When pM50 was co-expressed, the same pattern was observed, i.e. the signal for 
wt pM53 was present, but the signals for pM53∆2 and pM53s309 were not (Figure 
3.15A, Flag-IP, lanes 7 to 9). The NEC proteins, pM53 and pM50, and their 
homologues in other herpesviruses, interact with each other and the complex can be 
precipitated via either protein partner [22, 95]. In this setting, pM50 was 
immunoprecipitated with pFlagM53 at comparable levels in presence of pM53, 
pM53∆2 or pM53s309. This indicated that the wt NEC was formed regardless of the 
presence of the inhibitory deletion mutants (Figure 3.15A, Flag-IP, lanes 7 to 9). 
Unfortunately, wt pM53 had a propensity to bind the matrix non-specifically (Figure 
3.15B). Therefore, it could not be clarified whether the failure to co-precipitate the 
deletion mutants reflected their lost capacity to interact with wt pM53, or whether the 
mutations simply prevented them from binding to the matrix. 
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Figure 3.15: Expression of DN mutants of pM53 does not influence the wt 
pM53/pM50 interaction 
(A) 293 cells were transfected with an empty expression plasmid (lane 1) or plasmids 
expressing Flag-tagged M53 (lanes 2 to 5 and 7 to 9) in combination with wt M53 (lanes 3 and 
7) or the mutants M53∆2 (lanes 4 and 8) or M53s309 (lanes 5 and 9) in the absence (lane 2 to 5) 
or presence of M50 (lanes 7 to 9). Cells were harvested 48 hpt and 10% of each sample (lysed 
in TLB) was used to detect total protein levels (Total). The remaining 90% was subjected to 
immunoprecipitation using an anti-Flag matrix (Flag-IP). The pFlagM53 band is indicated by a 
black arrowhead on the M53 blots. (B) 293 cells were transfected with plasmids expressing 
Flag-tagged (lanes 1 to 4) and untagged M53 (lanes 5 to 8). Cells were harvested 48 hpt and 
10% of each sample was lysed in TLB and checked for pM53 protein expression. GAPDH was 
used as loading control (Total). The remaining 90% was subjected to immunoprecipitation with 
an anti-Flag matrix using different lysis (L) and washing (W) conditions. The eluates were 
probed for M53 (lower panel; indicated by Flag-IP). 
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3.2.5 CR2 mutations affect the nuclear distribution of the NEC  
 To characterise the fate of the wt NEC further, immunofluorescence analysis was 
performed to detect the intracellular localisation of pM53 and pM50 in M2-10B4 cells 
at 36 hpi. The homologues of the HSV-1 pUL31 and pUL34 proteins form a complex at 
the INM, thereby affecting the curvature of the membrane and allowing capsid 
translocation into the cytoplasm [46, 75, 118, 140]. In accordance with these reports, 
pM53 and pM50 co-localised at the nuclear rim to form the NEC in wt-infected cells; 
addition of dox did not change this localisation pattern (Figure 3.16A and B). A wt-like 
appearance was observed in the absence of dox in cells infected with 
MCMV-SVT-M53, a mutant expressing a second wt M53 allele (Figure 3.16C). 
Overexpression of the second M53 allele increased the amount of nucleosolic pM53 
protein with no apparent change in the co-localisation with pM50 at the nuclear rim 
(Figure 3.16D). In MCMV-SVT-∆2-infected cells, pM53 and pM50 showed a pattern 
comparable to that observed after wt infection in the absence of dox (Figure 3.16E). 
Additionally, a few pM53 aggregates, indicative for basal mutant expression, were 
already present in the absence of dox. Upon induction of the mutant M53 allele, the 
normal distribution of the NEC was disturbed and large aggregates containing pM53 
and pM50 were formed at the nuclear periphery (Figure 3.16F). This granular 
appearance of the NEC after pM53∆2 overexpression was similar to the accumulation 
of NEC in the presence of the CR4 truncation mutant s309 [130]. Based on these 
findings, it was hypothesised that the C-terminal tail of pM53 forms a functional unit 
and induces similar phenotypes when its overall integrity is disturbed. 
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Figure 3.16: Cellular localisation of the NEC proteins in the presence of mutant 
pM53 in infected cells 
M2-10B4 cells were infected with wt MCMV (panels A, B), MCMV-SVT-M53 (panels C, D) 
or MCMV-SVT-∆2 (panels E, F) at an MOI of 0.5 in the absence (−) or presence (+) of 
1 µg/mL doxycycline (dox) and fixed 36 hpi. Cells were co-stained with polyclonal antisera 
specific for pM53 and pM50 followed by Alexa-conjugated secondary antibodies and analysed 
using a confocal immunofluorescence microscope. DNA was visualized using TO-PRO 3. Scale 
bar, 10 µm. 
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 To confirm that the NEC aggregates were formed selectively after overexpression of 
pM53∆2 and not as a consequence of inhibiting nuclear capsid maturation in general, 
M2-10B4 cells were infected with a mutant virus harbouring an inducible GFP-coupled 
DN allele of the smallest capsid protein, SCP (MCMV-SVT-gfpSCP), which interferes 
with capsid maturation at an early stage [18, 142; unpublished observations] and 
analysed using confocal microscopy. While the signal generated by GFP-SCP appeared 
as granules in the nuclear interior, pM53 co-localised with pM50 was evenly distributed 
at the nuclear rim, as observed for wt MCMV infection. This distribution was observed 
in absence and presence of dox (Figure 3.17), indicating that NEC aggregation in 
MCMV-SVT-∆2-infected cells was caused specifically by pM53∆2 expression.  
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Figure 3.17: Localisation of the wt NEC proteins in the presence of DN GFP-SCP 
M2-10B4 cells were infected with MCMV-SVT-gfpSCP at an MOI of 0.5 in the absence (−) or 
presence (+) of 1 µg/mL doxycycline (dox) and fixed at 36 hpi. Cells were co-stained with 
polyclonal antisera specific for pM53 and pM50 followed by Alexa-conjugated secondary 
antibodies and analysed using a confocal immunofluorescence microscope. Scale bar, 10 µm. 
 
 Many proteins use multiple interactions to facilitate their function. Therefore, to 
investigate whether NEC aggregation was the direct result of pM53∆2 overexpression, 
and independent of other viral proteins except pM50, U-2 OS cells were transiently 
transfected with plasmids expressing either M50 or M50 together with M53 or M53∆2. 
The cells were then stained with polyclonal antisera against pM50 and pM53 at 36 hpi. 
 When expressed individually, pM53 and pM53∆2 were evenly distributed 
throughout the nucleosol (Figure 3.6), whereas pM50 alone was observed at the nuclear 
membrane and in the ER (Figure 3.18A). Co-expression of wt pM53 and pM50 
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localised both proteins to the nuclear rim due to formation of the NEC (Figure 3.18B). 
In the case of pM53∆2 co-expression with pM50, a proportion of both proteins co-
localised at the nuclear membrane, as did the wt proteins. However, a substantial 
proportion did not show the well-described nuclear rim staining, instead forming 
aggregates comparable to those observed in infected cells (Figure 3.18C). Based on 
these data, it was concluded that overexpression of a DN CR2 mutant of pM53 affected 
the nuclear distribution of the wt NEC in the absence of any other viral protein. 
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Figure 3.18: Cellular localisation of pM50 in the presence of mutant pM53 
U-2 OS cells were transiently transfected with plasmids expressing M50 (panel A), M53 and 
M50 (panel B) or M53∆CR2 and M50 (panel C) and fixed at 36 hpi. Cells were co-stained with 
polyclonal antisera specific for pM53 and pM50 followed by Alexa-conjugated secondary 
antibodies and analysed using a confocal immunofluorescence microscope. DNA was stained 
using TO-PRO 3. Scale bar, 10 µm. 
 
 
3.2.6 pM53∆2 binds poorly to pM50 
 Since formation of NEC aggregates simply requires the presence of both pM50 and 
the pM53 CR2 deletion mutant, the interaction between pM53∆2 and pM50 was 
analysed in more detail. For this, 293 cells were transfected for 48 hours with plasmids 
expressing M50 together with different Flag-tagged M53 mutants and 90% of the cells 
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were processed by co-immunoprecipitation with anti-Flag matrix, whereas the 
remaining 10% were used to check protein expression.  
 Western blotting (Figure 3.19) confirmed that pFlagM53 proteins and the pM50 
protein were expressed at comparable levels. However, the amount of pM50 
precipitated by the pM53 proteins differed markedly. As expected, high levels of pM50 
were precipitated by wt pM53 and the truncation mutant pM53s168, which consists of 
the variable region and the pM50 binding site in CR1. 
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Figure 3.19: Interaction of the pM53 CR deletion mutants with pM50 
293 cells were transiently transfected with plasmids expressing M50 together with different 
Flag-tagged M53 versions and harvested 48 hpt. Ten percent of each sample was lysed in TLB 
to detect total protein levels (Total). The remaining 90% were subjected to immunoprecipitation 
with an anti-Flag matrix and analysed by Western blotting with specific immune sera (Flag-IP). 
The Flag signal was detected with a monoclonal anti-Flag antibody directly coupled to 
horseradish peroxidase. EV, empty vector. 
 
 As shown previously [95], the binding-deficient mutant pM53i128 only bound 
background quantities of pM50. Remarkably, reduced pM50 binding was observed for 
the CR2 deletion mutants. The strength of pM50 binding declined from pM53∆2B to 
pM53∆2A to pM53∆2, which precipitated almost no pM50 (Figure 3.19). 
 To confirm that pM53∆2 was defective in pM50 binding, the protein-protein 
interaction was further studied using the protein fragment complementation assay 
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(PCA) established for the pM50/pM53 interaction [152]. In this assay, the N- and 
C-terminal parts of the TEM-1 ß-lactamase (BlaN and BlaC, respectively) are fused to 
pM50 and pM53. When wt pM50 and pM53 interact, the two Bla fragments are in close 
proximity and ß-lactamase activity is restored. Bla activity is quantified according to its 
nitrocefin hydrolysis rate (Figure 3.20).  
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Figure 3.20: Principle of the protein fragment complementation assay (PCA) 
Schematic representation of the principle of the protein complementation assay (PCA). The N- 
and C-terminal parts of the TEM-1 ß-lactamase (Bla) as reporter enzyme are fused to pM50 and 
pM53. Upon interaction of these two proteins, the proximity of the enzyme fragments BlaN and 
BlaC allows reconstitution of the active enzyme (green star). Adapted from [152]. 
 
 To assess the pM50 binding, 293T cells were transfected with plasmids expressing 
different combinations of BlaC-tagged M53 versions together with different M50 
versions fused to BlaN. Cells were lysed at 48 hpt and Bla activity was determined by 
nitrocefin conversion and absorbance measurement at 495 nm (Figure 3.21). The 
combination of pBlaC-M53 with pBlaN-M50 served as a positive control and yielded 
the maximum hydrolysis rate (vmax) of about 12 milliabsorption units/min. The negative 
control, consisting of pBlaC-M53 and pBlaN-M50DM, a mutant unable to bind pM53 
[22], generated a background signal of about 2 milliabsorption units/min. When 
pBlaC-M53∆2 was expressed together with pBlaN-M50, the nitrocefin hydrolysis rate 
was significantly reduced to approximately 50% of the control value, confirming the 
poor binding of pM53∆2 to pM50 (as observed in the Flag-IP experiments). A similar 
reduction in the rate of nitrocefin conversion was observed for pBlaC-M53∆3. By 
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contrast, BlaC-s309 together with BlaN-M50 yielded a nitrocefin hydrolysis rate similar 
to the wt value, indicating an appropriate interaction between these two proteins. 
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Figure 3.21: Interaction of the pM53 deletion mutants with pM50 in the PCA 
293T cells were transiently transfected with plasmids expressing BlaN-tagged M50 or M53 
binding-deficient M50 (M50DM) together with different versions of BlaC-tagged M53 proteins 
(wt M53, CR mutants ∆2 and ∆3, CR4 mutant s309). Cell lysates were prepared at 48 hpt and 
beta-lactamase activity determined by nitrocefin conversion. Absorption was measured at 
495 nm. Error bars represent the standard deviation of duplicate samples of at least three 
separate experiments.  
 
 In conclusion, pM53∆2 had a reduced capacity to bind pM50. As overexpression of 
this DN mutant led to impaired genome cleavage/packaging and membranous 
intranuclear NEC accumulation, it is likely that the CR2 of M53 plays a role in coupling 
genome cleavage with membrane deformation. Taken together, these data show that, 
despite their phenotypic similarities, the pM53∆2 and pM53∆3 mutants must act 
mechanistically different from the pM53s309 mutant. 
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3.3 Establishment of a high-throughput screening system 
for MCMV mutant alleles 
Although DN mutants are potent tools in genetic analyses, their identification using 
the classical strategy of two random genetic screens, which are both based on individual 
flip-in in E. coli followed by BAC selection and virus reconstitution, is time-consuming 
and labour-intensive. Thus, new approaches are called for that decrease the screening 
effort. 
 
3.3.1 Principle of the in-cell Flp-assisted (ICFA) complementation 
assay 
To enable a simplified high-throughput screening, the classical approach had to be 
modified at several stages. A schematic screen is depicted in Figure 3.22. The basis for 
this assay was to test whether the recombination of an MCMV BAC with a shuttle 
plasmid by Flp-mediated recombination can even be performed in MCMV permissive 
host cells instead of E. coli. To this end, a cell line of murine fibroblasts derived from 
NIH/3T3 was generated, which was stably transfected to express enhanced Flp 
recombinase (Flpe). Flpe is a modified form of the original Flp evolved by cycling 
mutagenesis, which catalyses the recombination reaction more efficiently at 37 °C [24]. 
These cells were co-transfected by electroporation in 96-well format using the 
Nucleofector™ technology (Lonza AG) with an MCMV BAC lacking the essential 
gene of interest and a plasmid constitutively expressing either that gene, to test for its 
complementation at the ectopic position by reconstitution, or a mutated version of this 
gene. Nucleofection is a novel, non-viral transfection technology to modify primary 
cells and cell lines which are difficult to transfect. It permits direct entry of the 
transfected DNA into the nucleus, thus providing the possibility to transfect even non-
dividing cells [12, 100, 173].  
Following nucleofection, the Flpe-expressing cells were mixed with regular 
NIH/3T3 fibroblasts at a defined ratio. By site-specific recombination between two FRT 
sites oriented in the same direction, Flp catalyses both, the insertion of genetic elements 
into target DNA, but also the excision of such stretches. Under non-selective conditions, 
the excision reaction is kinetically favoured over the integration [3]. To avoid 
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Figure 3.22: Principle of the in-cell Flp-assisted (ICFA) complementation screen 
Murine fibroblasts stably expressing enhanced eukaryotic Flp recombinase (Flpe) were mixed 
with BAC DNA, which lacked the gene of interest (GoI, yellow box), and the respective shuttle 
plasmid carrying a mutated form of the GoI and transfected by nucleofection. Transformed cells 
were mixed with non-modified fibroblasts at a ratio of 1:3, seeded on multi-well plates and viral 
plaque formation monitored. Viral reconstitution (formation of plaques) was expected if the 
mutated gene was able to complement the wt protein function (depicted as green wells), 
whereas the absence of plaque formation using the same conditions would indicate non-
complementing mutants (red wells). Since the unification of the shuttle plasmid and the target 
genome takes place within the host cell in the presence of Flpe expression, this new test was 
named in-cell Flp-assisted recombination-based (ICFAR) complementation assay. 
 
overwhelming excision of the newly inserted shuttle plasmid from the BAC, non-Flpe-
expressing cells were added in excess to provide sufficient target cells for viral 
propagation. Thus, by transmission of reconstituted viruses to neighbouring cells 
without Flpe, the viral genome containing the shuttle plasmid should be maintained, 
since in Flpe-negative cells it is not exposed to further Flp-specific modifications.  
 
Results 
As in the previous recombination based systems in bacteria, the ability of the 
(mutated) gene expressed from the shuttle plasmid to complement the endogenous wt 
gene was tested first and assessed by viral plaque formation. This new assay should 
eventually replace the viability screen. 
 
3.3.2 Complementation of essential genes using ICFA recombination 
(ICFAR) 
 At first it was tested whether the Flp-assisted recombination mediated directly in 
eukaryotic cells was indeed sufficient to restore reconstitution of MCMV BACs lacking 
essential genes. Three essential viral genes were chosen to validate the system, namely 
M53, M56 and M104. The M53 gene is known to be essential and was subjected to all 
ectopic complementation-based screens published before [95, 130], and thus provided a 
possibility to compare the fidelity of the new assay to the established complementation 
system. The essentiality of pM56, the MCMV homologue of the pUL28 herpesvirus 
protein family encoding the large subunit of the viral terminase [170], for MCMV 
replication was examined by transfecting MEF with an MCMV BAC lacking the M56 
ORF (∆M56). No viral progeny was detected for more than six weeks, supporting the 
crucial role of pM56 during virus production. The third gene, which was deleted from 
the MCMV genome, M104, encodes the portal protein required for translocation of the 
viral DNA into newly assembled capsids [120]. This protein is essential in all tested 
herpesviruses [124]. 
 To test the complementation of these three genes in the ICFA recombination assay, 
Flpe-expressing cells were co-transfected with MCMV BACs lacking one of those 
genes and either an empty expression vector or a shuttle plasmid expressing the 
respective gene and seeded together with unmodified NIH/3T3 on 24-well plates. 
Six dpt the samples were stained with an antibody specific for the IE1 protein pp89 and 
the number of fluorescent foci was quantified (Figure 3.23).  
 No IE1-positive plaques were detected after nucleofection with the three deletion 
BACs, confirming the essentiality of those genes for viral reconstitution. Conversely, 
co-transfection of each deletion BAC with its respective rescue plasmid resulted in 
robust production of viral progeny at 6 dpt. Whereas for the complementation of the 
M53 and the M56 deletion an average of 32 fluorescent foci was detected, 
complementation of the M104 deletion resulted in an average of 47 plaques (Figure 
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3.23A). This confirmed that the in-cell Flp-assisted complementation assay was feasible 
for virus reconstitution.  
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Figure 3.23: Verification of the ICFAR complementation assay 
(A) Flpe-expressing cells were nucleofected with indicated BACs and plasmids and mixed with 
NIH/3T3. Samples were fixed at 6 dpt, stained with an antibody specific for the IE1 protein and 
IE1-positive plaques were quantified. Depicted are mean and standard deviation of triplicate 
samples of two to three independent experiments. EV, empty vector. (B) Total RNA was 
isolated from NIH/3T3 (3T3) and Flpe cells (Flpe), reverse transcribed and PCRed with primers 
specific for the flpe gene. The control reaction (con) did not contain any template. M, 100 bp 
DNA ladder. (C) Flpe-expressing cells were treated as in (A), stained with antibodies specific 
for the IE1 (pp89) and the major capsid protein (MCP) and images taken using a fluorescence 
microscope. 
 
 In addition to the staining to detect pp89, a sample of M53 was probed with an 
antibody specific for the major capsid protein (MCP), a gene product expressed late in 
the replication cycle [142]. Few single cells containing the IE protein pp89 were 
detected by immunofluorescence microscopy in cells transfected with the ∆M53 BAC, 
but no MCP-specific signal was observed, verifying that no viral progeny was produced 
95 
 
 
Results 
in the absence of M53. In contrast, the cells surrounding the viral plaques in the sample 
co-transfected with the M53-expressing rescue plasmid displayed strong signals for 
both pp89 and MCP, confirming the production of infectious virions (Figure 3.23C).  
 To verify the expression of Flpe recombinase, the total RNA content was purified 
from an aliquot of NIH/3T3 and Flpe-expressing cells in each experiment, the mRNAs 
were reverse transcribed and the resulting cDNA was probed by PCR for transcripts of 
the flpe gene. A representative result is depicted in Figure 3.23B. The expected 
amplicon of 500 bp, which covers the 5’ half of the ORF, was detected exclusively in 
samples derived from Flpe-expressing cells, indicating that the flpe gene was actively 
expressed in these cells. 
 
3.3.3 The ICFAR complementation assay can be used to identify non-
complementing mutants 
The previous experiments indicated that the ICFA recombination resulted in the 
ectopic insertion of the co-transfected shuttle plasmid, leading to the production of 
infectious viral progeny. The next step was to investigate whether this system could be 
used to screen a mutant library with regard to its complementation capacity. For this, a 
number of mutants of the M53 library generated by transposon mutagenesis was 
selected and tested as described above (Figure 3.24). The M53 mutant library has been 
studied extensively and the capacity to complement the M53 deletion was known of 
each mutant used [95, 130].  
As previously, few IE1-positive foci were detected upon co-transfection of the 
∆M53 BAC with an empty shuttle plasmid, but viral reconstitution was not observed, 
whereas complementation of the M53 deletion with wt pM53 resulted in robust virus 
production. Expression of the complementation-competent mutants i43 and i104 also 
led to the formation of viral progeny, albeit the numbers of plaques formed were about 
half times lower than with wt pM53 in this experiment. The mutants i128, i207, i212 
and s309 failed in the previous screen to complement the M53 deletion [95]. This 
observation was also confirmed using the ICFA recombination-based assay, where no 
viral reconstitution was detected for any of these mutants. Furthermore, the plaque 
numbers obtained by phase contrast microscopy matched well with the quantification 
based on IE1-specific fluorescence. Thus, quantification of viral reconstitution was 
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possible without the requirement to specifically stain the samples for viral proteins 
(Figure 3.24B). 
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Figure 3.24: Validation of the ICFAR complementation assay using pM53 mutants 
of the Tn mutagenesis library 
(A) Overview of selected M53 mutants generated by transposon mutagenesis with regard to 
their ability (+) or failure (−) to either complement an M53 deletion BAC (middle row) or to 
inhibit the function of the wt pM53 during viral replication [95, 130]. nd, not determined. (B) 
Flpe-expressing cells were nucleofected with the ∆M53 BAC and the indicated shuttle plasmids 
and supplemented with NIH/3T3. Samples were fixed at 6 dpt and stained with an antibody 
specific for the IE1 protein. Plaques were quantified in parallel using fluorescence (grey bars) 
and phase contrast microscopy (black bars). EV, empty vector; i, insertion of five amino acids; 
s, stop mutation at this position. 
 
 Using the M53 mutant library as reference set, the results observed in this screen 
correlated exactly with the findings published before. Thus, the ICFA recombination 
assay can be used for the identification of non-complementing mutations. Consequently, 
this screen was named ICFAR complementation assay.  
 
3.3.4 Principle and validation of the ICFAR inhibitory assay 
 The ICFAR complementation screen aimed also at identifying mutants that fail to 
restore viral reconstitution. Only such non-complementing mutants have the potential to 
functionally inhibit the wt protein by a DN mechanism. However, most of the non-
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complementing mutants are simply non-functional and lack the potential to inhibit the 
wt function. To identify the few inhibitory mutants, they have to be re-analysed in a 
second assay, previously coined “inhibitory screen” (Figure 3.25).  
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Figure 3.25: Principle of the ICFAR inhibitory screen 
Murine fibroblasts stably expressing enhanced eukaryotic Flp recombinase (Flpe) were mixed 
with BAC DNA lacking the packaging signal (pac) and the respective shuttle plasmid carrying a 
mutated form of the GoI plus the complementing pac sequence, and transfected by 
nucleofection. Transformed cells were mixed with non-modified fibroblasts at a ratio of 1:3, 
seeded on multi-well plates and viral plaque formation was monitored. Reduced viral 
reconstitution was expected when the mutated form of the GoI was inhibitory for the wt protein 
(depicted as red wells), whereas non-inhibitory mutants would allow wt-like reconstitution 
(green wells). 
 
 This assay was developed similar to the complementation screen described above 
with the exception that the gene under study was still present in the acceptor BAC. 
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However, using a complete MCMV genome as acceptor BAC would not require Flp-
mediated ectopic insertion of the shuttle plasmid to enable virus production. 
Consequently, the escape of non-recombined BACs from the inhibitory function 
encoded by the shuttle plasmid remained possible. To ensure that only recombinants 
could be reconstituted, an additional essential genetic marker was transferred to the 
shuttle plasmid that could not be complemented in trans. Such an essential cis element 
is provided by the packaging signals (pac). Each MCMV genome is terminally flanked 
by two pac sequences (schematically depicted in Figure 3.12). These are recognised by 
the viral terminase during the encapsidation process, which induces cleavage of the 
concatemeric viral DNA, resulting in a unit length genome that is finally packaged 
[105]. To ensure proper cleavage, the pac sequences have to be present in the genome, 
i.e. the plasmid providing them needs to be part of the genome. 
 To establish the ICFAR inhibitory screen, the terminal region spanning the two pac 
signals was removed from the MCMV BAC and cloned into a shuttle vector (Figure 
3.26A). The shuttle plasmid further comprised two Gateway™ cloning-compatible 
DNA recombination sites (attR sites), which would allow to utilise this vector for the 
fast generation of a plasmid library. The inserted GoI was expressed under control of 
the promoter of the eukaryotic elongation factor 1α (EF-1α), which has been shown to 
be superior to the HCMV IE1 promoter in long-term application, since it is not silenced 
[171]. 
 First it was investigated whether virus reconstitution was possible from pac-lacking 
genomes. To test this, MEF were transfected with two independent ∆pac BAC clones 
and the production of viral progeny monitored. In both cases no viral plaques were 
observed for six weeks, confirming that the pac sequences are crucial for virus 
formation. Next it was examined whether the pac-containing shuttle plasmid was able to 
complement the pac deletion in the MCMV genome. For this, Flpe-expressing cells 
were nucleofected with the ∆pac BAC and either an empty vector or the pac-harbouring 
rescue plasmid and viral plaques quantified at 6 dpt (Figure 3.26B). No viral plaques 
were detected after nucleofection with the ∆pac BAC and an empty vector. In contrast, 
complementation using the pac-containing shuttle plasmid resulted in robust plaque 
formation, ranging between 40 and 60 plaques per sample due to recombination. 
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Figure 3.26: Complementation of the pac deletion using the IFCAR system 
(A) Construction of an MCMV BAC lacking the terminal packaging signals (pac). Schematic 
(left column) and observed (right column) restriction fragment pattern of wt MCMV (wt) and 
the pac deletion BAC (∆pac) using NsiI. Digest of wt MCMV resulted, amongst others, in 
fragments of 1, 1.5, 2.4, 3.1 and 3.8 kbp. In contrast, digest of the ∆pac BAC gave rise to an 
additional fragment of 1.25 kbp (green arrowhead). Numbers on the left side indicate size of the 
DNA fragments. M, 1 kbp DNA ladder. (B) IFCAR complementation of the pac deletion. Flpe-
expressing cells were nucleofected with the ∆pac BAC and a shuttle plasmid carrying the pac 
sequence and supplemented with NIH/3T3. Viral plaques were quantified at 6 dpt using phase 
contrast microscopy. Depicted are mean and standard deviation of two independent 
experiments. EV, empty vector. 
 
 Since it was shown that the pac signals were indeed crucial for viral reconstitution 
and that their deletion from the MCMV genome could be complemented using the 
ICFAR assay, the system had to be validated. Again the M53 mutant library was used as 
reference set. A couple of mutants known to be unable to complement the M53 deletion 
BAC [95], but harbouring the potential to inhibit the wt pM53 function upon their 
overexpression [130] were chosen and tested using the pac-based ICFAR assay (Figure 
3.27).  
 As before, no virus was reconstituted upon nucleofection of the ∆pac BAC together 
with an empty vector (containing no pac). Between 30 and 60 IE1-positive plaques 
were observed upon expression of wt M53 from the shuttle plasmid in addition to the 
100 
 
 
Results 
endogenous M53. The mutants i115, i128 and i146 were non-functional, yet did not 
interfere with wt pM53 in a DN mechanism. According to these expectations, plaque 
numbers comparable to the wt control were detected for the i115 and i128 mutants. 
Unexpectedly, only about half as much plaques formed in the presence of i146. The 
mutants i207 and i220 were known to be partially inhibitory during viral replication, i.e. 
reconstitution was delayed. In the presence of either mutant less than half of the plaque 
numbers of the wt M53 control were observed, confirming the partial inhibitory 
potential of these proteins. Conversely, about 10 plaques could be detected in the 
presence of the i313 and s309 mutants. However, both proteins have a strong DN 
potential and were completely inhibitory for virus production when expressed in the wt 
genome context [130]. Consequently, no vial progeny was expected for these samples. 
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Figure 3.27: Validation of the in-cell Flp-assisted inhibitory screen 
(A) Overview of selected M53 mutants generated by transposon mutagenesis with regard to 
their ability (+) or failure (−) to either complement an M53 deletion BAC (middle row) or to 
inhibit the function of the wt pM53 during viral replication [95, 130]. Double pluses indicate 
complete inhibition of wt pM53. (B) Flpe-expressing cells were nucleofected with the ∆pac 
BAC and the indicated shuttle plasmids and supplemented with NIH/3T3. Samples were fixed 
6 dpt and stained with an antibody specific for the IE1 protein. Depicted are mean and standard 
deviation of triplicate samples of two independent experiments. EV, empty vector; i, insertion 
of five amino acids; s, stop mutation at this position. 
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 To exclude that the DN mutant expression under control of the EF-1α promoter was 
too weak to provide sufficient protein amounts to inhibit virus production, the EF-1α 
promoter in the shuttle plasmid was replaced by the HCMV IE1 promoter and the assay 
repeated using wt M53 and the s309 mutant as examples. Yet again s309 failed to 
completely block reconstitution, resulting only in reduced plaque numbers between 17 
and 37% of the wt M53 control (data not shown). 
 
 Taken together, the ICFAR inhibitory assay successfully made use of an essential 
genetic element that cannot be trans-complemented, thereby supporting the integration 
of the shuttle plasmid. Using the M53 mutant library as reference set, the results were 
not as clear as expected, as the known strong DN examples i313 and s309 did not 
completely prevent virus production. However, the plaque numbers quantified for all 
the inhibitory mutants were considerably less than half of the value of the wt M53 
control. Thus, using a cut-off value of 50% of the control (or even less for the 
identification of strong DNs) should suffice to identify inhibitory mutants. Their proper 
DN potential has to be analysed subsequently in further assays based on conditional 
expression. 
 
 
3.4 Application of the ICFAR complementation system to 
study pM99 
 To allow the rapid identification of non-complementing mutations, i.e. mutant genes 
with DN potential, again mutant libraries of the GoI are required. Since the in vitro 
transposon mutagenesis system used in previous studies [95, 97] was not available any 
more, and an alternative system based on the MuA transposase, obtained from 
Finnzymes (Thermo Fischer), did not yield the expected mutagenesis frequency (data 
not shown), novel strategies to generate mutant libraries were demanded. One 
possibility was exploited by the domain shuffling and deletion approach described 
above for the M53 gene. However, not all herpesviral proteins show such distinct 
homology peaks in the sequence alignment with their homologues. For those proteins, 
the generation of mutant libraries by gene synthesis could be an option. Such a synthetic 
library should contain a comprehensive set of mutants covering the complete ORF or 
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part of it. To validate the ICFAR complementation approach further, M99 was chosen 
for mutagenesis. The M99 ORF is small and information about functionally important 
motifs were published for its HCMV homologue pUL99 [67, 90, 156], making this gene 
attractive for a test run. Here it was tested whether M99 complementation is reliable in 
the new assay. This would also provide a further example for the applicability of the 
ICFAR system. 
 
3.4.1 pM99 is essential for MCMV replication 
 At first it was tested whether M99, as its HCMV homologue pUL99, is an essential 
gene [21]. To this end, an M99 deletion BAC (∆M99) was generated. The first 64 bp of 
the M99 ORF overlap with the 3’-end of the M98 ORF, consequently the M99 ORF 
could not be deleted completely. The non-overlapping part was replaced by an ampR 
cassette using homologous recombination. To further prevent expression of the pM99 
N-terminus from the overlapping stretch, its start codon was modified from ATG to 
GTG, thereby removing the translational start signal. Since M99 is transcribed in a 
different reading frame than M98, this mutation did not change the aa sequence of 
pM98 (Figure 3.28).  
 To test the replicative capacity of MCMV in the absence of pM99, MEF were 
transfected with the ∆M99 BAC and plaque formation monitored. Whereas viruses were 
reconstituted from the wt MCMV BAC within few days, no viral progeny was detected 
originating from the ∆M99 BAC during six weeks, indicating that pM99 was critical for 
virus production. To confirm that the observed reconstitution defect was in fact due to 
the loss of pM99, a pM99 expression plasmid was inserted ectopically into the ∆M99 
BAC by Flp/FRT-mediated recombination (∆M99EPM99) and used to transfect MEF. 
In this case, viral plaques were detected within 5 dpt and complete cell lysis was 
reached within two weeks. 
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Figure 3.28: Construction of an M99 deletion BAC 
(A) Schematic illustration of the M99 deletion BAC (∆M99). The M99 ORF overlaps partially 
with the M98 ORF. The non-overlapping sequence was replaced by an ampR cassette using 
homologous recombination. Expression of the N-terminal part was prevented by exchanging the 
A in the start codon by a G (red box), which did not change the resulting aa sequence of pM98. 
(B) Wt nucleotide sequence of the M98/M99 overlap. The red box highlights the base pair that 
was changed. (C) Restriction fragment pattern of the wt MCMV and the ∆M99 BAC using SfiI. 
The 6.2 kbp fragment of the wt genome spanning the M99 ORF (red arrowhead) was replaced 
by a 7.2 kbp fragment containing the ampR cassette (green arrowhead).  
 
 
3.4.2 Flag-tagging of pM99 allows studies in the virus context 
 Since pM99 appeared to be essential for MCMV replication, it was tested whether 
Flag-tagging of its C-terminus was possible. Generally, it is preferable to generate a 
comprehensive mutant set using a tagged protein, as it allows studies on any mutant 
including those which carry insertions within the epitope for the recognition by the 
specific anti-serum. Therefore a rescue plasmid was constructed harbouring the 
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C-terminally tagged M99 ORF and inserted into the ∆M99 BAC (∆M99EPM99F). MEF 
were transfected with this modified BAC and the production of viral progeny 
monitored. Viral plaques were observed within six days and complete lysis within two 
weeks, indicating that also the Flag-tagged pM99 (pM99F) was functional and 
successfully complemented the M99 deletion. 
 To further study whether pM99F can be used as a model of pM99 in biochemical 
and cell biological assays, the properties of pM99F had to be compared to wt pM99. To 
do so, pM99 specific antisera were generated by immunising rabbits with two different 
pM99 peptide epitopes. To test their reactivity and specificity for pM99, lysates of 293 
cells transfected with a constitutive expression plasmid for pM99F and wt-infected 
M2-10B4 cells were subjected to Western blot analysis and probed for a specific pM99 
signal using the sera of the different steps of the immunisation process (Figure 3.29). 
The calculated size of pM99 is 11.8 kDa, of the Flag-tagged protein 13.2 kDa. 
However, since its homologues are post-translationally myristoylated and palmitoylated 
[7, 150], its size was expected to be slightly larger. Anti-Flag specific staining of the 
transfected sample revealed a signal close to 17 kDa, which was in the expected range. 
A correlating signal was observed for the final (SAB), the large (GP) and the small 
bleed (PP) of rabbit 700, with the strongest signal for GP700. The pre-immune serum 
showed a weak reactivity. Endogenous pM99 was also detected in lysates from wt-
infected cells using SAB700, GP700 and PP700. GP700 produced strongest pM99 
signal, but additionally an unspecific band at ~38 kDa was detected. A specific pM99 
signal was also detectable in transfected samples for PP701 and GP701, but only very 
weakly for SAB701. In contrast, this immune serum failed to recognise pM99 in lysates 
from wt-infected cells. Interestingly, the small bleed (GP) of both antisera had a higher 
reactivity than the final bleed. 
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Figure 3.29: Reactivity of pM99 specific antisera in Western blot 
293 cells transiently transfected with a plasmid expressing Flag-tagged pM99 (t) and M2-10B4 
cells infected with wt MCMV (i) were lysed in TLB at 48 hpt/hpi and probed with polyclonal 
antisera (700, 701) against different pM99 epitopes. pM99 expression in transfected cells was 
also confirmed using a monoclonal antibody specific for Flag. The observations are summarised 
in the bottom left table. PPI, pre-immune serum; PP, small bleed; GP, large bleed; SAB, final 
bleed; nc, not conclusive. 
 
 Using the newly available pM99-specific antisera, the expression kinetics of pM99 
was investigated using M2-10B4 cells infected with wt MCMV at an MOI of 1 in the 
absence and presence of phosphonoacetic acid (PAA). PAA specifically prevents the 
expression of genes that are dependent on active genome replication (true late genes) by 
inhibiting the viral polymerase [62]. A clear signal for pM99 was detected at 18 hpi and 
accumulated further until 24 hpi in the absence of PAA, whereas treatment with PAA 
completely abolished pM99 expression (Figure 3.30). The same pattern was observed 
for pM53, which is also a known late gene product [95], while expression of the IE 
protein pp89 was not blocked. Accordingly, pM99 was expressed with late kinetics, 
similar to the HCMV homologue pUL99 [70]. 
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Figure 3.30: MCMV pM99 is expressed with late kinetics 
M2-10B4 cells were infected with wt MCMV at an MOI of 1 and cultured in the absence (−) 
and presence (+) of 300 µg/mL PAA. Cell lysates were prepared at indicated time points, 
separated by SDS-PAGE and probed for pp89, pM53, pM99 and GAPDH by Western blotting 
with specific immune sera. 
 
 
 In addition to their specificity in Western blotting, the antisera reactivity was tested 
in immunofluorescence samples. U2-OS cells transfected with a plasmid expressing 
pM99F were stained with GP700 and GP701, as those gave the strongest signals in the 
Western blot analysis, as well as anti-Flag antibody. Analysis of the subcellular 
distribution of pM99 specific signals by confocal immunofluorescence microscopy 
revealed juxtanuclear punctuate stainings localised predominantly in a limited area. 
These signals co-localised well with the signal obtained by the anti-Flag staining, 
indicating that the pM99 antisera indeed detected pM99 in situ in transfected cells (data 
not shown). The same pattern was observed in U2-OS cells transiently expressing 
pM99F together with HA-tagged pM94 (pHAM94) (Figure 3.31A and B), which is a 
known interaction partner of pM99 [97]. pM99F and pHAM94 co-localised completely 
at the juxtanuclear compartment, presumably the endoplasmic reticulum-Golgi 
intermediate compartment (ERGIC), as was reported previously for their homologues 
[90, 150], thus confirming this interaction in situ in MCMV. 
 In wt-infected M2-10B4 cells, pM99-specific signals were also detected adjacent to 
the nucleus (Figure 3.31C), which possibly reflects its localisation within the viral 
assembly complex, where cytoplasmic maturation of viral particles takes place [149, 
155]. A similar juxtanuclear pattern was observed for pM99F and its binding partner 
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pM94 in M2-10B4 cells infected with a virus expressing Flag-tagged pM99 
(MCMV-∆M99EPM99F) (Figure 3.31D), confirming the presence of both pM99 and 
pM94 at the assembly complex.  
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Figure 3.31: Intracellular localisation of pM99 
U2-OS cells were transiently transfected with plasmids expressing Flag-tagged pM99 and HA-
tagged pM94 (A, B), and M2-10B4 cells were infected with indicated viruses (C, D). Cells were 
fixed at 36 hpt/hpi and probed with polyclonal antisera against pM99 (GP700, GP701) and 
monoclonal antibodies specific for Flag and HA, followed by Alexa-conjugated secondary 
antibodies. DNA was visualised using TO-PRO 3. Scale bar, 10 µm. BF, brightfield. 
 
 
3.4.3 ICFAR complementation of the M99 deletion 
 Since pM99 was essential for MCMV and ectopic insertion by the traditional 
Flp/FRT technique restored viral growth, it was tested whether the ICFAR 
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complementation system was applicable to complement the ∆M99 BAC with wt M99. 
To monitor successful nucleofection and protein expression, expression of pM99 was 
linked via an internal ribosomal entry site (IRES) to the expression of GFP.  
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Figure 3.32: pM99 expression under control of different promoters 
293 cells were transiently transfected with plasmids constitutively expressing the indicated 
M99-IRES-GFP constructs. pM99 expression in the first two columns was driven by the HCMV 
IE1 promoter, in the third and fourth column by the endogenous M99 promoter. F, Flag; i, 
IRES; P, M99 promoter. (A) Fluorescent signals emitted by GFP at 48 hpt. (B) Cell lysates were 
analysed by Western blotting and probed for pM99 and GAPDH. 
 
 At first it was examined whether pM99 expression rates varied significantly using 
different promoters. Thus, 293 cells were transiently transfected using plasmids 
expressing Flag-tagged or untagged pM99 either under control of the HCMV IE1 
promoter (PCMV) or under control of the endogenous M99 promoter (PM99) as well as 
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GFP in an IRES-induced manner. Fluorescence microscopy revealed that the GFP 
signal obtained induced by the M99 promoter was strongly reduced as compared to the 
PCMV-induced GFP signal (Figure 3.32A). Assuming that IRES-induced expression is 
directly dependent on promoter-driven expression, the GFP signal indicated that 
substantially less pM99 was produced under control of PM99 than compared to the 
HCMV IE1 promoter. This assumption was further confirmed by Western blot analysis 
probing for pM99 (Figure 3.32B). 
 
 Since it was not known whether the amount of pM99 required for viral 
reconstitution was restricted or whether strong pM99 overexpression would be 
detrimental for virus production, the PCMV and the PM99-driven constructs were tested in 
the ICFAR complementation assay. To facilitate automated quantification using 
fluorescent signals, the M99 ORF was deleted as described in Figure 3.28 from an 
MCMV BAC, in which mCherry expression was coupled by an IRES to the endogenous 
expression of the smallest capsid protein (SCP), giving rise to SCPiChe-ΔM99. This 
structural protein is expressed with late kinetics (unpublished observations), therefore 
an mCherry signal would imply active replication of the viral genome. Flpe-expressing 
cells were nucleofected with the SCPiChe-∆M99 BAC together with one of the M99-
expressing plasmids and viral plaque formation quantified at 6 dpt. 
 Whereas no viral progeny was observed upon nucleofection of SCPiChe-∆M99 
together with an empty shuttle vector, co-transfection with each of the M99-expressing 
constructs resulted in virus reconstitution (Figure 3.33). In comparison, 
complementation with pM99 expressed under control of PCMV, i.e. in high amounts, was 
less efficient. Only few plaques were detected upon PCMV-regulated pM99 and pM99F 
expression, indicating that excess pM99 obstructed virus production. In contrast, PM99-
driven expression of pM99 restored viral reconstitution more efficiently, yielding much 
higher plaque numbers.  
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Figure 3.33: ICFAR complementation of the M99 deletion 
Flpe-expressing murine fibroblasts were nucleofected with the SCPiChe-∆M99 BAC and the 
indicated shuttle plasmids. Cells were fixed at 6 dpt and (A) viral plaques quantified using 
fluorescence microscopy. Depicted are mean and standard deviation of two SCPiChe-∆M99 
BAC clones in two separate experiments. (B) Plaque appearance exemplified for the 
complementation with PM99-igfp. F, Flag-tag; i, internal ribosomal entry site; P, M99 
promoter. 
 
 Both fluorescence signals (mCherry from the BAC, GFP from the plasmid) were 
detected in all viral plaques examined. Since complementation with PCMV-driven pM99 
expression yielded only few plaques, most of the analysed plaques originated from 
PM99-regulated pM99 complementation. In these plaques the mCherry signal appeared 
to dominate (Figure 3.33B). This, however, might be explained with the relatively low 
GFP expression under control of PM99. 
 Taken together, this analysis successfully established the complementation of the 
M99 deletion, providing insights into the construction and investigation of potential 
pM99 mutants, namely to preferentially use constructs expressed under control of the 
M99 promoter. 
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3.4.4 Application of the ICFAR system to test M99 mutants 
 Since a comprehensive mutant library covering the M99 ORF is not yet available, a 
couple of mutants were generated based on the information available for the HCMV 
pUL99 protein. Alignment of 34 representative pUL11 homologues revealed just one 
homology peak, designated CR1, although the maximum similarity was quite low 
(Figure 3.34A). In HCMV pUL99 this region contains the pUL94 binding motif [90]. 
Furthermore, the N-terminal glycine was shown to be myristoylated and aa 44-57 
comprise an acidic cluster (AC). Both features are required for correct localisation of 
the protein and viral growth, whereas the C-terminal part is dispensable [67]. 
Corresponding to this, pM99 mutants were generated lacking the first glycine (∆Gly2), 
the potential pM94 binding domain (∆M94) or the acidic cluster (∆AC) (Figure 3.34B). 
The expression of all mutants was regulated by PM99. 
 Nucleofection of Flpe-expressing cells with the SCPiChe-∆M99 BAC together with 
one of the mutant M99-expressing plasmids repeatedly did not result in the formation of 
any viral progeny, whereas reconstitution was observed in the control reaction using the 
wt M99-expressing vector (Figure 3.34C). This indicated that also in MCMV pM99 
each of the three deleted features is crucial for the protein functionality. If any of those 
mutants was inhibitory for MCMV replication would need further testing applying the 
ICFAR inhibitory assay. 
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Figure 3.34: Construction and ICFAR complementation of pM99 mutants 
(A) The amino acid sequences of 34 pUL11 homologues (accession numbers are listed in the 
Supplement, Table 6.2) were aligned using the Vector NTI AlignX program (Invitrogen) via the 
BLOSUM 62 similarity matrix. The similarity plot was calculated using a 5 aa window size, 
with scores for weak and strong similarity and identity of 0.2, 0.5, and 1.0, respectively. The x 
axis represents the number of amino acids in the consensus sequence. The conserved region 
(CR) is indicated below the diagram. (B) Schematic overview of the pM99 mutants. Proteins are 
depicted as grey bars, the conserved region is indicated as black box (aa 12-43 in pM99). 
Deletion mutants are shown with bridged spacing. Numbers on the right indicate the amino 
acids of pM99 affected by the mutation. CR, conserved region. (C) Flpe-expressing cells were 
nucleofected with the indicated BAC and plasmids and plaque formation quantified at 6 dpt. 
Mutants are based on the PM99-igfp plasmid. 
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4 DISCUSSION 
 
 
 Each of the eight existing human herpesviruses is capable of provoking severe or 
even fatal disease in individuals having an immature or impaired immune system. 
Herpesvirus disease is almost exclusively controlled by antiviral therapy targeting the 
replication of the viral DNA [reviewed in 33]. However, novel antiviral strategies 
exploit the manipulation of protein-protein interactions to suppress viral replication 
[reviewed in 94]. Targets of this approach are proteins that act in essential complexes. 
One new possibility to disrupt such viral protein networks and thereby control virus 
replication is the application of peptides or other small molecules, as shown recently for 
the NEC of HCMV [153, 180]. Another option is provided by the utilisation of 
dominant negative mutants. Dominant negative mutants are derived from multi-
functional wt proteins that require protein-protein interaction(s) to fulfil at least one of 
their essential functions. In the DN mutant, a downstream function is inactivated. If the 
mutant is competitive to the wt allele of the targeted protein-protein interaction, it will 
enter into the physiological pathway and block it by either not executing its downstream 
activity or by preventing binding of other downstream targets [58]. 
 
4.1 Identification of DN mutants 
 In diploid eukaryotic organisms, gene products can exist in two different versions, as 
most of them are encoded by two alleles. Cellular DNs are mutants of one allele that 
inhibit the function of the second, intact protein. In herpesvirus genomes, usually just 
one allele codes for most of the genes including all core genes, therefore DNs have to be 
provided either in cis by an additional expression cassette or in trans by the host cell. 
 Classically, the function of an unknown gene is investigated by gene knockout. DN 
proteins possess several advantages that make their application superior to simple gene 
deletion. One major advantage is that by inactivating the wt protein by a DN the 
deletion phenotype is accessible in the presence of the wt allele, while trans-
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complementation of the target gene is not required. In addition, proteins often execute 
multiple functions in dynamic processes such as varying localisations and/or interaction 
with different partners. Deletion of such a gene product only reveals its most prominent 
(usually its most upstream) role, which may actually be a combination of several 
functions. In contrast, exchanging one domain by an inhibitory one can interfere with 
just one function and leave the others intact. Thereby different DNs are capable of 
arresting pathways or complexes at various steps, which is their second big advantage 
and cannot be achieved by any deletion. 
 
4.1.1 Classical approach to identify DNs 
 Although DN proteins are such valuable tools to dissect cellular as well as viral 
protein functions, they are not isolated easily. Many cellular DN mutations, such as 
inhibitory p53 variants in cancer cell lines, were identified by analysing the genotypes 
of certain diseases [16, 158]. Most of the viral DNs were either generated at random or 
found by chance. For example, GFP-tagging of the HCMV SCP in order to monitor 
virus entry by means of fluorescently labelled capsids failed with regard to the original 
purpose, but gave rise to strong DN proteins [18].  
 Unfortunately, comprehensive information on structural and functional domains, 
which would allow a rational design of DN mutants, is at present not available for most 
of the herpesviral gene products. Proteins of interest have therefore been modified using 
random mutagenesis techniques. Methods of choice for this are either alanine-scanning 
[38] or the linker-scanning transposon (Tn) mutagenesis [13, 57]. While in the alanine-
scanning single (or multiple) amino acids (aa) are substituted by alanine (or a stretch of 
alanines), the Tn mutagenesis introduces short additional aa insertions and, depending 
on the system, even C-terminal truncations. 
 The second approach has been successfully applied to identify critical regions of 
cellular and viral gene products [34, 80, 172] or even essential genes [182]. Our group 
used it to study and isolate DN mutants of the MCMV proteins pM50, pM53 and pM94 
[95, 97, 130, 141]. The generation of such mutant libraries is aided by commercially 
available products and delivers fast results with a good coverage of the ORF. The 
limiting step, however, is the subsequent analysis and evaluation of the obtained 
mutants. For example, for a protein of 300 aa, with a coverage of one mutation at every 
fifth aa, 60 mutants have to be analysed. Using the traditional screening method for 
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MCMV with bacterial flip-in [22], BAC isolation and transfection, this consumes a lot 
of time and resources, especially as most likely many of the mutants will be viable, i.e. 
complement the deletion of the wt gene. To reduce the workload and to quicken the 
outcome, one could imagine two possibilities. The first could be to decrease the number 
of mutants to be analysed by identifying important regions of the protein by targeted 
mutagenesis. These smaller regions can then be subjected to a random mutagenesis to 
obtain more subtle mutations. The second approach would be the establishment of a 
laboriously less demanding screening system to test the candidates faster. In this work 
both alternatives were tested and evaluated regarding their usefulness to generate or 
improve DN mutants affecting MCMV morphogenesis.  
 
4.1.2 DN isolation by targeted mutagenesis 
 Random screens for DN mutants are time-consuming and labour-intensive. Thus, it 
was of interest to investigate whether DNs can be constructed on a predictive basis. 
Usually DN mutants are designed with reference to detailed information about 
structure-function relationships. However, this knowledge is limited to only few 
proteins. That rational design of inhibitory mutants can principally work was shown by 
a genome-wide, systematic screen to identify DN mutants affecting poliovirus. Mutants 
were tested that resembled previously identified lethal mutations or were predicted by a 
computer algorithm to be protein destabilising. Several DN mutations were isolated in 
this study [37]. For herpesviruses, however, there is only sequence information from 
related viruses to provide a very rough basis for mutant design. Initial clues suggesting 
that such a sequence-based approach may work, however, could be deduced analysing 
the data gained by the random screen for DN mutants of the MCMV protein pM53. 
Analysis of about 100 random mutants indicated the accumulation of potential DNs 
within two conserved regions (CRs) of the protein, namely CR2 and CR4, which were 
classified according to the degree of amino acid homology to other members of the 
pUL31 family [95, 130]. Notably, these regions, however, did not appear to 
complement pM53 functions if they were derived from a pUL31 homologue belonging 
to a more distant herpesvirus sub-family [152]. Thus, it was concluded that these 
domains should code for a binding independent function which may be sub-family 
specific. 
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 Accordingly, a set of MCMV M53 mutants was constructed in this study in which 
the above described CRs of pM53 were disrupted by targeted mutagenesis, either by 
domain shuffling or by domain deletion. Conditional expression of these mutants in a 
viral context revealed their inhibitory potential. On the whole, the data observed for the 
designed mutants correlated well with the results of the earlier random screen, 
indicating that an approach based on sequence comparison can indeed be used to 
construct inhibitory mutants. Targeting CR2 gave even rise to improved DN effects. 
These mutants blocked virus production by up to four orders of magnitude, an effect 
that was about 100-fold stronger than that observed with the insertion mutants generated 
in the random screen. In addition, shuffling of CR4 also produced the DN mutant 
expected from the data obtained from the random screen.  
 Summarising, the M53 data accumulated during this study led to the assumption that 
it appears possible to design mutants with inhibitory phenotype on an exclusively 
prediction-based approach, although they might possess less inhibitory capacity 
compared to the mutants derived from a random mutagenesis. Nevertheless, one cannot 
conclude a general rule to predict the strength of a DN. If domain replacement leads to 
the identification of weak DNs, they could be improved by additional subtle mutations 
within the identified region. 
 Exchanging conserved regions of related virus subfamilies may always provide 
functional integrity to some extent, particularly if amino acids critical for enzymatic 
activity or binding of functional partners are maintained. Thus, the more distantly 
related the viruses are, which the genetic elements are derived from, the higher the 
chance to shuffle domains with non-complementing character. Therefore, replacing 
each conserved domain one by one with the respective domains of the most distant 
homologue seems to be the best approach to identify regions with inhibitory potential. 
The alternative to this would be directed deletions of the predicted CRs based on protein 
alignments. This study confirmed the feasibility of both methodologies. 
 Even if the mutants constructed by domain shuffling are not as inhibitory as DN 
mutants with subtle mutations, a great benefit of this approach is that the workload is 
minimised. Particularly for large ORFs, this issue is of high interest. Since verified 
sequence information from more than 30 homologues of all herpesvirus core genes are 
available, we believe that a genome wide screen targeting small conserved regions is 
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feasible and would probably provide DNs of multiple genes with the workload 
comparable to that needed to screen one gene with the random approach used so far. 
 
4.2 Characterisation of pM53 mutants 
 UL31 family members are essential multifunctional elements of the herpesvirus life 
cycle. As described in this study, specific targeting of pM53 CR2 resulted in mutant 
proteins that blocked viral replication up to 10,000-fold. This stronger inhibitory effect 
enabled for the first time a more detailed investigation of the role of pM53 in general 
and its CR2 in particular. 
 The prominent role of the pUL31 homologues is the formation of the NEC along 
with pUL34 homologues, and this NEC mediates capsid transport through the nuclear 
envelope [15, 26, 46, 49, 50, 71, 75, 83, 85, 95, 116, 134, 135, 140, 162, 163]. 
However, an increasing number of studies have identified additional functions for 
pUL31 including effects on genome cleavage, capsid targeting to the INM and 
induction of membrane curvature [130, 138, 184]. Here, M53 alleles lacking CR2 were 
constructed to further study the putative roles of pM53 during MCMV replication. It 
was observed that not only CR4- [130] but also CR2-deficient pM53 significantly 
reduced the number of viral unit length genomes and blocked capsid export from the 
nucleus. Furthermore, the binding capacity of the CR2 mutant for pM50 was impaired. 
Nevertheless, the mutant still induced re-localisation of the NEC in infected cells. This 
strongly indicates that mutations within this region of the protein interfere with the 
formation of homotypic interactions between NEC subunits, as discussed for HSV-1 
[138].  
 
4.2.1 Role of pM53 in nuclear maturation 
 The first UL31 deletion mutants of HSV-1 revealed a defect in viral DNA packaging 
[29], which was later also confirmed for alpha-, beta- and gamma-herpesviruses [52, 71, 
82, 130]. In Epstein-Barr virus (EBV), deletion of the UL31 homologue, BFLF2, results 
in the accumulation of DNA-lacking A and B capsids, together with a defect in 
intranuclear distribution, although the defective particles were still exported [52]. This 
study confirms previous findings in the MCMV system, i.e. that pM53 (the beta-
herpesvirus homologue of pUL31) is involved in the DNA cleavage/packaging process. 
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About 91% of the nuclear capsids in MCMV-SVT-∆2-infected cells lacked DNA, and 
there was a marked reduction in the number of unit length genomes. This effect alone 
does not explain the strong inhibitory effect, but it points out that the NEC is involved 
in genome cleavage/packaging. Therefore, it is possible that nuclear egress is monitored 
by a quality control mechanism that preferentially selects mature DNA-filled capsids for 
primary envelopment rather than DNA-lacking immature forms [25, 53]. Recently, 
capsid maturation in alpha-herpesviruses was suggested to be linked to nuclear egress 
by association of pUL31 with viral capsids. While in HSV-1 this interaction depended 
on pUL25 [184], a constituent of the C-capsid specific complex (CCSC) consisting of 
pUL17 and pUL25, these were not required for pUL31-capsid interaction in PrV [87]. 
Capsid-bound pUL31 was observed using a pUL34 deficient PrV, which stabilised the 
normally transient pUL31-capsid intermediate. Despite its enrichment on C capsids, 
pUL31 was also detected on A and B capsids, even though the terminase subunits as 
well as the portal protein were not required for this interaction [87 and unpublished 
observations]. In a yeast two-hybrid screen in VZV, the pUL31 homologue interacted 
with several other proteins [175]. Therefore, capsid binding of pUL31 is likely mediated 
by at least one so far unknown protein-protein interaction. Although the majority of 
pM53 protein signal was detected at the nuclear envelope using immunofluorescence 
microscopy, the pUL31 capsid association shows that a fraction of it is present close to 
the replication centres, thereby supporting viral maturation. An enzymatic function for 
pUL31 has not been reported yet, indicating that this protein possibly stabilises other 
protein complexes which then efficiently execute viral DNA cleavage and packaging. 
Notably, overexpression of pM53∆2 rapidly saturates its binding sites on pM50 at the 
nuclear rim, leading to a higher number of free proteins in the nucleosol, ready to attach 
to capsids. There the surplus might interfere with DNA cleavage either by blocking 
terminase activity or by de-stabilising a yet uncharacterised maturation complex. 
 
4.2.2 Role of pM53 in capsid targeting to the INM 
 Mature, DNA-filled capsids need to be transported to the nuclear periphery, where 
they transit through the nuclear envelope. Docking of mature capsids at the INM was 
abrogated in an HSV-1 UL34 mutant [138], suggesting a role for pUL34 in docking 
selectivity. In addition, capsids docked to the INM were observed very rarely during 
DN mutant expression in MCMV-SVT-∆2-infected cells. This could be a consequence 
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of impaired capsid maturation associated with reduced genome cleavage. Yet, it could 
also reflect a defect associated with capsid transport to the egress sites. The first 
scenario would agree with previous observations showing inefficient primary 
envelopment of viral mutants, which failed to complete the DNA packaging process [2, 
29, 32, 53, 103, 129]. The second explanation is supported by the EM data from the 
present study, where mature C capsids present in MCMV-SVT-∆2-infected nuclei were 
not observed at the INM, but mainly remained associated in capsid clusters formed 
within the nucleoplasm, arguing for a transport defect caused by the CR2 mutant. 
 It is believed that capsid-bound pUL31 guides mature DNA-filled capsids to INM-
bound pUL34 or pUL34/pUL31 complexes [66]. In this study, capsid-bound pM53∆2 
bound poorly to pM50, and there was no homotypic binding to wt pM53, which might 
account for the migration/targeting defect of the capsids. We therefore propose that the 
capsid clusters observed in cells infected with the CR2 deletion mutant in fact represent 
the DNA packaging sites. These sites cannot be detected by EM in the highly dynamic 
wt situation, because mature capsids are rapidly transported to the INM. Only the 
blockade of capsid migration by pM53∆2 makes this process visible.  
 
4.2.3 Role of pM53 in nuclear egress 
 Strong expression of the CR2 deletion mutant changed the distribution of the NEC 
and led to the formation of aggregates at the nuclear membrane. It was observed 
previously that pUL31 homologues are destabilised if they fail to bind to pUL34 
homologues [130, 185]. It was proposed that the DN function of pM53 mutants was due 
to displacement of wt pM53 from the NEC, which renders the wt protein prone to 
degradation. Yet, overexpression of pM53∆2 did not destabilise wt pM50. This effect is 
quite different from the effect of the s309 CR4 mutant, which led to the degradation and 
loss of both wt NEC proteins [130]. However, the CR2 mutant had no selective effect 
on the stability of either wt pM53 or wt pM50. This is in line with the reduced binding 
capacity of pM53∆2 for pM50. Thus, the DN effect cannot be explained by competition 
between the mutant and the wt protein for incorporation into the NEC. This suggests 
that another, as yet unknown protein-protein interaction (mediated by pM53) is required 
for correct NEC formation at the nuclear rim. It might also explain why s309 has higher 
DN potential, since both wt pM50 and wt pM53 are degraded in cells infected with 
s309-expressing viruses.  
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 Studies on a charged cluster DN mutant of HSV-1 pUL34, the homologue of pM50, 
implicated this protein, together with CR3 of pUL31, in the induction of INM curvature 
[138]. Notably, no CR3-derived pM53 mutant with inhibitory potential was retrieved 
from the insertion library [130] or by using the domain shuffling approach. However, 
despite the lack of functional significance, a reduced binding capacity of the CR2 and 
CR3 mutants for pM50 was observed, which confirms the data obtained for the HSV-1 
homologues. Incidentally, Roller and colleagues discussed a multi-level interaction 
within the NEC proteins [138]. Although the major binding motif in the MCMV NEC is 
clearly located in CR1, the present analysis now reveals that the pM53 CR2 region also 
contributes to the binding of pM50.  
 Finally, nuclear membrane dynamics contribute substantially to primary 
envelopment of herpesviruses. When nuclear egress of the capsids was blocked, 
membrane stacks were formed in MCMV-SVT-∆2-infected nuclei, as observed with 
other DN mutants of MCMV NEC proteins [141]. These membrane aberrations were 
probably derived from the INM, but we did not observe vesicles similar to those 
monitored in the HSV-1 pUL34 CL13 mutant [139]. Haugo and colleagues observed 
nuclear envelope blebbing, along with an electron dense layer, upon infection with 
mutant UL34 HSV-1, which protruded into the cytoplasm [56]. The membrane 
phenotypes induced by different viruses and mutants in different cell types are 
remarkably distinct. Yet, they point to the same fact, namely that the NEC alters the 
membrane dynamics of the nuclear envelope. 
 Another striking feature of the pM53 DN was the apparent failure to form a 
cytoplasmic assembly complex. Due to the block in nuclear maturation, hardly any 
cytoplasmic capsids were observed in MCMV-SVT-∆2-infected cells. Coincidently, the 
typical ring-shaped vesicle accumulations derived from the Golgi and TGN 
compartment, which have been described studying HCMV infected cells [42], could not 
be detected in MCMV-infected cells expressing the pM53 DN, whereas in cells infected 
with mutant HCMV or MCMV viruses lacking one of the two SEC proteins, which are 
blocked in cytoplasmic maturation, a defined assembly site was still observed [97, 161]. 
This may indicate that the presence of a critical number of cytosolic capsids is required 
to induce the formation of the viral assembly complex. Alternatively, by vesicle 
formation and fusion with the outer nuclear membrane the NEC proteins are 
translocated to the cytoplasm during wt infection. Thus, it is also possible that the NEC, 
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in addition, executes a further downstream function in the cytoplasm, which is required 
for the initiation of the assembly complex. 
  
 Until recently, the nuclear export pathway exploited by herpesviruses had been 
thought to be unique to them. However, Speese and colleagues, during their 
investigation of the Drosophila synaptic development, found ribonucleoprotein particles 
(RNPs) that complexed with lamin C and the C-terminal end of a cellular signalling 
receptor, DFz2C, which is transported from the plasma membrane to the nucleus. These 
large granules do not undergo conformational adaptations to fit the nuclear pore 
complex export machinery as reported for other RNPs [40]. Instead, they also enter the 
cytoplasm by a mechanism of transition through the nuclear envelope accompanied by 
envelopment and de-envelopment [168] akin to that described for herpesviruses. Both 
exit strategies share the disassembly of the lamina underlying the nuclear membrane, 
which is disrupted by multiple phosphorylation events. In herpesvirus infection, viral 
and cellular kinases are recruited to the INM to dissolve the lamin layer [15, 27, 73, 
115, 118, 123, 136, 144]. The NEC proteins pUL31 and pUL34 are thought to induce 
membrane curvature, thereby facilitating vesicle formation [71]. Speese et al. 
demonstrated that a cellular kinase, atypical PKC, is required for lamina remodelling 
and formation of DFz2C granule containing invaginations of the INM [168]. Based on 
their observations, Speese et al. propose that herpesviruses not only hijacked the lamina 
disassembly pathway operationally during nuclear export, but a complete nuclear exit 
mechanism used by endogenous RNPs. The data presented here, however, point 
towards a more general role of the NEC in herpesvirus morphogenesis. Clearly 
processes other than the nuclear egress were inhibited by the DN mutants of pM53. For 
the first time a mutant of an NEC protein was described to induce inhibition of DNA 
synthesis. This may indicate that the role of the NEC is more fundamental in nuclear 
viral morphogenesis than it was believed before and that the NEC may be required for 
efficient execution of all functions which require the reorganisation of chromatin 
dynamics during infection [127]. Supporting this idea it was reported that the HSV-1 
homologues affect the late chromatin reorganisation in infected cells [162, 163]. 
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4.3 High-throughput screening for essential functions of 
MCMV 
Identification of DN proteins can be separated into consecutive steps. At first, a 
mutant library of an essential gene of interest is generated. Traditionally, this is carried 
out using random Tn mutagenesis, yielding numerous candidate genes. These are 
inserted into a viral BAC deficient for this gene, and analysed with respect to their 
ability to restore virus reconstitution. Mutants that fail to complement the wt gene point 
out key regions of the protein. The DN potential of those mutants is then tested by their 
expression in the wt genome context. The time expenses of this scheme can be reduced 
in two aspects. First of all, the number of mutants to begin with can be reduced by 
disrupting different regions of the protein by targeted mutagenesis as described for 
pM53 in the current study. Thereby, essential domains are identified by investigating 
only a limited number of mutants, which can then be subjected on demand to a more 
thorough mutagenesis with an even higher coverage of the parts of interest. 
Where a targeted mutagenesis is not possible, for example for proteins without 
distinct sequence homology peaks such as pM94, the second approach to reduce the 
effort will be valuable, namely to rapidly test many mutants in a high-throughput 
screening system. To this end we developed a host cell based flip-in system that omits 
the necessity of the manipulation of the MCMV genome in bacteria.  
 
4.3.1 Evaluation of the ICFAR system 
 In the classical approach, the expression cassette encoding the (mutant) gene of 
interest was inserted into the MCMV BAC via site-specific recombination, which was 
performed in bacteria and demanded the subsequent purification of recombinant BACs 
from bacterial cultures. In the new system, the in-cell Flp-assisted recombination 
(ICFAR) system, this step was replaced by allowing recombination to take place within 
the mammalian target cells, which were modified to stably express Flpe recombinase, 
an evolved form of the original Flp recombinase better adapted to catalyse the 
recombination reaction at 37 °C [24]. The presence of the Flpe-encoding mRNA, i.e. the 
indicator for active transcription, was confirmed by reverse transcription of isolated 
RNA and PCR of the resulting cDNA in parallel to each experiment and was detectable 
for several weeks of sub-culturing. The Flpe-expressing cells were transfected using a 
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technology established recently by the Lonza AG termed nucleofection, which 
facilitates the direct ingress of the transfected DNA into the nucleus of the treated cell 
[12, 100, 173]. This provides the chance to transfect even non-dividing cells, which is 
not an issue for the NIH/3T3 cell line, from which the Flpe-expressing cells are derived, 
but which is quite useful for MEF, which do not divide any more after reaching 
confluence. Another advantage of this technique is that it reduces the effort to transfect 
high numbers of samples under comparable conditions. In comparison, for transfection 
reactions utilising lipids or liposomes the DNA has to be mixed with the transfection 
reagent and added onto the cells or into the cell culture medium. This requires the 
successive preparation of one reaction mix per sample. For nucleofection, cells are 
harvested and resuspended within the transfection solution, before the whole mixture is 
added to the DNA preparation. That not only grants analogous treatment and conditions 
for the cells, which are handled as one block, but also permits to set up up to 96 samples 
in parallel in a much shorter time frame. 
 The ICFAR system was successfully tested and evaluated using BACs devoid of an 
essential viral gene or genetic feature as well as already characterised mutants of an 
M53 library created by random mutagenesis. Flpe-expressing cells were nucleofected 
with one of the deletion BACs and its respective rescue plasmid and complementation 
of the genetic defect assessed by plaque formation. Whereas nucleofection with the 
∆M53, the ∆M56 and the ∆M104 BAC together with an empty shuttle vector did not 
produce viral progeny, the complementation with the respective wt genes reproducibly 
resulted in plaque formation. The same was true for the complementation of the deletion 
of the pac sequences, which are essential for encapsidation and cleavage of newly 
replicated MCMV genomes into the viral capsids [105]. Nucleofection with the ∆pac 
BAC and the respective pac-containing rescue plasmid successfully restored virus 
production, resulting in 40 to 60 plaques per sample. This confirmed that the in-cell Flp-
assisted complementation assay is feasible for virus reconstitution. Furthermore, the 
results are quantifiable already at 6 dpt and do not need to be maintained for 6 weeks. 
Mutations that are partially functional and lead to delayed virus reconstitution may 
perhaps be negative in this screen. These, however, can be analysed in more detail in 
the inhibitory screen. All in all, the ICFAR complementation assay is performed much 
faster than the traditional complementation using the bacterial flip-in, reducing the 
required time by several weeks. 
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Since the ICFAR complementation system was not only developed to reconstitute 
viruses, but to identify non-complementing mutations in a target gene, it was tested with 
a reference set of M53 mutants [95]. According to the expectations, the complementing 
mutants (i43, i104) led to the formation of viral progeny, whereas the non-functional 
mutants (i128, i212) as well as the inhibitory mutants (i207, s309) did not induce virus 
production. These observations confirmed the applicability of the ICFAR 
complementation assay to identify non-complementing mutations that might be 
inhibitory for viral growth.  
 In the next step, the ICFAR system was applied to isolate inhibitory mutations. For 
this, a couple of M53 mutants that have been shown to be non-complementing for the 
M53 deletion BAC [95], but with diverse potential to inhibit the wt pM53 function upon 
their overexpression [130] were tested using the pac-based ICFAR assay. In agreement 
with the expectations, expression of non-functional but non-inhibitory mutants (i115, 
i128, i146) did not interfere with viral growth and resulted in plaque numbers 
comparable to wt pM53 overexpression, whereas expression of the partially inhibitory 
mutants (i207, i220) decreased viral plaque formation to less than half of the control 
value. However, the known strong DN proteins (s309, i313) were not able to inhibit 
virus production completely, as it had been shown previously in other assay systems 
[130]. The limited inhibitory potential could also not be increased by exchanging the 
expression-regulating promoter. This might require closer investigation with regard to 
the expression levels of the mutant gene products, for example by quantitative PCR or 
Western blot analysis. 
 Nevertheless, the ICFAR inhibitory assay successfully made use of an essential 
genetic element that cannot be complemented in trans (the pac sequences), thereby 
supporting the integration of the shuttle plasmid. Using the M53 mutant library as 
reference set, the results were not as clear as expected, as even the known strong DN 
examples i313 and s309 did not completely prevent virus production. However, the 
plaque numbers quantified for all the inhibitory mutants were considerably less than 
half of the value of the wt M53 control. Thus, using a cut-off value of 50% of the 
control (or even less for the identification of strong DNs) it would be possible to at least 
identify strong inhibitory mutants. Their DN potential can be quantified subsequently in 
further assays. 
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4.3.2 Towards an automated readout 
 The ICFAR complementation system was established using deletion BACs and 
simple rescue plasmids. To detect virus reconstitution more easily, staining with 
antisera specific for viral proteins was required, which again added to the expenses of 
the assay. This drawback was circumvented by fluorescently labelling both the viral 
backbone as well as the shuttle plasmid. In the viral genome, the mCherry expression 
cassette was coupled via an IRES to the structural protein SCP. This resulted in a robust 
fluorescent signal upon the onset of late viral replication, effectively marking 
productively infected cells. In addition, the gene under investigation on the rescue 
plasmid was coupled via an IRES to an egfp gene. Two advantages are provided by 
these fluorescence signals, namely infected cells and plaques can be identified by 
fluorescence microscopy without any protein-specific antibody staining. Furthermore, 
the plaques could be quantified using an automated detection system fitted with 
appropriate software. 
 Expression analysis revealed that protein levels depend on the strength of the 
promoter used. In some cases, where only a minute amount of a protein is required to 
facilitate viral growth, the IRES-driven GFP signal was very weak and too weak to be 
sensed by the automated detection device. In that case the IRES coupling the GFP 
expression to the weak promoter could be replaced by a poly(A) sequence to complete 
the expression cassette of the gene under study and GFP expression could be initiated 
by an alternative, stronger promoter. This modification would greatly enhance the 
fluorescent signal and fit the construct for automated detection. Then, indeed, the GFP 
signal would no longer allow an estimation of the expression levels of the protein under 
study, but this may not always be required during the screening process. 
 Moreover, complementation of the M99-deficient BAC demonstrated that the rescue 
plasmid harbouring the pac sequences can be utilised in the ICFAR complementation 
assay as well. Reconstitution of the ∆M99 BAC with an ectopic flip-in of this plasmid 
(∆M99EPM99) produced viral progeny that could productively infect a new cell 
generation, indicating that a second pac signal does not result in the formation of 
defective MCMV genomes. Due to this observation it is possible to use the same rescue 
plasmid as acceptor for the mutant genes in both ICFAR screens, the complementation 
and the inhibitory one, which circumvents the re-cloning of non-complementing 
mutants of the first screen into a new shuttle plasmid for the second screen.  
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4.3.3 Establishment of the ICFAR complementation system to study 
pM99 
Based on previously characterised M53 mutants, it was demonstrated that the 
ICFAR complementation system was applicable to identify non-complementing 
mutations within a target gene. However, to show its reliability, we wanted to test the 
system by screening mutants of a hitherto not analysed gene. For this, the MCMV M99 
ORF was chosen, which encodes a small protein of 112 aa, so that a comprehensive 
mutant library should be manageable.  
 M99 belongs to the conserved family of UL11 homologues, which were, together 
with the homologues of pUL16 (pM94), implicated in the process of secondary 
envelopment of tegumented viral capsids within the cytoplasm [6, 31, 78, 90, 97]. But 
so far, the role(s) of pM99 in this process have been concluded solely from its 
homology to pUL11 proteins in other herpesviruses. Thus, a thorough analysis was 
required to confirm its role in MCMV replication and provided the basic tool-kit for the 
screening.  
 Deletion of the M99 ORF from the wt MCMV BAC prevented virus reconstitution 
in transfected MEF, a defect that was reversed by pM99 expression at an ectopic 
position in the genome. This indicated that pM99 is crucial for viral growth, which has 
also been observed for the HCMV homologue pUL99 [45, 187]. This is in contrast to 
alpha-herpesviruses as well as EBV, where inactivation of the homologous ORFs did 
not prevent virus formation, only plaque sizes and viral titres were reduced [31, 78, 96, 
146], suggesting that the functions required for secondary envelopment are carried out 
at least in part redundantly in those viruses.  
 Early studies on HSV-1 demonstrated that pUL11 is expressed with delayed early 
kinetics [96], whereas pUL99 is a true late gene product [70, 76]. Here it was shown 
that expression of pM99 depends on viral genome replication as well. Furthermore, 
infection with HSV-1 resulted in three protein species derived from the UL11 ORF. 
Propagation of plaque-purified HSV-1 isolates revealed that the original inoculum 
contained a mixture of two HSV-1 clones, which expressed either the two larger or the 
smallest protein species, but never all three of them [96]. A similar pattern was not 
observed for pM99, which was produces as uniform single species of the expected size, 
confirming that pM99 occurs solely in one post-translationally modified state. The same 
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was true for pUL99, which has been characterised as 28 kDa protein [110] as well as for 
pUL11 of PrV [78]. 
 In agreement with previous studies on the HSV-1 and HCMV homologues [4, 78, 
92, 149, 150], analysis of the intracellular distribution of pM99 revealed the 
accumulation at a juxtanuclear compartment. In transiently transfected cells this likely 
represents the ER-Golgi intermediate compartment (ERGIC), whereas in infected cells 
the signal possibly reflects its localisation at the viral assembly compartment, where 
cytoplasmic capsids accumulate and secondary envelopment takes place [156]. The 
location of the assembly compartment was also pointed out by the staining visualising 
DNA that is detectable outside the nucleus. A previous study detected pUL11-specific 
stainings abundantly in nuclear bodies of infected cells [4]. This was not the case for 
pM99, which was observed exclusively in the cytoplasm. Furthermore, several studies 
have identified pUL16 (pUL94 in HCMV) as binding partner for pUL11 [28, 90, 93, 97, 
126, 186]. Accordingly, the intracellular distribution of pM94 was investigated and 
observed at the same site as pM99 in close proximity to the nucleus. These data support 
the role of pM99 in secondary envelopment, as it co-localised with pM94 at the 
assembly complex, possibly targeting mature capsids to the TGN and plasma 
membrane. Moreover, reconstitution kinetics of this virus similar to wt MCMV and the 
intracellular distribution of the expressed pM99F akin to wt pM99 confirmed the 
feasibility to C-terminally tag the pM99 protein by maintaining its biological 
functionality.  
 Following the characterisation of the biological and biochemical properties of pM99 
including its confirmed essentiality, the M99 deletion was complemented using the 
ICFAR system. Since it was not known whether pM99 overexpression would be 
detrimental for the reconstituting virus, expression cassettes using the endogenous M99 
promoter (PM99) and the strong HCMV IE1 promoter (PCMV) were tested. Although 
complementation with either construct resulted in viral plaque formation, pM99 
expression under control of the endogenous PM99 was much more efficient in facilitating 
viral growth. Reconstitution of viruses from isolated DNA may be affected at several 
stages, possibly due to deregulation of viral gene expression upon overload with viral 
genomes or due to the toxicity caused by overexpressed viral proteins. Abundant 
expression of certain viral proteins, particularly early expression of proteins with late 
kinetics, may interfere with virus replication. The data obtained for the pM99 
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complementation strongly highlight the necessity of tightly regulated protein 
expression, as it is achieved in wt MCMV [137]. Supportive observations were made 
for the bacterial flip-in of a PCMV-driven pM99 expression cassette into the ∆M99 BAC. 
The recombinant BAC failed repeatedly to reconstitute virus (data not shown). Thus, a 
major conclusion can be drawn from the ICFAR complementation assay, namely that 
unregulated and early expression of pM99 is inhibitory for virus production. In contrast 
to that, pM53 and pM94, which are also expressed with late kinetics [95, 97], do not 
impair viral replication when expressed early and in excess amounts [present study; 97]. 
In order to identify and study DN mutants of a specific protein, it is crucial to consider 
the inhibitory potential of protein surplus. In our case, using the PCMV-regulated 
expression cassette to complement the wt M99 deletion would likely give false-negative 
results solely due to overexpression of the pM99 version.  
 Plaque formation upon ICFAR ∆M99 complementation was monitored by detecting 
the fluorescent signals emitted by mCherry (encoded by the BAC) and GFP (encoded 
by the shuttle plasmid). Both signals were observed in all plaques, although not all 
infected cells appeared to be GFP-positive. This might, particularly in the case of GFP 
expression coupled to PM99, be explained with the quite low expression levels induced 
by this promoter. On the other hand, the partial co-localisation of GFP and mCherry 
could be an indicator that pM99 is expressed only in the initially transfected cells. If the 
rescue plasmid was not inserted into the BAC efficiently or flipped-out again, the 
genomic basis for pM99 expression is realised only in the directly transfected cells, but 
not passed on to the neighbouring cells. In this case it might be that pM99 is packaged 
into the mature virion [9, 68, 69] and transported to the newly infected cell, which 
might be sufficient to facilitate further viral growth at the rim of the plaque until the 
pM99 supply is depleted. This would also imply that, once expressed, pM99 is stable 
enough to remain functional in the cytoplasm of a newly infected cell. Furthermore, it 
supports the finding that minute pM99 amounts already suffice to enable virus 
production. Insufficient Flp/FRT-mediated recombination was also observed using a 
shuttle plasmid expressing viable GFP-tagged SCP [19], which was co-transfected with 
the ∆pac BAC (data not shown). Virus reconstitution was detectable, though only part 
of the infected cells were GFP-positive, again hinting at low flip-in levels or preference 
of the plasmid excision reaction following flip-in. This might also account in part for 
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the minor virus production in the presence of the pM53 DN mutants in the inhibitory 
ICFAR screen and requires closer investigation. 
 A study on the HCMV homologue pUL99 reported on cell-to-cell spread of a 
pUL99 deficient virus [160]. Although neither infectious particles could be detected in 
the supernatant nor the cells transfected with ∆M99 BAC DNA did change their 
morphology to an infected appearance, this possibility cannot be absolutely excluded 
for M99-deficient MCMV. To investigate this further, a pM99-expressing 
complementing cell line would be necessary which enables the propagation of viral 
progeny lacking pM99. Subsequently, MCMV-∆M99-infected cells could be analysed 
by EM and the cytoplasmic distribution of viral particles studied. 
 To validate the new system, a couple of mutants were tested already which were 
rationally designed. Three mutants were constructed based on functional domains 
described for the HCMV homologue pUL99 [67, 90], which included the potential 
myristoylation site, a conserved acidic cluster and the potential pM94 binding domain, 
and were deleted from the M99 ORF. Repeatedly, none of these mutants was able to 
complement the wt pM99 function, indicating that those domains are as well important 
for the functionality of pM99. In the next step, the three mutants should be tested in the 
inhibitory screen to check whether the mutations result in non-functional proteins, 
which cannot interfere with wt pM99, or whether the mutant proteins are inhibitory for 
MCMV replication.  
 Furthermore, detailed analyses would be required to study the properties of the 
mutant proteins. For example, the intracellular distribution of the ∆Gly2 mutant should 
be investigated. Since the N-terminal glycine supposedly is the acceptor for the myristic 
acid, which anchors the pUL11 homologues at membrane surfaces [8, 92, 149], loss of 
this amino acid should result in a modified protein localisation. Additionally, it needs to 
be investigated whether the pM94 binding domain deduced from the pUL99 homologue 
is indeed responsible for the interaction between pM99 and pM94.  
 
4.4 Concluding remarks 
The data presented here confirm that the domain targeting approach can be 
successfully applied to identify DN mutants, although this depends on regions in the 
protein with sequence homology to related proteins. Therefore it cannot be employed on 
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any viral protein. Incidentally, pM99 seems to be such a candidate, as two of the three 
mutations introduced (the pM94 binding and the acidic cluster) could have been 
deduced from the sequence alignment of the homologous proteins. Nonetheless, it is not 
known yet whether the pM99 mutations have DN potential or whether they are just non-
functional. 
Focussing on the pM53 CR2 mutant, the data accumulated during this study both 
confirm and extend the current model of herpesvirus nuclear egress. Apparently, pM53 
and its homologues seem to target mature DNA-filled nucleocapsids to the INM, where 
they transit into the cytoplasm by budding through the nuclear envelope. 
The second part of this study described the establishment of a fast and high-
throughput-ready complementation system based on Flp/FRT-mediated recombination 
in mammalian cells. It was shown that the system is indeed suitable for the high-
throughput screening to rapidly identify non-complementing mutations, which can then 
be tested in a second round for their inhibitory potential. Nevertheless, the inhibitory 
screen demands further improvement with respect to efficient flip-in and genome 
stabilisation.  
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6 SUPPLEMENTARY INFORMATION 
 
6.1 Homologous herpesvirus proteins 
Table 6.1: Nomenclature of selected homologous ORFs/proteins in herpesviruses 
HSV/PrV HCMV MCMV EBV MHV68 
UL11 UL99 M99 BBLF1 ORF38 
UL16 UL94 M94 BGLF2 ORF33 
UL17 UL93 M93 BGLF1 ORF32 
UL25 UL77 M77 BVFR1 ORF19 
UL31 UL53 M53 BFLF2 ORF69 
UL34 UL50 M50 BFRF1 ORF67 
 
 
 
Table 6.2: Accession numbers of pUL11 homologue sequences 
Listed are the accession numbers of the pUL11 homologues used for the alignment depicted in 
Figure 3.34A. Protein sequences were downloaded from the Protein Knowledgebase 
(UniProtKB) on http://www.uniprot.org. 
A5A411_9ALPH Q5Y0U2_9ALPH Q9QP14_ILTV TG11_PSHV1 
D1FXX1_FHV1 Q6X222_9ALPH Q9YZA4_9ALPH TG11_SHV21 
E2IUF9_SHV1 Q77CB3_BHV1C TG11_EHV1B TG11_VZVO 
F5HHY1_HHV8P Q782T5_9ALPH TG11_GAHVM UL11_EBVA8 
G8H0M3_9BETA Q806B8_CHV1 TG11_HHV11 UL11P_HCMVA 
G8XT03_9BETA Q85040_SUHVK TG11_HHV2H VG38_ALHV1 
G8XUG4_9BETA Q8QS01_9BETA TG11_HHV6U VG38_ICHVA 
G9CUB8_9ALPH Q8UZG1_9GAMA TG11_HHV7J  
Q2QBG6_CHV16 Q9E1H9_MEHV1 TG11_MUHVK  
     
 
 
Supplement 
6.2 Oligonucleotides 
Table 6.3: Oligonucleotides used for cloning 
No. Name Sequence (5'- 3') 
01  Apa2-for ATCGGGTCACAGTCCTCACGCC 
02  Apa2-rev CAACATCCGTGGGTCGACACC 
03  CHfor CGCAAGTTCTACTTCGGGTTCC 
04  CHrev ACACGCTCGAGGACTCTAGCCGCAGACATCGC 
05  CR4MHVfor GAGTCCTCGAGCAGAATACCTACCATACCGGCCGA 
06  Flag∆SakM53for TAAACTTAAGCTTGGCGCGCC 
07  FlagM53SalIrev GTCGGGGTGGTCGACCTC 
08  LITrev ATTCAGGCTGCGCAACTGTTGG 
09  M53∆CR2AB-for TAAACTTAAGCTTGGCGCGC 
10  M53∆CR2A-5’rev Phosphate-CGTCGTCTCCTTGCAGGTGG 
11  M53∆CR2A-3’for Phosphate-AACGTGATGAAGCACCGCAAG 
12  M53∆CR2AB-rev TCCACCTTCCTCTGCAGCATC 
13  M53∆CR2B-5’rev Phosphate-GGTCTGGTTGATGAAGGCCAC 
14  M53∆CR2B-3’for Phosphate-GGCTTCCGTAAAAACATGGAAC 
15  M53∆CR3-5’rev Phosphate-CATGTTCTTACGGAACCCGAAGTAG 
16  M53∆CR3-3’for Phosphate-CGATGTCTGCGGCTAGAGTCG 
17  M56-1for GTGTGGGTACCACGCGTGGCCACCATGGCCATGAATA
CGTTACAAAAACTGTG 
18  M56-1rev GTGTACCGGTGCTCCTCGTAGCACTGAAAAC 
19  M56-2for GTGTGTACCGGTCTGCTGGCGAGGTTGTGCGA 
20  M56-2rev GTGTGTAAGCTTTTCCCCTCCTGCCCCGGCCC 
21  M56-3for GTGTGGATCCCCCCTTTTCAATCGCTTGCACGA 
22  M56-3rev GTGTGTCGTACGTTATATAGTGCGACGGACAG 
23  M56-4for GTGTCGTACGGACTGGATGACAGTCGGATACATG 
24  M56-4rev GTGTGTATGCATGGATCCTCACTTGTACAGGCAAGGA
GGC 
25  M99for GATCGAGGCGCGCCGGTACCCGGTAAGAAGACGGGTC
TCG 
26  M99Flagrev ATCGATCGCGGCCGCTTATTTGTCGTCGTCGTCTTTG
TAGTCGCCGGAGCCCAAGGCCCTGACTTTTTTCTTC 
27  M99syn-for AAGGCGCGCCGCTAGCGGTACCATGGGTGCAGAGTG 
28  M99rev TTTAGGCCTGTCGACTCACAAGGCCCTGACTTTTTTC
TTC 
29  M99∆Gly2-for GCCGCTAGCGGTACCATGGCAGAGTGCTGTAAACAGC
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Supplement 
Table 6.3: Oligonucleotides used for cloning, continued 
No. Name Sequence (5'- 3') 
30  M99∆M94-5’rev CAGGGAGTCCGCGGCGTAGGG 
31  M99∆M94-3’for GACGAAGACCAGGTCGGCG 
32  M99∆AC-5’rev AGACGTATCCGTCAGCACAGAGAATTCGG 
33  M99∆AC-3’for TTCGTGCAGAAACAGCTCACGAC 
34  MCMVpac_for GTGTGTCGGACCGGGTTTAGATAAAAATGTGACCG 
35  MCMVpac_rev GTGTGTCATATGAAAACCCTGGACTCCCCCGAAC 
36  P(M99)-for GCTTAATTAACTGTTCCTCAAGGCCGCGTTC 
37  P(M99)-rev TTTGCTAGCAGCGCGAGACCCGTCTTCTTAC 
 
 
Table 6.4: Primers used for BAC mutagenesis 
Name Sequence (5'- 3') Comments 
H5-DPAC CTCGTTAACCGAGCACATGTTTTTTTAACGAC
TCCTCCACACACATATGATGTGGGCGGACAAA
ATAGTTGG 
H3-DPAC GGGTACCGAGCTCGAATTCACTGGCCGTCGTT
TTACAACGTCGTGACTGGGTGTGGGCGGACAA
TAAAGTCTTAAACTGAA 
replacement of pac 
sequences by kanR 
cassette by 
homologous 
recombination 
H5-
M99amp 
GTGGGTGCAGAGTGCTGTAAACAGCTATGTCG
CAGCCTGCATCCCTACGCCGCGGACTCCCTGA
GAACCATCACCCTAATCAAGTTT 
H3-
M99amp 
CTCTTTCTCCCTTTCTCCCCCCCTCACGGTCG
ATCGATAGATAGATATCAGAGTAAACTTGGTC
TGACAGTTACC 
replacement of 
M99 ORF by ampR 
cassette by 
homologous 
recombination 
 
 
Table 6.5: Primers used for confirmative and qPCR 
Name Sequence (5'- 3') 
Flpe-for ATGGCTCCCAAGAAGAAGAG 
Flpe-rev GTGATCTCCCAGATGCTTTC 
LBR-for GGAAGTTTGTTGAGGGTGAAGTGGT 
LBR-rev CCAGTTCGGTGCCATCTTTGTATTT 
5’-M54 CGCCAGTCTGTATCCGTCCAT 
3’-M54 ATCATCCGTTGCATCTCGTTG 
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ABBREVIATIONS 
 
aa  amino acid(s) 
amp ampicillin 
BAC bacterial artificial chromosome 
Bla  beta-lactamase 
bp  base pairs 
BSA bovine serum albumin 
°C  degree Celsius 
C-  carboxy terminal 
cam chloramphenicol 
cm  centimetre 
CMV cytomegalovirus 
CR(s) conserved region(s) 
Δ  deletion 
DN  dominant negative 
DNA desoxyribonuleic acid 
dNTP desoxynucleotide triphosphate 
dox doxycycline 
dpi  day(s) post-infection 
E. coli Escherichia coli  
EBV Epstein-Barr virus 
(E)GFP (enhanced) green fluorescent protein 
ER  endoplasmic reticulum 
FCS foetal calf serum 
FRT Flp recombination target 
g  grams  
g  gravity acceleration 
GoI gene of interest 
HCMV human cytomegalovirus 
hpi  hours post-infection 
hpt  hours post-transfection 
HSV herpes simplex virus 
ICFA(R) in-cell Flp-assisted (recombination) 
IE  immediate early 
INM inner nuclear membrane 
IP  immunoprecipitation 
IRES internal ribosomal entry site 
KAc potassium acetate 
kan  kanamycin 
kbp kilo base pairs 
L  litre 
LB  Luria-Bertani 
LBR lamin B receptor 
log  order of magnitude 
M  molar 
MCMV murine cytomegalovirus 
MCP major capsid protein 
MEF mouse embryonic fibroblast(s) 
 
µg, µL micrograms, microlitre 
mg, mL milligrams, millilitre 
mm millimetre 
mM millimolar 
MHV murine herpesvirus 
min minute(s) 
MOI multiplicity of infection 
mRNA messenger RNA 
N-  amino terminal 
NEC nuclear egress complex 
ng  nanograms 
NLS nuclear localisation signal 
nm  nanometre 
nt  nucleotide(s) 
o/n  overnight 
ODx optical density at the wavelength  
  of x nm 
ONM outer nuclear membrane 
ORF open reading frame 
PAA phosphonoacetic acid 
pac  packaging signal(s) 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
pfu  plaque forming units 
PIC protease inhibitor cocktail 
PrV pseudorabies virus 
r/t  room temperature 
RNA ribonucleic acid 
RNP ribonucleoprotein 
rpm rotations per minute 
SCP smallest capsid protein 
SDS sodium dodecyl sulfate 
SEC secondary envelopment complex 
s  second(s) 
SV40 simian virus 40 
(T)EM (transmission) electron microscopy 
tet  tetracycline 
TetR tet repressor 
TGN trans-Golgi network 
Tn  transposon 
TLB total lysis buffer 
U  unit 
UV  ultra violet 
VZV varicella-zoster virus 
w/v weight per volume 
wt  wild type 
zeo  zeocin 
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